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Relaxin is a peptide hormone emanating from the corpus luteum of the ovary which 
circulates during pregnancy.  Although traditionally associated with female reproductive 
processes, recent evidence has suggested relaxin may play a vital role in regulating renal and 
cardiovascular function.  Analogous to pregnancy, chronic administration of recombinant human 
relaxin (rhRLX) to nonpregnant female or male rats induces renal vasodilation and reduces the 
myogenic reactivity of small renal arteries (SRA).  Additionally, elimination of circulating 
relaxin in pregnant rats with specific antibodies prevents the pregnancy associated changes in the 
renal circulation.   
Based on these findings we postulated that relaxin exerts similar vasodilatory effects in 
the systemic circulation and examined its role in modulating systemic hemodynamics and 
vascular wall mechanical properties.  Analogous to pregnancy, administration of rhRLX to 
nonpregnant female or male rats elicited increases in cardiac output and global arterial 
compliance, as well decreases in systemic vascular resistance.  Additionally, neutralizing 
circulating relaxin in midpregnant rats eliminated the pregnancy associated changes in the 
systemic circulation.   
In order to understand the mechanistic bases for the relaxin-induced increase in global 
arterial compliance, we examined the hormone’s effects on vascular wall remodeling.  From a 
geometric perspective, SRA isolated from rhRLX-treated rats and mice were characterized by 
larger wall area resulting from relaxin-mediated smooth muscle cell (SMC) hyperplasia, and not 
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hypertrophy.  From a compositional perspective, these arteries were characterized by decreased 
collagen.  Opposite results were obtained with removal of endogeneous relaxin: SRA from 
relaxin knock-out mice exhibited increased collagen content and decreased SMC density 
compared to wild-type mice.  Finally, from a tissue mechanics perspective, SRA from rhRlx-
treated mice exhibited strain-dependent reductions in tissue strain energy such that the greatest 
reduction was observed at the highest circumferential and axial strains. 
We conclude that relaxin exerts systemic vasodilatory effects in both pregnant and 
nonpregnant states and in a gender-independent manner.  Our findings indicate that the relaxin-
induced increase in global arterial compliance is, at least in part, due to vascular wall 
compositional and geometric remodeling.  Finally, our data indicate that the relaxin-induced 
compositional remodeling of SRA contributes to tissue mechanical properties under conditions 
of high circumferential and axial loads. 
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1.0  INTRODUCTION AND BACKGROUND 
Systemic arterial load is defined as the mechanical opposition to movement of blood flow 
out of the left ventricle [1].  It is described by two components.  One is the steady arterial load 
commonly known as systemic vascular resistance (SVR).  This is quantified as the ratio of mean 
arterial pressure (MAP)-to-cardiac output (CO) and results mainly from arteriolar properties.  
The other component is pulsatile arterial load, which arises solely as a consequence of the 
inherently pulsatile nature of the cardiac pump.  It is determined by the following: vessel 
geometry and wall visco-elasticity, the branching property of the vasculature that gives rise to 
wave propagations and reflections, and the mechanical properties of blood.  Global arterial 
compliance (AC) is one measure of pulsatile arterial load, and is typically derived from CO and 
the diastolic decay of the aortic pressure waveform [2]. 
Increased arterial stiffness (or decreased compliance) is observed in many physiological 
(normal aging, post-menopausal state) and pathological (accelerated aging, chronic hypertension, 
diabetes, diastolic heart failure) conditions, typically resulting in an increase in arterial load and 
modifications of systemic hemodynamics that negatively impact both the heart and the vessels.  
For example, increased arterial stiffness results in a reduction in diastolic pressures, which can 
compromise coronary perfusion.  With the reduction in diastolic pressure (and increase in 
systolic pressure), pulse pressure increases.  There is considerable evidence linking increased 
pulse pressures to various cardiovascular pathologies including myocardial and vascular 
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hypertrophy [3].  Increased pulse pressure also results in an increase in pulsatile shear stress on 
the endothelium which promotes formations of reactive oxygen species rather than nitric oxide 
[4].  This process neutralizes the beneficial effects of nitric oxide and results in endothelial 
dysfunction.   
Conversely, there are certain physiological phenomena which result in an acute or 
chronic reduction in arterial load.  Understanding the mechanistic basis for such conditions may 
provide some insight into developing therapeutic agents for treating cardiovascular pathologies 
wherein an increase in arterial load is a major underlying cause.  One such condition is 
pregnancy, during which there are significant reductions in both the steady and pulsatile 
components of arterial load.  These changes result primarily from significant vasodilation of the 
systemic circulation as well as alterations in vascular wall mechanical properties and structure.     
1.1 MATERNAL CARDIOVASCULAR ADAPTATIONS TO PREGNANCY 
The serial changes in systemic hemodynamics and arterial properties that occur during 
pregnancy are believed to be a necessary adaptation to ensure adequate uteroplacental perfusion 
for fetal development.  These alterations in cardiovascular function are believed to result from 
the actions of the nervous system and circulating humoral factors, as well as functional and 
structural modifications within the heart and vascular tissue.  These changes include an increase 
in heart rate and stroke volume, yielding a significant increase in cardiac output (CO) that is 
maximum by the end of the first or beginning of the second trimester.  Additionally, SVR (the 
steady component of arterial load) is significantly decreased during pregnancy, reaching a nadir 
by the end of the first or beginning of the second trimester.  This combined with the increase in 
3 
CO results in a slight decrease in mean arterial pressure [5].  Also during pregnancy, global AC 
(the pulsatile component of arterial load) reaches a peak by the end of the first trimester just as 
SVR reaches a nadir [6].  At least in theory, the rise in global AC is critical to the maintenance of 
cardiovascular homeostasis during pregnancy for several reasons: (1) it prevents excessive 
decline in diastolic pressure which otherwise would fall to precariously low levels due to the 
significant decline in SVR; (2) it minimizes the pulsatile or oscillatory work wasted by the heart 
which otherwise would increase in disproportion to the rise in total work required of and 
expended by the heart during pregnancy; and (3) it preserves steady shear-type (or prevents 
oscillatory shear-type) stress at the blood-endothelial interface despite the hyperdynamic 
circulation of pregnancy, thereby favoring production of nitric oxide rather than superoxide and 
other damaging reactive oxygen species by the endothelium.   
The increase in global AC observed during pregnancy most likely result from a decrease 
in smooth muscle tone, maternal angiogenesis, or alterations in the passive mechanical properties 
and vascular wall stiffness of systemic arteries.  To this end, several works examining passive 
mechanical behavior of various arteries from pregnant species showed an increase passive 
compliance of these arteries when compared to nonpregnant counterparts.  Initially, many studies 
focused on examining the changes in the uterine vasculature during pregnancy.  These studies 
reported that uterine arteries and veins from different pregnant species exhibit significant 
vasodilation (as measured by an increase in lumen diameter) and increased passive compliance 
[7-11] when compared with those from respective, nonpregnant controls.  Other works focused 
on the effects of pregnancy on passive mechanical properties of arteries associated with non-
reproductive organs.  Specifically, mesenteric arteries from late pregnant rats have been shown 
to exhibit increased passive compliance [12] whereas carotid arteries from late pregnant sheep 
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exhibited no changes in passive compliance [7].  To determine the mechanisms underlying this 
pregnancy-induced increase in passive compliance, some studies examined the changes in the 
biochemical constituents of the vascular wall (i.e., collagen and elastin) during pregnancy.  As 
expected, uterine arteries and veins from pregnant animals were characterized by reduced 
collagen content when compared to nonpregnant animals [7], while elastin content was 
decreased or remained unaltered during pregnancy [7, 9].  Similarly, collagen and elastin content 
were both significantly reduced in mesenteric arteries from late pregnant rats [12].   
To summarize, pregnancy is a physiological condition characterized by significant 
systemic vasodilation (reduced SVR) resulting in an increase in CO.  Additionally, there is a 
significant increase in global AC during pregnancy most likely resulting from a decrease in 
smooth muscle tone, maternal angiogenesis, and alterations in the passive mechanical properties 
and vascular wall stiffness of systemic resistance arteries.  Of note, the systemic vasodilation 
observed during early pregnancy is believed to be a result of vasodilation of mainly non-
reproductive vascular beds such as the renal circulation.  At the onset of the present work, the 
factor(s) mediating these changes in systemic hemodynamics and global arterial compliance 
during pregnancy was(were) not completely understood.  Traditionally, sex hormones have been 
postulated to mediate these changes in cardiovascular function during pregnancy [5, 13-15].  
However, recently a role for the ovarian hormone, relaxin, has been advanced [16-20]. 
1.2 RELAXIN 
Most investigations conducted by reproductive biologists have dealt with relaxin in the 
context of pregnancy.  The traditional sources of relaxin have been reproductive tissues such as 
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the corpus luteum of the ovary from which the hormone emanates and circulates during the luteal 
phase of the menstrual cycle and during pregnancy in women [21].  The concept that relaxin can 
affect cardiovascular function and, more specifically, blood vessel structure and function has 
gained considerable support.  Much of our recently gained knowledge of relaxin in this new light 
has arisen from studies of maternal renal and cardiovascular function in the gravid rat model 
where relaxin has emerged as a prominent modulator of cardiovascular function. 
1.3 PREGNANCY-INDUCED RENAL VASODILATION: A ROLE FOR RELAXIN 
The renal circulation during pregnancy is characterized by profound vasodilation and 
hyperfiltration.  This results in an increase in effective renal plasma flow and glomerular 
filtration rate while renal vascular resistance is reduced.  In addition, the myogenic reactivity of 
small renal arteries is significantly reduced during pregnancy.  Similar to the changes in overall 
cardiovascular function during pregnancy, it was initially believed sex hormones mediated these 
pregnancy-associated changes in renal function.  However, numerous studies revealed little or no 
influence of estrogen on the renal circulation, while progesterone showed only a modest effect 
[22]. Recent investigation implicated relaxin as the mediator of renal vasodilation and 
hyperfiltration during pregnancy [16, 23]. 
Conrad and colleagues reported that prolonged administration of porcine relaxin or 
recombinant human relaxin (rhRLX) to chronically instrumented, conscious, nonpregnant female 
rats increased both effective renal plasma flow and glomerular filtration rate to levels observed 
during midterm pregnancy when renal function peaks in this species [16].  This response to 
relaxin was also observed in both male and overiectomized female rats [16, 24] suggesting other 
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reproductive hormones such as estrogen and progesterone are not necessary for these relaxin-
mediated changes in the renal circulation.  In addition, the pregnancy-associated osmoregulatory 
changes (i.e. reductions in plasma sodium concentration and osmolality) were reproduced by 
chronic relaxin infusion in these studies [16, 24].  Chronic relaxin administration also attenuated 
the renal vasoconstrictor response to angiotensin II infusion comparable to pregnancy [25-27].  
Furthermore, the myogenic reactivity of small renal arteries isolated from relaxin-treated rats 
was reduced [28], comparable to the reductions observed in small renal arteries isolated from 
midterm pregnant rats [23]. 
Using relaxin neutralizing antibodies or removing circulating relaxin from midpregnant 
rats by ovariectomy, Conrad and colleagues showed the gestational renal vasodilation, 
hyperfiltration and reduced myogenic reactivity of small renal arteries were totally abolished in 
the absence of relaxin [23].  Additionally, the osmoregulatory adaptations of pregnancy at 
midterm were prevented [23].  In short, these studies demonstrated relaxin is essential for the 
renal circulatory and osmoregulatory changes of pregnancy in the gravid rat model. 
1.4 MOLECULAR MECHANISMS OF RELAXIN 
Through the use of nitric oxide (NO) synthase inhibitors, Conrad and colleagues 
demonstrated an essential role for NO in the renal vasodilation, hyperfiltration and reduced 
myogenic reactivity of small renal arteries from pregnant and relaxin-treated nonpregnant rats 
[16, 27-29].  Further, they showed endogenous endothelin (ET) acting through the endothelial 
ETB receptor subtype plays an essential role in the pregnant and relaxin-mediated changes in the 
renal circulation [24, 25, 28-30].  Comparable to the findings using inhibitors of nitric oxide 
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synthase, acute administration of the endothelial ETB receptor antagonist, RES-701-1, inhibited 
the gestational renal vasodilation and hyperfiltration, thereby resulting in a convergence of 
glomerular filtration rate, effective renal plasma flow, and effective renal vascular resistance in 
conscious gravid and virgin rats [30].  Furthermore, there was a reversal of the reduced 
myogenic reactivity of small renal arteries isolated from gravid rats [29]. 
 Combining these findings with the ability of relaxin to upregulate matrix 
metalloproteinase (MMP) activity, at least in fibroblasts, and the potential for vascular MMPs, 
such as the gelatinases, MMP-2 and MMP-9, to process big ET to yield ET1-32, with the latter 
being capable of activating endothelin receptors [31, 32], Conrad and colleagues postulated that 
during pregnancy, relaxin may alter one or more of the steps in the vasodilatory pathway 
depicted in Figure 1.  Using chronically instrumented conscious rats, they demonstrated that a 
specific gelatinase inhibitor and a general inhibitor of MMPs both reversed the renal vascular 
changes induced by relaxin administration to nonpregnant rats.  Further, the typical reduction in 
myogenic reactivity of small renal arteries from relaxin-treated, nonpregnant rats and from 
pregnant rats was reversed by 4 different inhibitors of MMPs in vitro including an MMP-2-
neutralizing antibody.  Finally, small renal arteries from relaxin-treated, nonpregnant, ETB-
receptor deficient rats, did not exhibit a reduction in myogenic reactivity despite an increase in 
vascular MMP-2 activity.  These results indicate an essential role for vascular gelatinase, which 
is in series with, and upstream of, the endothelial ETB/NO signaling pathway in the renal 
vasodilatory response to relaxin and pregnancy [25]. 
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Figure 1. Working model for the slow vasodilatory actions of relaxin.  
┤, indicates inhibitors of relaxin vasodilation.  VEGF and PlGF, vascular endothelial  and 
placental growth factor activities, respectively; ET, endothelin; MMP, matrix metalloproteinase; 
RBF, renal blood flow; GFR, glomerular filtration rate; GM6001, a general MMP inhibitor; 
cyclic CTT, a specific peptide inhibitor of MMP-2; TIMP-2, tissue inhibitor of 
metalloproteinase; RES-701-1, a specific ETB receptor antagonist; SB209670, a mixed ETA and 
ETB receptor antagonist; L-NAME, nitro-L-arginine methyl ester; L-NMA, NG-monomethyl-L-
arginine.  Note that phosphoramidon (an inhibitor of the classical endothelin converting 
enzyme), STT (control peptide for cyclic CTT); heat inactivated TIMP-2, BQ-123 (a specific 
ETA receptor antagonist), D-NAME and IgGs (control antibodies for MMP neutralizing 
antibodies) did not affect the slow vasodilatory actions of relaxin. Modified from Jeyabalan A et 
al. Adv Exp Med Biol. 2007 [33]. 
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2.0  HYPOTHESES 
Circulating relaxin mediates maternal renal vasodilation, hyperfiltration and reduced 
myogenic reactivity of small renal arteries in rats [23].  Based on this observation and because 
serum levels of relaxin in rats increase early in pregnancy concurrent with the changes in 
cardiovascular function [15, 21, 34], we postulate that this hormone might also contribute to the 
broader cardiovascular changes of pregnancy, i.e., the increases in CO and global AC, as well as 
the reduction in SVR.  In addition, because the effects of relaxin on the renal circulation were 
observed in male rats, we believe relaxin’s ability to regulate cardiovascular function is not 
limited to the female sex or to the pregnancy state.  Finally, we postulate that similar to 
pregnancy, the increase in global AC observed with relaxin administration is a result of altered 
arterial passive mechanical properties through vascular wall remodeling.  Based on these 
postulates, we developed the following specific aims to determine the role of relaxin in 
regulating cardiovascular function in the presence or absence of pregnancy, with particular 
emphasis on the hormone’s effects on arterial passive mechanical properties and vascular wall 
remodeling. 
10 
3.0  SPECIFIC AIMS 
Hypothesis 1. Exogenous administration of recombinant human relaxin (rhRLX) to 
nonpregnant animals elicits dose-dependent alterations in systemic hemodynamics and arterial 
mechanical properties that are comparable to those seen in normal pregnancy. 
Specific Aim 1A.  To determine systemic hemodynamics and arterial load in conscious, 
nonpregnant female rats administered rhRLX. 
Specific Aim 1B.  To determine the dose-response of systemic hemodynamics and 
arterial load in conscious, nonpregnant female rats administered rhRLX. 
 
Hypothesis 2. Effects of exogenous administration of rhRLX on systemic hemodynamics and 
arterial mechanical properties are gender independent. 
Specific Aim 2.  To determine systemic hemodynamics and arterial load in conscious, 
male rats administered rhRLX and compare these responses to those observed in female rats. 
 
Hypothesis 3. Endogenous (circulating) relaxin mediates the alterations in systemic 
hemodynamics and arterial properties that occurs during normal pregnancy. 
Specific Aim 3.  To determine systemic hemodynamics and arterial load in conscious, 
mid and late-pregnant rats administered control or relaxin neutralizing antibodies. 
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Hypothesis 4.  The relaxin-mediated increase global arterial compliance in pregnant and 
nonpregnant animals is a result altered arterial passive mechanical properties. 
Specific Aim 4A.  To evaluate the passive mechanical properties of small renal and 
external iliac arteries isolated from rhRLX-treated, nonpregnant  female rats and mice. 
Specific Aim 4B.  To evaluate the passive mechanical properties of small renal and 
messenteric arteries isolated from mid-pregnant rats administered control or relaxin neutralizing 
antibodies.  
 
Hypothesis 5.  Vascular wall remodeling contributes to the relaxin-mediated alterations in 
arterial passive mechanical properties. 
Specific Aim 5A.  To analyze smooth muscle cell characteristics (size and count) in small 
renal and external iliac arteries isolated from rhRLX-treated mice. 
Specific Aim 5B.  To determine elastin and collagen content in small renal and external 
iliac arteries isolated from rhRLX-treated mice. 
 
Hypothesis 6.  Locally-produced endogenous relaxin regulates arterial passive mechanical 
properties through vascular wall remodeling. 
Specific Aim 6A.  To evaluate the passive mechanical properties of small renal arteries 
isolated from Rlx+/+ and Rlx-/- mice. 
Specific Aim 6B.  To analyze smooth muscle cell characteristics (size and count) in small 
renal and external iliac arteries isolated from Rlx+/+ and Rlx-/- mice. 
Specific Aim 6C.  To determine elastin and collagen content in small renal and external 
iliac arteries isolated from Rlx+/+ and Rlx-/- mice. 
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4.0  MATERIALS AND METHODS 
4.1 SYSTEMIC HEMODYNAMICS AND ARTERIAL PROPTERTIES IN RELAXIN-
TREATED RATS 
4.1.1 Animals 
Long-Evans male and female rats of 12-14 weeks old were purchased from Harlan 
Sprague-Dawley (Frederick, Maryland USA).  They were provided PROLAB RMH 2000 diet 
containing 0.48% sodium (PME Feeds Inc., St. Louis, MO USA) and water ad libitum.  The rats 
were maintained on a 12 h light/dark cycle.  The Institutional Animal Care and Use Committee 
of the Magee-Womens Research Institute approved all animal procedures.  The rats were 
habituated to Nalgene metabolism cages for one week (VWR Scientific Products), followed by 
another week in a harness/7.5 cm spring assembly (Harvard Apparatus, Holliston, MA USA).   
4.1.2 Animal Instrumentation 
After the habituation period, the rats were anesthetized with 60 mg/kg ketamine i.m. and 
21 mg/kg pentobarbital i.p., and placed in the prone position on a heating pad.  After application 
of 70 % ethanol and betadine to all exposed skin areas, ampicillin was administered s.c. (0.2 ml 
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of a 125 mg/ml solution) and atropine was also administered s.c. (0.075 ml of a 0.4 mg/ml 
solution). 
Next, a sterile tygon catheter (18 in long, 0.015 in ID, 0.030 OD) connected to a syringe 
containing Ringer’s solution, as well as a sterile  thermodilution microprobe (22 cm long, F #1.5; 
Columbus Instruments, Columbus, OH USA) were threaded through the spring.  The tygon 
catheter was subsequently threaded through the hole in the harness and then tunneled 
subcutaneously from the midpoint between the shoulder blades out the small incision behind the 
ear using an 18-gauge trocar.  The thermodilution catheter was also threaded through the harness 
assembly and then tunneled subcutaneously from the midpoint between the scapulae out the skin 
incision in the left costal margin.  The spring was then reattached to the harness. 
The rat was repositioned on the back.  A 1.0 cm skin incision was made in the left 
inguinal region.  The external iliac artery was isolated and prepared for catheterization.  The 
thermocouple was then tunneled subcutaneously exiting at the inguinal incision. The 
thermocouple was next inserted into the external iliac artery being directed rostrally, so that it 
passed easily into the internal iliac artery and subsequently into the aorta.  After it was advanced 
4.0 cm, the thermocouple lay approximately 1.0 cm below the left renal artery.  
Next, a horizontal 2.0 cm incision was made over the trachea, 1.0 cm above the cricoid 
notch.  Through this incision, a large subcutaneous pocket was dissected in the neck and above 
the left shoulder.   The right jugular vein and carotid artery were then isolated and prepared for 
catheterization, the latter facilitated by placing a small roll of gauze under the neck to elevate this 
deep structure.  Using the 18-gauge trocar, the tygon catheter was tunneled subcutaneously from 
the small incision behind the right ear out the incision in the neck.  The tygon catheter was 
implanted in the right jugular vein and advanced 3.0 cm, thereby placing the catheter tip at the 
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confluence of the anterior vena cava and the right atrial appendage.  The battery/transmitter of a 
sterile mouse pressure catheter (TA11PA-C20; ca. F #1.2; Data Sciences International, St. Paul, 
MN USA) was inserted in the subcutaneous pocket.  The mouse pressure catheter was then 
implanted in the right carotid artery 2.8 cm, thereby placing the catheter tip at the confluence of 
the right carotid artery and aortic arch.  All wounds were closed with 4-0 silk or autoclips.   After 
instilling 0.05 ml of a heparin solution into the jugular catheter and plugging it with a straight 
pin, the rat was placed in the metabolism cage and given ampicillin by drinking water for 2 days 
(100 mg/50 ml with 2 tablespoons of dextrose).  The spring and catheters that exit the cage top 
were secured.  Terbutrol was given s.c. for post-operative analgesia as soon as the rats were 
recovered sufficiently from the anesthesia.   
After completion of the measurement for the last time point, the rat was anesthetized with 
60 mg/kg pentobarbital i.v.  and the position of the jugular catheter relative to the right atrium, 
the placement of the pressure catheter relative to the aortic arch, and the position of the 
thermocouple relative to the left renal artery were recorded. 
 
4.1.3 Administration of Recombinant Human Relaxin (rhRLX) 
We used three different doses of rhRLX intended to yield concentrations of circulating 
relaxin that ranged from levels seen during the early stages of pregnancy to those observed 
during the late stages [21, 24, 25, 35].  For chronic administration of low dose rhRLX (1.0-4.0 
μg/h), two Alzet model 2002 or one model 1002 osmotic minipumps (Durect Corporation, 
Curpertino, CA USA) was inserted subcutaneously in the back of the animal under isoflurane 
anesthesia.  For medium (25 μg/h) or high (50 μg/h) dose administration, one Alzet model 2ML2 
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osmotic minipump was implanted.  The rhRLX (Connetics, Palo Alto, California USA) was 
provided as a 5.0 mg/ml solution in 20 mM sodium acetate, pH 5.0 and was diluted in the same 
buffer. 
4.1.4 Experimental Protocol 
Time control studies were first performed in 5 rats, in order to document the stability of 
systemic hemodynamics over a 17 day period after surgery.  In these animals, measurements 
were recorded on days 4-5, 7-8, 9-10, 13-14, and 16-17 after surgery. 
The low, medium, and high dose rhRLX protocols entailed 6, 7 and 9 rats, respectively.  
In addition, the vehicle for rhRLX (20mM sodium acetate, pH 5.0) was administered to another 6 
rats.  After 2 baseline measurements of systemic hemodynamics on days 5 and 7 after surgery, 
either low, medium, or high dose rhRLX or vehicle was administered by osmotic minipump.  
Systemic hemodynamics were again assessed on days 3, 6, 8 and 10 after initiation of low or 
medium dose rhRLX or vehicle infusion.  Systemic hemodynamics were assessed on days 3 and 
6 after initiation of high dose rhRLX. 
Each measurement consisted of 4 to 6 recordings of cardiac output and blood pressure 
waveforms obtained when the rat was either sleeping or resting.  At least 10 min was allowed 
between recordings.  These measurements were obtained between 9am and 3pm. 
4.1.5 Measurement of Cardiac Output 
To measure cardiac output, we used the thermodilution technique [36].  Ringer’s solution 
of known volume and temperature was injected into the anterior vena cava using the Micro 
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Injector 400 (Columbus Instruments).  The cardiac output was calculated from the change in 
blood temperature (Cardiotherm 400R, Columbus Instruments).  The cardiac output as 
determined by the Cardiotherm 400R was calculated as: 
CO ൌ
ሾሺBT െ ITሻ כ VIሿ
׬ BTሺtሻ
 
where, BT is the blood temperature (recorded by the thermocouple implanted in the abdominal 
aorta), IT is the injectate temperature (room temperature), VI is the injectate volume (150 μL), 
and BT(t) is the blood temperature as a function of time. 
4.1.6 Measurement of Instantaneous Aortic Pressure Waveforms 
Instantaneous aortic pressure was recorded using a blood pressure telemetry system (Data 
Sciences International, St. Paul, MN USA) [37].  The aortic pressure was recorded by a pressure 
catheter implanted in the aortic arch via the right carotid artery and transmitted to an external 
receiver.  Steady-state aortic pressure was digitized online using a PC-based data acquisition 
system with 16 bit resolution and 2000 Hz sampling rate and stored as text files for off-line 
analysis.  Each measurement consisted of a 30 second sampling duration. 
4.1.7 Aortic Pressure Analysis 
Analysis of the acquired data and calculation of global AC was performed by a custom 
computer program developed using MATLAB software (MathWorks Inc., Natick, MA USA).  
Briefly, individual beats were selected (3 – 15 cycles) from the 10 seconds of the aortic pressure 
recording, immediately preceding the measurement of cardiac output.  The ensemble was 
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averaged as described by Burattini et al. [38] to yield a single representative beat for each trial.  
The mean arterial pressure (MAP), peak systolic pressure (Ps), and end diastolic pressure (Pd) 
were calculated from this averaged beat.  Pulse pressure (PP) was calculated as Ps – Pd.  Systemic 
vascular resistance (SVR) was calculated by dividing the MAP by CO. 
4.1.8 Global Arterial Compliance 
Two measures of global arterial compliance were calculated.  The first, ACarea, was 
calculated from the diastolic decay of the aortic pressure waveform [P(t)] using the area method 
[2]: 
ACୟ୰ୣୟ ൌ
Aୢ
ሾSVR כ ሺPଵ െ Pଶሻሿ
 
where P1 and P2 are the pressures at the beginning and end of the diastolic decay curve, 
respectively, and Ad is the area under the P(t) waveform over this region.   
The second measure of global arterial compliance was calculated as the stroke volume 
(SV)-to-pulse pressure (PP) ratio [39]:   
AC ൌ
SV
PP
 
Stroke volume was defined as: 
SV ൌ
CO
HR
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4.2 SYSTEMIC HEMODYNAMICS AND ARTERIAL PROPERTIES IN MID AND 
LATE-PREGNANT RATS 
4.2.1 Animals 
See Section 4.1.1 above.  After being habituated to the experimental conditions, rats were 
either housed with males or remained as virgin controls.  The presence of spermatozoa in the 
vaginal lavage was considered day 0 of gestation. 
4.2.2 Animal Instrumentation 
See Section 4.1.2 above for details regarding the surgical procedure used. Of note, 
pregnant rats studied at mid-gestation were instrumented between days 4 and 6 of gestation while 
rats studied at late-gestation were instrumented between days 8-10.  
4.2.3 Administration of relaxin-neutralizing antibodies 
Neutralizing antibodies against rat relaxin (MCA1) or control antibodies against 
fluorescein (MCAF) were administered via daily i.v. injection between 12 and 4 PM for up to 8 
days beginning on day 8 of gestation.  Each injection containing 5.0 mg of antibody in 0.5 ml of 
phosphate buffered saline (PBS) was infused over 5 minutes into the femoral venous catheter 
[23, 40, 41].  Other pregnant rats were administered PBS vehicle to serve as a second untreated-
pregnant control group. 
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4.2.4 Measurements of Hemodynamics and Determination of Arterial Mechanical 
Properties 
See Section 4.1.5 – 4.1.8 above for experimental procedures used.  Of note, systemic 
hemodynamics and arterial properties were assessed on two separate days between gestational 
days 11 and 15 in rats studied at mid-gestation and days 18 and 21 in rats studied at late-
gestation.  The average values of each given variable assessed on the two separate days from 
each animal was taken to be the representative value of that variable for that animal. 
4.3 PASSIVE ARTERIAL MECHANICAL PROPERTIES 
4.3.1 Animals 
Table 1 below lists the different animal models and arteries used in this work.  The 
protocols used for administration of relaxin and vehicle or relaxin neutralizing and control 
antibodies are described in Sections 4.1.3 and 4.2.3 above. 
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Table 1. Animal Models Utilized to Study Effects of Relaxin on Passive Arterial Mechanical 
Properties 
Species Gender Stage of Pregnancy 
Treatment  or 
Genotype Artery 
Mechanical 
Test 
Rat Female Nonpregnant Relaxin/Vehicle Small Renal Uniaxial 
Rat Female Midpregnant MCA1/MCAF Small Renal Uniaxial 
Rat Female Midpregnant MCA1/MCAF Mesenteric Uniaxial 
Mouse Female Nonpregnant Relaxin/Vehicle Small Renal Uniaxial 
Mouse Female Nonpregnant Relaxin/Vehicle Ext. Iliac Uniaxial 
Mouse Female Nonpregnant Relaxin/Vehicle Small Renal Biaxial 
Mouse Female Nonpregnant Relaxin/Vehicle Ext. Iliac Biaxial 
Mouse Male N/A Rlx+/+ Small Renal Uniaxial 
Mouse Male N/A Rlx-/- Ext. Iliac Uniaxial 
4.3.2 Isolation and Preparation of Arterial Segments 
For isolation of small renal arteries, a kidney was removed and placed in ice-cold HEPES 
buffered physiological saline solution (PSS, a modified Kreb’s buffer).  The HEPES PSS was 
composed of (in mmol/L): sodium chloride 142, potassium chloride 4.7, magnesium sulfate 1.17, 
calcium chloride 2.5, potassium phosphate 1.18, HEPES 10, glucose 5.5, and was pH 7.4 at 
37oC.  A stereo dissecting microscope, fine forceps and iridectomy scissors were used to isolate 
interlobar arteries as described by Gandley et al. [29].  Briefly, the arteries were exposed by 
carefully dissecting the overlying tissue.  The main renal artery is typically divided into three 
branches in each half of the kidney which then further bifurcates to form two smaller arteries that 
give rise to the arcuate arteries. Segments of these smaller arterial branches were dissected free 
from surrounding medullary tissue.  For isolation of mesenteric arteries, the mesenteric arcade 
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was removed and placed in ice-cold HEPES buffered PSS.  Segments of first-order mesenteric 
arteries were then carefully dissected free from the surrounding fatty tissue.  Finally, for isolation 
of external iliac arteries the animals were placed in the supine position and an incision was made 
along the both hind legs to expose the iliac arteries.  Segments of the external iliac arteries along 
with the surrounding tissue were then removed and placed in ice-cold HEPES buffered PSS.  The 
arterial segments were then carefully dissected free from the surrounding tissue. 
Following isolation, arterial segments were then transferred to an isobaric arteriograph 
(Living Systems Instrumentation, Burlington, VT USA) and mounted on two glass micro-
cannulae suspended in the chamber.  After the residual blood was flushed from the lumen of the 
artery, the distal cannula was occluded to prevent flow.  Of note, for biaxial mechanical testing 
the distal cannula was replaced with a metal hook that was attached to a force transducer (Aurora 
Scientific, Model 400A) which enabled us to measure axial force (see Appendix A).  In this 
configuration, the artery was occluded with a suture and then tied to the metal hook. In both 
configurations, the proximal cannula was attached to a pressure transducer, a pressure servo-
controller and a peristaltic pump.  The servo-controller maintained a selected intraluminal 
pressure that can be changed in a stepwise manner. An electronic dimension analyzing system 
obtained arterial diameter measures.  Prior to experimentation, the vessels were heated to 37oC 
(the arteriograph chamber was maintained at this temperature for the duration of the experiment) 
and incubated in the bath with 0.01 M papaverine and 0.01 M EGTA in calcium-free HEPES 
PSS.   
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4.3.3 Pressure-Diameter Data at Fixed Axial Load 
4.3.3.1 Experimental Protocol 
After a 30 min equilibration period, transmural pressure was increased in up to 14 steps 
from at 0 to 120 mmHg.  Inner and outer diameters as well as wall thickness were measured 
following each pressure step when the vessel had reached a steady state.  These measurements 
were used to compute uniaxial stiffness parameters as described by Cholley et al [42]. 
4.3.3.2 Uniaxial (Circumferential) Stress-Strain Analysis 
Measurements of the inner (Di0) and outer diameters (Do0) and wall thickness (H0) in the 
unloaded configuration (typically occurred at transmural pressures between 0 and 5 mmHg) were 
used to compute the unstressed muscle area (AM0): 
AM଴ ൌ π כ H଴ כ ሺD୧଴ ൅ H଴ሻ 
Assuming an incompressible arterial wall, wall thickness was calculated at each given pressure 
step (HI) using the calculated unloaded muscle area and the lumen area (Ai) for that given 
pressure: 
HI ൌ ඨ
AM଴ ൅ A୧
π
െ ඨ
A୧
π
 
From this inner (Ri), outer (Ro), and midwall radii (Rm) was calculated as: 
R୧ ൌ ඨ
A୧
π
 
R୭ ൌ ඨ
AM଴ ൅ A୧
π
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R୫ ൌ
R୧ ൅ R୭
2
 
and midwall strain (εm) was calculated as: 
ε୫ ൌ
R୫
R୫଴
 
where Rm0 represents the midwall radius in the unloaded state.  Circumferential wall stress (σ) 
was calculated from the intraluminal pressure (P) as: 
σ ൌ 2 כ P כ ൬
R୧ כ R୭
R୫
൰
ଶ
כ ൫R୭
ଶ െ R୧
ଶ൯
ିଵ
     
Finally, the σ–Rm and σ–εm relationships were fitted to a third-order polynomial function: 
σ ൌ A଴ ൅ ሺAଵ כ R୫ሻ ൅ ൫Aଶ כ R୫
ଶ൯ ൅ ൫Aଷ כ R୫
ଷ൯, or 
σ ൌ A଴ ൅ ሺAଵ כ ε୫ሻ ൅ ሺAଶ כ ε୫ଶሻ ൅ ሺAଷ כ ε୫ଷሻ 
where A0, A1, A2 and A3 are constants.  These derived constants were then used to compute 
average values of σ at prescribed values of Rm and εm for each given artery. 
4.3.4 Pressure-Diameter Data at Varying Axial Loads 
4.3.4.1 Experimental Protocol 
As stated above (see section 4.3.2), for biaxial mechanical testing the proximal end of the 
arterial segment was tied to a force transducer thus enabling us to measure axial force.  
Simultaneously, pressure-diameter and force-length data were attained using this setup.  
Transmural pressure was increased in up to 12 steps from at 0 to 120 mmHg at a given axial 
length; each cycle was then repeated at incrementing axial stretches.  Inner (Di) and outer (Do) 
diameters, wall thickness (H), axial length (L) and force (F) were measured following each 
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pressure step when the vessel had reached a steady state.  These measurements were then used 
compute biaxial stiffness parameters as described by Schulze-Bauer et al. [43]. 
4.3.4.2 Biaxial Stretches and Cauchy Stresses 
Circumferential (λθ) and axial (λz) stretches were calculated as: 
λ஘ ൌ
R୭
R୭଴
 
λ୸ ൌ
L
L଴
 
where Ro0 and L0 represent the vessel outer radius and axial length in the load-free configuration.  
Circumferential (σθθ) and axial (σzz) Cauchy stresses were calculated from the collected data as: 
σ஘஘ ൌ P כ ቆ
R୭ כ λ஘
ଶ
H
െ 1ቇ 
σ୸୸ ൌ
F
π כ H כ ሺ2 כ R୭ െ Hሻ
൅
σ஘஘
2
 
where, H0 represents wall thickness in the load-free configuration and P represents the 
intraluminal pressure.   
4.3.4.3 Second Piola-Kirchhoff Stresses and Green Lagrange Strains 
 
The second Piola-Kirchhoff stresses, Sθθ and Szz, were defined as: 
S஘஘ ൌ
σ஘஘
λ஘
ଶ 
S୸୸ ൌ
σ୸୸
λ୸
ଶ 
From the circumferential and axial stretches, the Green-Lagrange strains are calculated as: 
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E஘஘ ൌ
λ஘
ଶ െ 1
2
 
E୸୸ ൌ
λ୸
ଶ െ 1
2
 
where, Eθθ and Ezz represent Green-Lagrange circumferential and axial strains, respectively.   
4.3.4.4 Strain Energy Function 
Circuferential and axial stresses can also be expressed as derivatives of a given strain-
energy function (Ψ) as follows: 
S஘஘
ந ൌ
∂ψ
∂E஘஘
 
S୸୸
ந ൌ
∂ψ
∂E୸୸
 
We tested several different strain-energy functions to determine which one best described our 
data.  The 7-parameter polynomial model [44]: 
ψ ൌ ൫Cଵ כ E஘஘
ଶ൯ ൅ ሺCଶ כ E஘஘ כ E୸୸ሻ ൅ ൫Cଷ כ E୸୸
ଶ൯ ൅ ൫Cସ כ E஘஘
ଷ൯ ൅ ൫Cହ כ E஘஘
ଶ כ E୸୸൯ ൅
൫C଺ כ E஘஘ כ E୸୸
ଶ൯ ൅ ൫C଻ כ E୸୸
ଷ൯, 
the 4-parameter exponential model [45]: 
ψ ൌ Cଵ כ ൣexp൫Cଶ כ E஘஘
ଶ ൅ Cଷ כ E஘஘ כ E୸୸ ൅ Cସ כ E୸୸
ଶ൯ െ 1൧, 
and the 7-paramter mixed polynomial-exponential model [46]: 
ψ ൌ ൫Cଵ כ E஘஘
ଶ൯ ൅ ሺCଶ כ E஘஘ כ E୸୸ሻ ൅ ൫Cଷ כ E୸୸
ଶ൯ ൅ Cସ כ ൣexp൫Cହ כ E஘஘
ଶ ൅ C଺ כ E஘஘ כ E୸୸ ൅
C଻ כ E୸୸
ଶሻ െ 1൧. 
Of these three, we found that the mixed polynomial-exponential model best described our 
data.  Using this model, we derived the 7 constitutive parameters (C1, C2, C3, C4, C5, C6, and C7) 
that best-fit each vessel using the Levenberg-Marquardt algorithm in Matlab.  From these 
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parameters we computed the 2-dimensional behavior of strain energy (i.e. the magnitude of 
strain energy at simultaneously varying levels of axial and circumferential strain) for each vessel.   
4.4 SMOOTH MUSCLE CELL CHARACTERISTICS 
4.4.1 Animals 
This work was done in vehicle and relaxin treated female C57-BL/6J mice 6-8 weeks of 
age, male wild-type (Rlx+/+) and relaxin knock-out (Rlx-/-) mice 8-12 weeks old (provided by Dr. 
Laura J. Parry, Department of Zoology, Univeristy of Melbourne, Parkville, Victoria, Australia).  
For this work, we studied external iliac, and small renal arteries in both sets of mice. 
4.4.2 Arterial Cross-Sections 
Isolated external iliac arteries were fixed in 2% Paraformaldehyde-PBS at 4ºC for 4 hours 
after which they were rinsed in PBS and cryoprotected in 30% sucrose at 4ºC for at least 24 
hours. These arteries were then embedded in OCT and cut into several 6μm thick sections and 
collected on Superfrost Plus microscope slides.  To obtain cross-sections of small renal arteries, 
an entire kidney was fixed in Paraformaldehyde, and cryoprotected in sucrose after which it was 
embedded in OCT in a configuration that ensured that the cut was in the cross sectional direction 
of small renal arteries.    The slides were stored in a freezer (-80oC) until the sections were ready 
to be stained at which point each section was rehydrated with PBS and stained using the 
techniques described below (see Section 4.4.4).  
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4.4.3 Smooth Muscle Cell Isolation 
Small renal arteries were isolated from vehicle or rhRLX-treated mice as described above 
(see Section 4.3.2).  Arterial segments were then cut into smaller pieces and placed in a small 
eppendorf tube.  An enzyme solution containing 2 mg/ml collagenase (Worthingon Corp., 
Lakewood, NJ) and 0.8 mg/ml elastase (Sigma-Aldrich, St. Louis, MO) in DMEM culture 
medium (Invitrogen/Gibco, Carlsbad, California) was poured into the tube.  The tube was then 
closed with a cap and incubated at 37oC for 1-2 hours.  The enzyme solution was gently 
triturated periodically during this incubation period to help with tissue dispersion.  Following 
digestion, the solution was centrifuged at 300 RPM.  The pellet was resuspended in culture 
medium.  The cells were then seeded on collagen-coated Superfrost Plus microscope slides and 
incubated for another hour after which cells were stained and imaged using the techniques 
described below. 
4.4.4 Immunofluorescence Staining 
Each slide (both arterial cross-sections and seeded cells) was permeabilized with 0.1% 
triton X for 15 min after which they were rehydrated with 3 washes of PBS followed by 5 
washes of 0.5% BSA.  The slides were then treated with blocking solution (2% BSA) for 1 hour 
at room temperature followed by 5 washes with 0.5% BSA.  They were then incubated with a 
primary antibody for smooth muscle actin (Sigma-Aldrich, St. Louis, MO) at room temperature 
followed by an additional 5 washes with 0.5% BSA.  Next the slides were stained with a FITC-
conjugated secondary antibody for another hour (Sigma-Aldrich, St. Louis, MO) at room 
temperature followed by 5 washes with 0.5% BSA and 5 more washes with PBS.  Of note, some 
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samples were stained directly with a Cy3-conjugated smooth muscle actin antibody (Sigma-
Aldrich, St. Louis, MO) followed by 5 washes with 0.5% BSA and 5 more washes with PBS.  
Finally the nuclei were stained with Hoescht or DAPI (Sigma-Aldrich, St. Louis, MO) for 30 
seconds followed by 2 washes with PBS.  The slides were then cover-slipped with gelvatol 
mounting media and stored at 4oC in the dark.  The slides were imaged with an Olympus Provis 
fluorescence microscope. 
4.4.5 Arterial Smooth Muscle Cell Density and Size 
Fluorescent images were analyzed using ImageJ software (Wayne Rashband, National 
Institutes of Health, USA).  Figure 2A represents a sample image obtained after a cross-section 
of a small renal artery was stained for smooth muscle actin and nuclei.  The arterial wall was 
identified as the area of the artery stained positive for smooth muscle actin (red) while nuclei 
stained with Hoescht (or DAPI) appeared as blue.   Nuclei belonging to smooth muscle cells 
(SMC) were designated as those that lay within the smooth muscle actin-positive region of the 
arterial wall.  Smooth muscle cell density for each arterial cross-section was quantified as the 
ratio of number of SMC to arterial wall area.  Each individual, discernable SMC within a cross-
section was outlined and the average SMC size per cross-section was measured.  The mean SMC 
density and size for each artery was determined by analyzing at least 4 non-consecutive cross-
sections of that artery.  Of note, each field of view contained a single arterial cross-section as 
shown in Figure 2A.  Figure 2B represents a sample image obtained after cells isolated from a 
small renal artery were stained for smooth muscle actin and nuclei.  Smooth muscle cells were 
identified as the cells stained positive for smooth muscle actin (red).  Individual cell sizes were 
measured and the average cell size per artery was computed. 
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Figure 2. Arterial Cross-Section Stained for α-SMA and Nuclei. 
(A) Mouse kidneys were sectioned at 6 μm thickness. Small renal arteries were identified by 
positive staining for smooth muscle actin.  Smooth muscle actin was stained as red, while nuclei 
were stained as blue. The scale bar equals 10 μm.  (B) Isolated small renal arteries were 
enzymatically digested and cells were seeded on a collagen-coated Superfrost Plus microscope 
slide.  Smooth muscle actin was stained as red, while nuclei were stained as blue. The scale bar 
equals 10 μm.   
 
4.5 ARTERIAL WALL BIOCHEMICAL COMPOSITION 
4.5.1 Animals 
This work was done in conjunction with our work examining the effects of relaxin on 
vascular smooth muscle cell characteristics.  Accordingly, we used the same animal models.  See 
Section 4.4.1 above.  
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4.5.2 Total Protein Content 
Total protein content was determined using the Pierce BCA Protein Assay Kit (Pierce, 
Rockford IL) per instructions provided by the manufacturer.  Briefly, the arteries were cleaned of 
any extraneous tissue, lyophilized, minced and digested for 48 hours in a pepsin-HCL solution 
(0.05 g of pepsin in 50 ml of 0.01N HCL; 100 μl per 0.001 g of tissue).  Following the digestion, 
the solution was vortexed and a 25 μl sample was added to 100 μl of the BCA Working Reagent.  
This solution was incubated at 37oC for 30 minutes and then allowed to cool to room 
temperature.  Absorbance was determined at 550nm on a spectrophotometer (Kinetic Microplate 
Reader; Molecular Devices, Sunnyvale, CA).   
4.5.3 Collagen Content 
Isolated arteries were assayed for total collagen levels using the Sircol collagen dye 
binding assay (Biocolor Ltd., Northern Ireland) according to the manufacturer’s instructions.  
Briefly, the arteries were be cleaned of any extraneous tissue, lyophilized, minced and digested 
for 48 hours in a pepsin-HCL solution (0.05 g of pepsin in 50 ml of 0.01N HCL; 100 μl per 
0.001 g of tissue).  Following the digestion, the solution was vortexed and a 50 μl sample was 
collected.  One milliliter of Sirius red dye was then added to this sample and mixed on a rocking 
platform for 1 hour.  The samples were then centrifuged (10,000 RPM for 10 min) and the 
precipitate was digested in 1 ml of acetic acid solution included in the kit.  Absorbance was 
determined at 550 nm (Kinetic Microplate Reader; Molecular Devices, Sunnyvale, CA).  
Relative collagen content was quantified as the ratio of collagen concentration to total protein 
concentration. 
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4.5.4 Elastin Content 
Elastin levels were determined using the Fastin Elastin assay kit and protocol provided by 
the same manufacturer (Biocolor Ltd., Northern Ireland).  Briefly, arteries were lyophilized 
overnight and tissues dry weight was recorded.  Each artery was then placed into 0.25 M oxalic 
acid (2ml of oxalic acid solution per 0.1g of tissue).  The samples were then heated to 90°C for 
1 hour, and centrifuged (3000 RPM @ 4oC for 10 min).  The supernatant was collected.  The 
same volume of oxalic acid as before was added to the remaining pellet and the above procedure 
of heating and centrifugation was repeated four additional times.  Each of the collected 
precipitates was pooled and added to 1 ml of elastin precipitating reagent.  The samples were 
then placed in the refrigerator (4oC) overnight.  After 24 hours the extracts were spun down 
(2000 RPM @ 4oC for 10 min) and the supernatants were poured off.  One milliliter of elastin 
dye reagent and 100μl of 90% ammonium sulfate was added to the extracts.  The solution was 
mixed on a rocking platform for 1 hour after which the samples were spun down again (12000 
RPM for 10min at room temperature) and the supernatant discarded.  Finally, 1 ml of destaining 
agent was added to the extracts.   Absorbance was determined at 550nm on a spectrophotometer 
(Kinetic Microplate Reader; Molecular Devices, Sunnyvale, CA).  Relative elastin content was 
quantified as the ratio of the mass of elastin to tissue dry weight. 
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4.6 STATISTICAL ANALYSES 
Data are presented as means + SEM and P < 0.05 was taken to be significant. 
4.6.1 Systemic Hemodynamics and Arterial Mechanical Properties  
4.6.1.1 Vehicle and rhRLX-Treated Conscious Female and Male Rats 
Two-factor repeated-measures ANOVA was used to compare mean values of systemic 
hemodynamics and arterial mechanical properties among vehicle and rhRLX-treated rats.  The 
same analysis was used to compare mean values between low dose male and female rats at 
various time points. If significant main effects or interactions were observed, comparisons 
between groups were performed using Fisher’s LSD or Dunnett’s test.  Student’s unpaired ‘t’ test 
was used to compare the composite mean values during infusion of rhRLX (i.e., values averaged 
over all time points during rhRLX or vehicle infusion) with baseline. 
4.6.1.2 Conscious Mid and Late-Pregnant Rats 
One-factor randomized block ANOVA was used with 3 levels corresponding to the 
MCA1 and MCAF-treated mid or late-pregnant rats, and the virgin controls.  If a significant 
main effect was observed, then comparisons among groups were performed using Fisher’s least 
significant difference (LSD) test. 
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4.6.2 Arterial Passive Mechanics 
4.6.2.1 Uniaxial Analysis 
Least squares regression analysis was performed on stress-midwall radius relationships.  
Analysis of excess variance (or extra sum of squares) [47] was used to compare these 
relationships between vehicle and relaxin-treated groups.   
4.6.2.2 Biaxial Analysis 
 
Student’s unpaired ‘t’ test was used to compare the mean values of maximum strain 
energies of small renal arteries isolated from vehicle and rhRLX-treated mice. 
4.6.3 Smooth Muscle Cell Characteristics and Arterial Wall Biochemical Composition 
Student’s unpaired ‘t’ test was used to compare the mean values of SMC density and size, 
arterial collagen content, and arterial elastin content of rhRLX-treated animals versus vehicle 
control.  Similarly, Student’s unpaired ‘t’ test was used to compare the corresponding data from 
Rlx-/- and Rlx+/+ mice. 
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5.0  RESULTS 
5.1 SYSTEMIC HEMODYNAMICS AND ARTERIAL PROPERTIES IN 
CONSCIOUS FEMALE RATS 
Specific Aim 1A.  To determine systemic hemodynamics and arterial load in conscious, 
nonpregnant female rats administered rhRLX. 
Specific Aim 1B.  To determine the dose-response of systemic hemodynamics and arterial load 
in conscious, nonpregnant female rats administered rhRLX. 
5.1.1 Female Time Control Rats 
Portions of this work have been previously published elsewhere [48].  In order to 
determine the stability of systemic hemodynamics and arterial load using our conscious rat 
technique we studied control rats over a 17-day period after surgery (Table 2).  Heart rate (HR) 
declined significantly due to a training effect as has been previously reported [49].  Stroke 
volume (SV) reciprocally increased such that cardiac output (CO) was unchanged.  All other 
variables did not change significantly over the 17-day period after surgery, thus this conscious 
rat model can be used to obtain meaningful data under experimental conditions. 
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Table 2. Absolute Values of Systemic Hemodynamics and Arterial Properties in Female, Time 
Control Rats 
Days 
After 
Surgery 
ΔT 
(oC) 
CO 
(mL/min) 
HR* 
(bpm)
SV* 
(mL) 
ACarea 
(μl/mmHg)
SVR 
(mmHg.s/mL) 
MAP 
(mmHg) 
4-5 0.37±0.01 119±3 428±7 0.28±0.01 6.8±0.3 57±2 107.6±0.8
7-8 0.37±0.01 121±3 378±8 0.32±0.01 7.2±0.3 55±2 107.3±1.5
9-10 0.38±0.01 120±4 382±8 0.31±0.01 6.9±0.3 55±2 108.1±1.5
13-14 0.35±0.01 115±4 354±5 0.32±0.01 7.3±0.3 58±2 107.0±1.5
16-17 0.32±0.02 122±3 349±7 0.36±0.01 8.0±0.4 52±2 103.7±2.2
Mean±SEM. N=5 rats (longitudinal measurements were made in each animal at the time-points 
specified above).  ΔT, change in blood temperature after injection of Ringer’s solution into the 
right heart; CO, cardiac output; HR, heart rate; SV, stroke volume; ACarea, global arterial 
compliance calculated using area method; SVR, systemic vascular resistance; MAP, mean 
arterial pressure.  *P < 0.05 by single factor repeated measures ANOVA. 
5.1.2 Female Rats Administered Vehicle (Control) 
Portions of this work have been previously published elsewhere [48].  These results were 
derived from 3 rats administered the vehicle for rhRLX at the infusion rate of 4 μg/h, and from 
another 3 rats administered the vehicle for rhRLX at the infusion rate of 25 μg/h for 10 days 
(these correspond to the infusion rates for the low and medium dose administration of rhRLX, 
respectively).  The results were comparable, and therefore, combined.  Figures 3 and 4 depict 
the percent change from baseline of systemic hemodynamics and arterial properties.  Similar to 
the time control studies, there was a significant decrease in heart rate, which was offset by an 
insignificant rise in stroke volume, such that CO remained unchanged.  All other variables 
remained relatively constant.  Combining all of the time points during administration of vehicle 
yielded overall changes in CO, global AC, and SVR of -1.4 + 1.3, 2.2 + 4.6, and 0.4 + 3.4 % of 
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baseline, respectively (all P NS vs. baseline).  As expected, there was no measurable rhRLX in 
the serum, and the osmolality was 309 + 6 mOsm/kg water. 
 
 
Figure 3. Temporal Pattern of Changes in Systemic Hemodynamics in Conscious Female Rats 
Administered Low Dose rhRLX 
 
Percent change from baseline for (A) cardiac output, (B) heart rate, (C) stroke volume, and (D) 
mean arterial pressure in female rats administered low dose recombinant human relaxin (rhRLX; 
4 μg/h) or vehicle.  † P < 0.05 vs. baseline, * P < 0.05 vs. vehicle at the same time point by 
Fisher’s or Dunnett’s posthoc tests. 
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Figure 4. Temporal Pattern of Changes in Systemic Arterial Properties in Conscious Female 
Rats Administered Low Dose rhRLX 
 
Percent change from baseline for (A) systemic vascular resistance, (B) global arterial compliance 
(ACarea), and (C) ratio of stroke volume-to-pulse pressure in female rats administered low dose 
recombinant human relaxin (rhRLX; 4 μg/h), or vehicle.  † P < 0.05 vs. baseline, * P < 0.05 vs. 
vehicle at the same time point by Fisher’s or Dunnett’s posthoc tests. 
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5.1.3 Female Rats Administered Low Dose rhRLX (4 μg/h) 
Portions of this work have been previously published elsewhere [48].  The absolute 
values for systemic hemodynamics and arterial properties from female rats administered low 
dose rhRLX are shown in Table 3, while Figs. 3 and 4 show the temporal pattern of percentage 
change from baseline.  Low dose rhRLX significantly increased CO relative to baseline and to 
vehicle infusion (Fig. 3A).  The infusion of rhRLX prevented the decline normally observed in 
HR (c.f. vehicle, Fig. 3B), and the hormone significantly increased SV (Fig. 3C).  Thus, 
increases in both SV, and to a lesser degree, HR combined to raise the CO relative to vehicle-
infused rats.  Systemic vascular resistance fell significantly relative to baseline and to vehicle 
infusion (Fig. 4A), while MAP remained unchanged (Fig. 3D).  Global AC as measured by the 
area method significantly increased relative to baseline and to vehicle infusion (Fig. 4B).  There 
was no significant change in pulse pressure; however, the ratio of stroke volume-to-pulse 
pressure, another index of arterial compliance, increased significantly during the infusion of low 
dose rhRLX relative to baseline and to vehicle infusion (Fig. 4C). 
For variables that showed a significant change with low dose rhRLX administration (i.e., 
significant P value for relaxin and/or interaction), we further examined the time course of these 
changes.  This was accomplished by post hoc pairwise comparisons of data at different time 
points (Fisher’s LSD).  Both CO and SV were significantly higher than baseline at day 3.  While 
SV continued to increase until day 8 (P < 0.05, day 8 vs. day 3) (Fig. 3C), there were no 
significant changes with time in CO beyond day 3 (Fig. 3A).  This was partly a result of a small, 
but insignificant, fall in HR from day 3 to day 8 (Fig. 3B).  SVR and both measures of global AC 
were significantly altered at day 3; thereafter there were no further significant changes (Fig. 4).  
In general, maximal changes in systemic hemodynamics and arterial properties following low 
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dose rhRLX administration were observed at the earliest time point examined (day 3), with no 
further temporal alterations. 
Combining all of the time points during administration of low dose rhRLX yielded an 
overall increase in CO and global AC of 19.2 + 4.8 and 21.4 + 3.6 % above baseline, 
respectively, and an overall decrease in SVR of 15.5 + 2.4 % below baseline (all P < 0.01 vs. 
baseline).  Serum rhRLX and osmolality were 14 + 2 ng/ml and 284 + 2 mOsm/kg water, 
respectively.  The latter significantly decreased compared to vehicle infusion (P < 0.05 by 
Student’s “t” test). 
 
Table 3. Absolute Values of Systemic Hemodynamics and Arterial Properties in Female Rats 
Administered Low Dose rhRLX 
Days After 
Minipump 
ΔT 
(oC) 
CO* 
(mL/min) 
HR 
(bpm) 
SV* 
(mL) 
ACarea* 
(μl/mmHg)
SVR* 
(mmHg.s/mL)
MAP 
(mmHg) 
Baseline 0.34±0.02 128±2 417±6 0.31±0.01 6.2±0.3 51±2 108.9±3.4
2-3 0.31±0.01 151±6 436±9 0.35±0.01 7.2±0.3 43±3 107.3±3.1
6 0.31±0.01 149±7 419±6 0.36±0.02 7.1±0.5 46±3 111.3±3.2
8 0.31±0.01 159±7 427±11 0.37±0.02 7.4±0.5 44±2 114.1±3.6
10 0.31±0.01 153±5 418±10 0.37±0.01 7.7±0.5 44±2 112.1±3.8
Mean±SEM.  N=6 rats (longitudinal measurements were made in each animal at the time-points 
specified above).  Two baseline measurements were made on days 5 and 7 after surgery.  These 
results were averaged for each rat.  ΔT, change in blood temperature after injection of Ringer’s 
solution into the right heart; CO, cardiac output; HR, heart rate; SV, stroke volume; ACarea, 
global arterial compliance calculated using area method; SVR, systemic vascular resistance; 
MAP, mean arterial pressure.  *P < 0.05 by single factor repeated measures ANOVA. 
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5.1.4 Female Rats Administered Medium Dose rhRLX (25 μg/h) 
Portions of this work have been previously published elsewhere [50].  The absolute 
values for systemic hemodynamics and arterial properties from female rats administered medium 
dose rhRLX are shown in Table 4.  The results for the medium dose infusion were comparable 
to the low dose administration in direction, but were somewhat less, although not significantly 
so, in magnitude.  The temporal analysis of changes in individual variables with medium dose 
rhRLX was performed in a manner similar to that for the low dose rhRLX.  Once again, CO 
(Figure 5A), SV (Figure 5C), SVR (Figure 6A), and global AC (SV/PP method) (Figure 6C) 
were maximally altered by the earliest time point examined (day 3), with no further significant 
changes thereafter.  The temporal response of global AC as calculated by the area method 
(Figure 6B) deviated slightly from this general pattern as ACarea at day 6 was not significantly 
different from that at baseline.  Although we do not have a specific explanation, we believe this 
to be an aberration.  This belief is based on the observations that the second measure of global 
AC at all time points (Fig. 6C) and ACarea at day 3 (Fig. 6B) were significantly higher than 
baseline. 
Combining all of the time points during administration of medium dose rhRLX yielded 
an overall increase in CO and global AC of 14.1 + 3.2 and 15.6 + 4.7 % above baseline, 
respectively, and an overall decrease in SVR of 9.7 + 2.4 % below baseline (all P < 0.02).  
Serum relaxin and osmolality were 36 + 3 ng/ml and 287 + 1 mOsm/kg water, respectively.  The 
latter significantly decreased compared to vehicle infusion (P < 0.05 by Student’s “t” test). 
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Table 4. Absolute Values of Systemic Hemodynamics and Arterial Properties in Female Rats 
Administered Medium Dose rhRLX 
Days After 
Minipump 
ΔT 
(oC) 
CO* 
(mL/min) 
HR 
(bpm) 
SV 
(mL) 
ACarea* 
(μl/mmHg)
SVR* 
(mmHg.s/mL)
MAP 
(mmHg) 
Baseline 0.37±0.02 129±6 438±10 0.30±0.02 7.7±0.7 53±3 111.6±3.7
2-3 0.33±0.02 141±7 454±13 0.31±0.02 8.5±0.8 49±4 110.2±4.9
6 0.35±0.02 147±4 432±10 0.34±0.01 8.1±0.4 48±2 116.9±3.8
8 0.35±0.03 150±5 451±9 0.33±0.01 9.4±0.7 45±2 112.1±2.8
10 0.34±0.02 146±9 442±6 0.33±0.02 9.2±1.0 48±3 115.2±5.8
Mean±SEM.  N=7 rats (longitudinal measurements were made in each animal at the time-points 
specified above).  Two baseline measurements were made on days 5 and 7 after surgery.  These 
results were averaged for each rat.  ΔT, change in blood temperature after injection of Ringer’s 
solution into the right heart; CO, cardiac output; HR, heart rate; SV, stroke volume; ACarea, 
global arterial compliance calculated using area method; SVR, systemic vascular resistance; 
MAP, mean arterial pressure.  *P < 0.05 by single factor repeated measures ANOVA. 
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Figure 5. Systemic Hemodynamics in Conscious Female Rats: Dose Response 
 
Temporal changes in systemic hemodynamics in response to three doses of recombinant human 
relaxin administration in female rats: low (4 μg/h), medium (25 μg/h), and high (50 μg/h).  
cardiac output (A), heart rate (B), stroke volume (C), and mean arterial pressure (D) data are 
presented as percentages of baseline.  * P < 0.05 vs. baseline (post-hoc Fisher’s LSD). 
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Figure 6. Systemic Arterial Properties in Conscious Female Rats: Dose Response. 
 
Temporal changes in systemic arterial properties in response to three doses of recombinant 
human relaxin administration in female rats: low (4 μg/h), medium (25 μg/h), and high (50 
μg/h).  Systemic vascular resistance (A) and two measures of global arterial compliance, ACarea 
(B) and SV/PP (C), data are presented as percentages of baseline.  * P < 0.05 vs. baseline (post-
hoc Fisher’s LSD). 
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5.1.5 Female Rats Administered High Dose rhRLX (50 μg/h) 
Portions of this work have been previously published elsewhere [50].  Absolute values of 
systemic hemodynamics and arterial properties from female rats administered high dose rhRLX 
are listed in Table 5 and their temporal patterns following the initiation of rhRLX infusion are 
depicted in Figs. 5 and 6.  Serum rhRLX concentration for the high dose infusion (71.5 + 1.6 
ng/ml) was much greater than that of low (14 + 2 ng/ml) and medium (36 + 3 ng/ml) dose 
infusion.  However, there was no change from baseline in any of the systemic hemodynamics 
(Fig. 5) or arterial properties (Fig. 6).  Thus, the effects of rhRLX on systemic hemodynamics 
and arterial properties are apparently biphasic whereby, low (4 μg/ml) and medium (25 μg/ml) 
doses are effective, but high doses are not (50 μg/ml). 
 
Table 5. Absolute Values of Systemic Hemodynamics and Arterial Properties in Female Rats 
Administered High Dose rhRLX 
Days after 
minipump 
ΔT 
(oC) 
CO 
(mL/min) 
HR 
(bpm) 
SV 
(mL) 
ACarea 
(μl/mmHg)
SVR 
(mmHg.s/mL)
MAP* 
(mmHg) 
Baseline 0.34±0.02 134±5 425±14 0.32±0.02 7.0±0.4 53±2 115.9±2.7
3 0.32±0.02 141±6 438±6 0.32±0.01 7.2±0.3 52±2 120.2±3.3
6 0.31±0.01 146±6 437±8 0.33±0.02 7.4±0.4 51±3 121.1±2.8
Mean±SEM.  N=8 rats (longitudinal measurements were made in each animal at the time-points 
specified above).  Two baseline measurements were made on days 5 and 7 after surgery.  These 
results were averaged for each rat.  ΔT, change in blood temperature after injection of Ringer’s 
solution into the right heart; CO, cardiac output; HR, heart rate; SV, stroke volume; ACarea, 
global arterial compliance calculated using area method; SVR, systemic vascular resistance; 
MAP, mean arterial pressure.  *P < 0.05 by single factor repeated measures ANOVA. 
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5.1.6 Summary 
Our data to this point indicate that chronic administration of rhRLX to nonpregnant 
female rats results in an increase in CO and a reduction in systemic arterial load in a biphasic 
manner.  Previous work indicated that the vasodilatory effects of relaxin in female rats were also 
observed in male rats [24].  Accordingly, we next examined the effects of relaxin on systemic 
hemodynamics and arterial properties in male rats. 
5.2 SYSTEMIC HEMODYNAMICS AND ARTERIAL PROPERTIES IN 
CONSCIOUS MALE RATS 
Specific Aim 2.  To determine systemic hemodynamics and arterial load in conscious, male rats 
administered rhRLX and compare these responses to those observed in female rats. 
5.2.1 Male Rats Administered Low Dose rhRLX (4 μg/h) 
Portions of this work have been previously published elsewhere [50].  The temporal 
patterns of systemic hemodynamic variables, expressed as a percentage of baseline values, are 
illustrated in Figure 7 and absolute values of these variables are presented in Table 6.  For the 
purpose of comparison, the data from female rats administered low dose rhRLX are also 
presented in Fig. 7.  Low dose rhRLX significantly increased CO relative to baseline in male rats 
(Fig. 7A).  There was a slight (~6%), but statistically insignificant, rise in HR in the relaxin-
treated male rats (Fig. 7B).  However, there was a greater rise in SV (Fig. 7C) indicating that the 
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elevation in CO resulted primarily from an increase in SV and, to a lesser degree, from a rise in 
HR.  Mean arterial pressure was not significantly changed during rhRLX infusion (Fig. 7D).  At 
the final time point (i.e., day 10 after the onset of rhRLX infusion), there was no statistically 
significant difference between the effects of rhRLX administration on systemic hemodynamics 
in the male and female rats. 
The temporal effects of rhRLX infusion on systemic arterial properties in male rats, 
expressed as a percentage of baseline values, are depicted in Figure 8.  Once again data from 
female rats are also shown for comparison.  Systemic vascular resistance fell significantly 
relative to baseline (Fig. 8A), while both measures of arterial compliance (ACarea and SV/PP) 
were significantly increased (Figs. 8B and 8C).  At the final time point (i.e., day 10 after the 
onset of rhRLX infusion), the changes in systemic arterial properties were not statistically 
different between male and female rats. 
Although the final (peak) responses were similar, relaxin-induced changes in male rats 
tended to be delayed, especially for SVR (Fig. 8A) and ACarea (Fig. 8B).  We expected the two-
way analysis of variance to yield a significant interaction effect.  However this was not the case 
because the difference between male and female responses was typically confined to the first 
time point following the initiation of rhRLX infusion (i.e., day 3) and we do not have sufficient 
power to detect this single time point difference.  In some instances, the interaction effect did 
come close to being significant, e.g., interaction for HR and SVR had P values of 0.09 and 0.14, 
respectively. 
Combining all of the time points during administration of rhRLX yielded overall 
increases in CO and global AC of 20.5 + 4.2 and 19.4 + 6.9% from baseline, respectively, and an 
overall decrease in SVR of 12.7 + 3.9% from baseline (all P < 0.05 vs. baseline).  There was no 
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statistical difference between these results in male rats and those we observed in female rats.  
Serum rhRLX was 17.7 + 1.1 ng/ml, a value similar to that observed in female rats administered 
the same rhRLX regimen, 14.0 + 2.0 ng/ml. 
 
 
Figure 7. Systemic Hemodynamics in Conscious Male Rats Administered Low Dose rhRLX. 
 
Temporal changes in systemic hemodynamics in response to low dose (4 μg/h) recombinant 
human relaxin administration in male and female rats.  cardiac output (A), heart rate (B), stroke 
volume (C), and mean arterial pressure (D) data are presented as percentages of baseline.  * P < 
0.05 vs. baseline (post-hoc Fisher’s LSD).  Although our previous analysis (Figure 3) of SV 
response in female rats alone indicated a significant increase at day 3, the simultaneous analysis 
of male and female responses did not yield a significant interaction term.  Therefore, significant 
increments in SV are shown only for days 6, 8, and 10. 
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Figure 8. Systemic Arterial Properties in Conscious Male Rats Administered Low Dose rhRLX 
 
Temporal changes in systemic arterial properties in response to low dose (4 μg/h) recombinant 
human relaxin administration in male and female rats.  Systemic vascular resistance (A) and two 
measures of global arterial compliance, ACarea (B) and SV/PP (C), data are presented as 
percentages of baseline.  * P < 0.05 vs. baseline (post-hoc Fisher’s LSD).  Although our previous 
analysis (Figure 4) of ACarea and SV/PP responses in female rats alone indicated significant 
increases at days 3 and 6, the simultaneous analyses of male and female responses did not yield 
significant interaction terms.  Therefore, significant increments in ACarea and SV/PP are shown 
only for days 8 and 10. 
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Table 6. Absolute Values of Systemic Hemodynamics and Arterial Properties in Male Rats 
Administered Low Dose rhRLX 
Days after 
minipump 
ΔT 
(oC) 
CO* 
(mL/min) 
HR* 
(bpm) 
SV* 
(mL) 
ACarea* 
(μl/mmHg)
SVR* 
(mmHg.s/mL)
MAP 
(mmHg) 
Baseline 0.32±0.03 148±9 416±12 0.36±0.03 7.5±0.6 49±3 115.8±2.4
3 0.31±0.01 160±6 440±8 0.36±0.01 7.6±0.5 46±1 121.3±3.6
6 0.29±0.02 169±4 441±6 0.38±0.01 7.9±0.3 43±1 119.9±1.7
8 0.27±0.02 178±6 445±4 0.40±0.01 8.7±0.4 41±1 118.8±2.0
10 0.28±0.02 183±11 442±5 0.41±0.02 8.8±0.5 41±2 121.6±2.6
Mean±SEM.  N=7 rats (longitudinal measurements were made in each animal at the time-points 
specified above).  Two baseline measurements were made on days 5 and 7 after surgery.  These 
results were averaged for each rat.  ΔT, change in blood temperature after injection of Ringer’s 
solution into the right heart; CO, cardiac output; HR, heart rate; SV, stroke volume; ACarea, 
global arterial compliance calculated using area method; SVR, systemic vascular resistance; 
MAP, mean arterial pressure.  *P < 0.05 by single factor repeated measures ANOVA. 
 
5.2.2 Summary 
Chronic administration of low dose rhRLX to conscious male rats results in an increase in 
CO and a reduction in systemic arterial load comparable to female rats.  This finding in 
combination with our other data (see Section 5.1) indicate that administration of rhRLX to 
nonpregnant rats elicits pregnancy-like changes in the systemic circulation.  We next examined 
the role of relaxin in mediating the cardiovascular adaptations to pregnancy. 
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5.3 SYSTEMIC HEMODYNAMICS AND ARTERIAL PROPERTIES IN 
CONSCIOUS PREGNANT RATS 
Specific Aim 3.  To determine systemic hemodynamics and arterial load in conscious, mid and 
late-pregnant rats administered control or relaxin neutralizing antibodies. 
5.3.1 Mid-Pregnant Rats Administered Relaxin Neutralizing Antibodies 
Portions of this work have been previously published elsewhere [51].  Systemic 
hemodynamic variables for midterm pregnant and virgin rats are illustrated in Figure 9.  There 
was no statistically significant difference in HR or MAP among the virgin rats, the rats 
administered relaxin neutralizing antibodies (MCA1), and those administered the control 
antibodies (MCAF; Fig. 9B & 9D).  Stroke volume (Fig. 9C) and CO (Fig. 9A) were both 
significantly increased in midterm pregnant rats administered the irrelevant MCAF antibody 
against fluorescein compared to virgin controls (both P < 0.05).  Importantly, the SV (0.38±0.02 
ml) and CO (165±5 ml/min) of the midterm pregnant rats administered the PBS vehicle/diluent 
for the antibodies were comparable to the values observed in the control MCAF antibody-treated 
gravid rats (both P = NS).  In contrast, both SV and CO were significantly decreased in midterm 
pregnant rats treated with rat relaxin neutralizing antibodies compared to the gravid animals 
administered MCAF antibody (both P < 0.05) and comparable to virgin levels (both P = NS). 
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Figure 9. Systemic Hemodynamics in Mid-Pregnant Rats Administered Relaxin Neutralizing 
Antibodies 
 
Systemic hemodynamics in mid-pregnant rats administered relaxin-neutralizing antibody 
(MCA1) or control antibody (MCAF), and virgin rats.  Mid-pregnant rats were administered 
daily injections of antibodies beginning on gestational day 8.  (A) Cardiac output, (B) heart rate, 
(C) stroke volume, and (D) mean arterial pressure.  * P < 0.05 vs. MCA1 (post-hoc Fisher’s 
LSD).  † P < 0.05 vs. Virgin (post-hoc Fisher’s LSD). 
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Systemic arterial properties for midterm pregnant and virgin rats are illustrated in Figure 
10.  Systemic vascular resistance in the MCAF-treated midterm pregnant rats was significantly 
lower compared to the virgin controls.  Treatment with relaxin-neutralizing antibodies 
completely eliminated this pregnancy-associated reduction in SVR (Fig. 10A).  Global AC as 
measured by ACarea and SV/PP was significantly increased in the MCAF-treated pregnant rats as 
compared to the virgin control group.  Again, treatment with relaxin neutralizing antibodies 
completely abolished this pregnancy-associated increase in global AC (Figs. 10B & 10C).  
Systemic vascular resistance and global AC for the MCAF-treated rats were similar to levels 
observed in the control pregnant rats administered PBS (SVR: 39.4±1.7 mmHg.s/ml; ACarea: 
9.7±0.5 μl/mmHg; SV/PP: 11.6±0.7 μl/mmHg; both P = NS). 
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Figure 10. Systemic Arterial Properties in Mid-Pregnant Rats Administered Relaxin 
Neutralizing Antibodies 
 
Systemic arterial properties in mid-pregnant rats administered relaxin-neutralizing antibody 
(MCA1) or control antibody (MCAF), and virgin rats.  Mid-pregnant rats were administered 
daily injections of antibodies beginning on gestational day 8.  (A) Systemic vascular resistance, 
and two measures of global arterial compliance, (B) ACarea and (C) SV/PP.  * P < 0.05 vs. 
MCA1 (post-hoc Fisher’s LSD).  † P < 0.05 vs. Virgin (post-hoc Fisher’s LSD). 
  
54 
5.3.2 Late-Pregnant Rats Administered Relaxin Neutralizing Antibodies 
We began investigating the role of relaxin in maintaining the cardiovascular adaptations 
to pregnancy during the late stages of gestation by assessing systemic hemodynamics and arterial 
properties from late pregnant rats administered relaxin neutralizing antibodies.  It is important to 
note the data presented here are results from our preliminary work on this subject and will 
represent only a subset of the final study.  Due to time constraints, we were only able to study a 
few animals in the antibody-treated groups (3 MCA1-treated rats and 1 MCAF-treated rat; 
antibodies were administered beginning on day 8 of gestation) prior to the preparation of this 
document.  Of note, data from 1 MCAF-treated rat was combined with data from 6 control late 
pregnant rats administered the PBS vehicle as our previous work has shown that MCAF antibody 
does not alter hemodynamics or arterial properties (see Section 5.1.7). 
Systemic hemodynamic variables for late-pregnant and virgin rats are illustrated in 
Figure 11.  Similar to mid-pregnant rats there was no statistically significant difference in MAP 
among the control, virgin and MCA1 antibody-treated pregnant groups (Fig. 11D).  Also similar 
to mid-pregnant rats, CO (Fig. 11A) was significantly increased in control late-pregnant rats 
compared to virgin rats.  Further, CO was significantly lower in late-pregnant rats treated with 
MCA1 relaxin neutralizing antibodies compared to the control late-pregnant animals.  However, 
unlike midterm pregnant rats, the relaxin-neutralizing antibody did not completely eliminate the 
pregnancy-associated increase in CO as there was still a significant increase in CO from virgin 
levels in the MCA1-treated rats.  Also unlike midterm pregnant rats, HR was significantly 
elevated in control late-pregnant rats compared to MCA1-treated and virgin rats and, although 
not statistically significant, the MCA1-treated rats exhibited a slightly higher HR than the virgin 
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animals (Fig. 11B).    Finally, a similar pattern was observed for SV although this pattern did not 
prove to be statistically significant (Fig. 11C). 
 
Figure 11. Systemic Hemodynamics in Late-Pregnant Rats Administered Relaxin Neutralizing 
Antibodies 
 
Systemic hemodynamics in late-pregnant rats administered relaxin-neutralizing antibody 
(MCA1) or control antibody (MCAF), and virgin rats.  Late-pregnant rats were administered 
daily injections of antibodies beginning on gestational day 8.  (A) Cardiac output, (B) heart rate, 
(C) stroke volume, and (D) mean arterial pressure.  * P < 0.05 vs. MCA1 (post-hoc Fisher’s 
LSD).  † P < 0.05 vs. Virgin (post-hoc Fisher’s LSD). 
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Systemic arterial properties for late-pregnant and virgin rats are illustrated in Figure 12.  
As expected, SVR in the control late-pregnant rats was significantly lower compared to the 
virgin rats.  However, treatment with relaxin-neutralizing antibodies only partially eliminated 
this pregnancy-associated reduction in SVR.  Thus, SVR in the MCA1-treated late-pregnant rats 
was higher than the control late pregnant animals yet still significantly reduced from the virgin 
group (Fig. 12A).   Similarly, global AC as measured by ACarea, was significantly increased in 
the control late-pregnant rats as compared to the virgin group and treatment with relaxin 
neutralizing antibodies abolished this pregnancy-associated increase (Figs. 12B).  Although 
global AC in the MCA1-treated group was slightly elevated from virgin levels, this increase did 
not reach statistical significance.  A similar pattern was observed in SV/PP although there were 
no statistically significant differences among the three groups (Fig. 12C).  
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Figure 12. Systemic Arterial Properties in Late-Pregnant Rats Administered Relaxin 
Neutralizing Antibodies 
 
Systemic arterial properties in late-pregnant rats administered relaxin-neutralizing antibody 
(MCA1) or control antibody (MCAF), and virgin rats.  Late-pregnant rats were administered 
daily injections of antibodies beginning on gestational day 8.  (A) Systemic vascular resistance, 
and two measures of global arterial compliance, (B) ACarea and (C) SV/PP.  * P < 0.05 vs. 
MCA1 (post-hoc Fisher’s LSD).  † P < 0.05 vs. Virgin (post-hoc Fisher’s LSD). 
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5.3.3 Summary 
Our data here indicate that relaxin triggers the adaptations in the systemic circulation 
during the early stages of pregnancy.  Our work in late pregnant rats suggest that although 
relaxin still plays a role in maintaining these adaptations during the late stages of pregnancy, it is 
most likely not the only mediator.  Next, we examined whether the relaxin-mediated increase in 
global AC is a result of altered passive arterial mechanical properties. 
5.4 PASSIVE ARTERIAL MECHANICAL PROPERTIES 
Specific Aim 4A.  To evaluate the passive mechanical properties of small renal and external iliac 
arteries isolated from rhRLX-treated, nonpregnant  female rats and mice. 
Specific Aim 4B.  To evaluate the passive mechanical properties of small renal and messenteric 
arteries isolated from mid-pregnant rats administered control or relaxin neutralizing antibodies. 
5.4.1 Uniaxial (Circumferential) Stress-Strain Analysis 
These in vitro experiments were performed to examine the effects of relaxin on passive 
(i.e., in the absence of active smooth muscle tone) mechanical properties of the isolated arteries.  
As mentioned before, primary measurements consisted of vessel inner and outer diameters at 
various levels of intraluminal pressure (see Section 4.3.3).  Circumferential wall stress (σ) along 
with midwall radius (Rm) and strain (εm) were calculated from these primary measurements and 
the relationships between these variables were used to quantify vessel wall elastic behavior. 
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5.4.1.1 Small Renal Arteries from Female Rats Administered Low Dose rhRLX (4 μg/h) 
Portions of this work have been previously published elsewhere [48].  Figure 13 
illustrates the average σ-Rm and σ-εm relationships for small renal arteries isolated from female 
rats administered low dose rhRLX or vehicle.  The σ-Rm relationship (Fig. 13A) was 
significantly different between the two groups (P < 0.001 by analysis of excess variance) such 
that σ was smaller for a given Rm in the relaxin-treated group.  In contrast, there was no 
difference in the σ-εm relationships of these groups (Fig. 13B).  Finally, arteries from rhRLX-
treated rats were characterized by significantly increased unstressed muscle area (AM0) when 
compared to arteries from control rats (Figure 14).    
 
Figure 13. Stress-Midwall Radius and Stress-Midwall Strain Relationships of Small Renal 
Arteries from Female Rats Administered Low Dose rhRLX. 
 
(A) Circumferential stress (σ)-midwall radius (Rm) and (B) σ-strain (εm) relationships for small 
renal arteries isolated from rats treated with low dose rhRLX (4 μg/h) or vehicle for 5 days.  
Original data from each animal were first fitted to a 3rd order polynomial, which was then used to 
obtain interpolated data (i.e., σ values for a given Rm or εm).  Interpolated σ data at a common 
value of Rm or εm were averaged over all animals within a group to yield the relationships shown 
here.  * P < 0.001 by analysis of excess variance using the original data. 
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Figure 14. Unstressed Muscle Area of Small Renal Arteries from Female Rats Administered 
Low Dose rhRLX 
 
Unstressed muscle area (AM0) of small renal arteries isolated from rats treated with low dose 
rhRLX (4 μg/h) or vehicle for 5 days.  AM0 computed from measurements of the inner and outer 
diameters, and wall thickness in the unloaded configuration.  * P < 0.05 vs. vehicle group. 
5.4.1.2 Small Renal Arteries from Female Mice Administered Low Dose rhRLX (1 μg/h)  
Portions of this work have been previously published elsewhere [52].  We found 
comparable results in small renal arteries isolated from rhRLX-treated and vehicle-administered 
(control) mice (Figures 15 and 16).  Specifically, arteries from rhRLX-treated mice were 
characterized by significantly lesser magnitudes of σ for a given Rm when compared to control 
mice (Figs. 15A).  In addition, there were no differences between the σ-εm relationships of small 
renal arteries from rhRLX-treated versus control mice.  Of note, although rhRLX-treated mice 
exhibited slightly increase AM0 compared to control mice, this increase was not statistically 
significant (Figure 16).   
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5.4.1.3 Small Renal Arteries Male Untreated Rlx-/- Mice 
Small renal arteries from Rlx+/+ mice were characterized by significantly lesser 
magnitudes of σ for a given Rm when compared to control and Rlx-/- mice with no differences 
between the σ-εm relationships (Figure 17).  Analogous to our findings in rats, arteries from 
Rlx+/+ mice were also characterized by significantly increased AM0 when compared to Rlx-/- mice 
(Figure 18). 
 
 
Figure 15. Stress-Midwall Radius and Stress-Midwall Strain Relationships of Small Renal 
Arteries from Female Mice Administered Low Dose rhRLX 
 
(A) Circumferential stress (σ)-midwall radius (Rm) and (B) σ-strain (εm) relationships for small 
renal arteries isolated from mice treated with low dose rhRLX (1 μg/h) or vehicle for 5 days.  
Original data from each animal were first fitted to a 3rd order polynomial, which was then used to 
obtain interpolated data (i.e., σ values for a given Rm or εm).  Interpolated σ data at a common 
value of Rm or εm were averaged over all animals within a group to yield the relationships shown 
here.  * P < 0.05 by analysis of excess variance using the original data. 
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Figure 16. Unstressed Muscle Area of Small Renal Arteries from Female Mice Administered 
Low Dose rhRLX 
 
Unstressed muscle area (AM0) of small renal arteries isolated from mice treated with low dose 
rhRLX (1 μg/h) or vehicle for 5 days.  AM0 computed from measurements of the inner and outer 
diameters, and wall thickness in the unloaded configuration. 
 
 
Figure 17. Stress-Midwall Radius and Stress-Midwall Strain Relationships of Small Renal 
Arteries from Male Rlx+/+ and Rlx-/- Mice 
 
(A) Circumferential stress (σ)-midwall radius (Rm) and (B) σ-strain (εm) relationships for small 
renal arteries isolated from Rlx+/+ and Rlx-/-, untreated mice.  Original data from each animal 
were first fitted to a 3rd order polynomial, which was then used to obtain interpolated data (i.e., σ 
values for a given Rm or εm).  Interpolated σ data at a common value of Rm or εm were averaged 
over all animals within a group to yield the relationships shown here.  * P < 0.01 by analysis of 
excess variance using the original data.  
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Figure 18. Unstressed Muscle Area of Small Renal Arteries from Male Rlx+/+ and Rlx-/- Mice 
 
Unstressed muscle area (AM0) of small renal arteries isolated from Rlx+/+ and Rlx-/-, untreated 
mice.  AM0 computed from measurements of the inner and outer diameters, and wall thickness in 
the unloaded configuration.  * P < 0.05 vs. Rlx-/- group. 
 
5.4.1.4 External Iliac Arteries from Female Mice Administered Low Dose rhRLX (1 μg/h) 
To determine if these effects of relaxin on passive mechanical properties were evident in 
other arteries we examined external iliac arteries from rhRLX-treated mice.  Interestingly, we 
found relaxin’s effects on passive mechanical properties were in fact artery-type specific.  i.e. 
external iliac arteries from rhRLX-treated mice were not characterized by any significant 
alterations in σ-Rm or σ-εm (Figure 19) relationships.  Additionally, AM0 was unaltered in these 
arteries when compared to arteries from control mice (Figure 20). 
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Figure 19. Stress-Midwall Radius and Stress-Midwall Strain Relationships of External Iliac 
Arteries from Female Mice Administered Low Dose rhRLX 
 
(A) Circumferential stress (σ)-midwall radius (Rm) and (B) σ-strain (εm) relationships for 
external iliac arteries isolated from mice treated with low dose rhRLX (1 μg/h) or vehicle for 5 
days.  Original data from each animal were first fitted to a 3rd order polynomial, which was then 
used to obtain interpolated data (i.e., σ values for a given Rm or εm).  Interpolated σ data at a 
common value of Rm or εm were averaged over all animals within a group to yield the 
relationships shown here.  P = NS by analysis of excess variance using the original data. 
 
 
Figure 20. Unstressed Muscle Area of External Iliac Arteries from Female Mice Administered 
Low Dose rhRLX 
 
Unstressed muscle area (AM0) of external iliac arteries isolated from mice treated with low dose 
rhRLX (1 μg/h) or vehicle for 5 days.  AM0 computed from measurements of the inner and outer 
diameters, and wall thickness in the unloaded configuration. 
65 
 
5.4.1.5 Small Renal and Mesenteric Arteries from Mid-Pregnant Rats Administered Relaxin 
Neutralizing Antibodies 
Portions of this work have been previously published elsewhere [51].  Since mid-
pregnant rats were characterized by a relaxin-mediated increase in global AC, we expected to 
observe relaxin-mediated alterations in arterial passive mechanical properties as well.  To 
examine this, we assessed the passive mechanical properties of small renal and mesenteric 
arteries isolated from mid-pregnant rats using the same techniques described above (see Section 
4.3.3).  Contrary to our expectations, both small renal and mesenteric arteries from mid-pregnant 
rats administered the control antibody (MCAF) did not exhibit any significant changes in σ-Rm 
or σ-εm relationships compared to arteries from virgin rats (Figures 21 and 22).  Furthermore, 
these relationships were not altered by administration of relaxin neutralizing antibodies (MCA1) 
to mid-pregnant rats.  There were no significant alterations in AM0 of both artery types from the 
pregnant (MCAF or MCA1) rats and virgin controls (Figure 23).  
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Figure 21. Stress-Midwall Radius and Stress-Midwall Strain Relationships of Small Renal 
Arteries from MCA1 or MCAF-Treated Mid-Pregnant Rats 
 
(A) Circumferential wall stress (σ)-midwall radius (Rm) and (B) σ-strain (εm) relationships for 
small renal arteries isolated from MCA1 or MCAF-treated mid-pregnant rats and virgin controls.  
Original data from each animal were first fitted to a 3rd order polynomial, which was then used to 
obtain interpolated data (i.e., σ values for a given Rm or εm).  Interpolated σ data at a common 
value of Rm or εm were averaged over all animals within a group to yield the relationships shown 
here.  P = NS by analysis of excess variance using the original data. 
 
 
Figure 22. Stress-Midwall Radius and Stress-Midwall Strain Relationships of Mesenteric 
Arteries from MCA1 or MCAF-Treated Mid-Pregnant Rats 
 
(A) Circumferential wall stress (σ)-midwall radius (Rm) and (B) σ-strain (εm) relationships for 
mesenteric arteries isolated from MCA1 or MCAF-treated mid-pregnant rats and virgin controls.  
Original data from each animal were first fitted to a 3rd order polynomial, which was then used to 
obtain interpolated data (i.e., σ values for a given Rm or εm).  Interpolated σ data at a common 
value of Rm or εm were averaged over all animals within a group to yield the relationships shown 
here.  P = NS by analysis of excess variance using the original data.  
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Figure 23. Unstressed Muscle Area of Small Renal and Mesenteric Arteries from MCA1 or 
MCAF-Treated Mid-Pregnant Rats 
 
Unstressed muscle area (AM0) of small renal and mesenteric arteries isolated from MCA1 or 
MCAF-treated mid-pregnant rats and virgin controls.  AM0 computed from measurements of the 
inner and outer diameters, and wall thickness in the unloaded configuration. 
 
5.4.1.6 Summary 
Relaxin (both exogenously administered and locally produced) induces an increase in the 
passive compliance of small renal arteries from nonpregnant rats and mice.  In addition, there is a 
relaxin-mediated geometric modification of the vascular wall of these arteries (i.e. AM0 was 
increased in small renal arteries from rhRLX-treated mice and decreased in those from Rlx-/- 
mice).  Contrary to our expectations, small renal and mesenteric arteries from mid-pregnant rats 
did not exhibit any relaxin or pregnancy-mediated alterations in passive compliance or geometric 
properties.  Finally, there were no relaxin-induced alterations in the stiffness properties of small 
renal arteries as quantified by their uniaxial (circumferential) σ-εm behavior.  Since arterial wall 
properties are known to vary with direction, we considered the possibility that we were limited in 
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our approach by only characterizing arterial mechanical behavior in the circumferential direction.  
Thus, we next examined the vascular wall stiffness properties of small renal and external iliac 
arteries using a biaxial constitutive model. 
5.4.2 Biaxial (Circumferential and Axial) Stress-Strain Analysis 
We modified our testing apparatus to enable us to characterize the biaxial mechanical 
behavior of isolated arteries. These arteries were subjected to pressure cycles from 0 to 120 
mmHg at various axial stretches and vascular wall mechanical properties were quantified in 
terms of tissue strain energy as discussed above (see Section 4.3.4).  A representative 
mechanical response of an artery under multi-dimensional loading conditions is illustrated in 
Figure 24.   
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Figure 24. Representative Biaxial Stress-Strain Behavior of an Artery under Multi-Dimensional 
Loading Conditions 
 
(A) Circumferential 2nd Piola-Kirchhoff stress (Sθθ)-circumferential Green-Lagrange strain (Eθθ) 
and (B) axial 2nd Piola-Kirchhoff stress (Szz)-Eθθ relationships from a mouse external iliac artery.  
Each curve is generated from pressure-diameter measurements made under a given axial Green-
Lagrange strain (Ezz).  Original data (symbols) were fitted to a 7 parameter mixed polynomial-
exponential model of biaxial strain energy using the Levenberg-Marquardt algorithm.   Solid 
lines represent computed Sθθ and Szz data at given values of Eθθ. 
 
5.4.2.1 Small Renal Arteries from rhRLX-Treated Mice 
As discussed before, we tested several different strain-energy functions and found the 
mixed polynomial-exponential model best described our data as it yielded the highest correlation 
coefficients.  Tables 7 and 8 lists the best fit constitutive parameters yielded using this model for 
each small renal artery sample along with the 95% confidence intervals for each predicted 
parameter and the correlation coefficients of the 2nd Piola-Kirchhoff stresses.  Interestingly, 95% 
confidence intervals for certain parameters indicate that these parameters may not be 
significantly different from zero.  This suggests that not all the parameters in this model may be 
needed to adequately predict strain energy as a function of biaxial Green-Lagrange strains.  It is 
important to note, however, that in our subsequent analysis of these data we do not make any 
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interpretations based on absolute parameter values.  Instead, our primary goal was to accurately 
predict the relationship between biaxial Green-Lagrange strains and 2nd Piola Kirchoff stresses.  
We believe that we were able to achieve this goal as indicated by the high correlation 
coefficients.  Accordingly, the mixed polynomial-exponential model can be applied to our data 
to determine 2nd Piola Kirchoff stresses, and the resulting strain energy, for given biaxial Green-
Lagrange strains. 
From the best fit constitutive parameters we initially computed the tissue strain energy 
under equibiaxial strain (i.e. Eθθ = Ezz) as a scalar index of overall tissue stiffness at varying 
levels of strain [53].  As shown in Figure 25, small renal arteries from rhRLX-treated mice 
compared to those from control counterparts exhibited slightly reduced magnitudes of 
equibiaxial strain energy especially at higher levels of strain although this small trend was not 
statistically significant.  This suggested that under such loading conditions, relaxin treatment did 
not yield any significant alterations in the vascular wall mechanical behavior of these arteries.  
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Table 7. Best Fit Constitutive Parameters of Small Renal Arteries Isolated from Control Mice 
Vessel  C1 C2 C3 C4 C5 C6 C7 R2 (Sθθ) R2 (Szz)
SRA #1 11097 (1184, 21509) 
9178 
(-16149, 34699) 
12694 
(3063, 22244) 
8193 
(-29855, 45725) 
0.18 
(-0.07, 0.41) 
1.3 
(-1.76, 4.35)
-0.57 
(-2.16, 1.00) 0.93 0.91 
SRA #2 12313 (8624, 17889) 
6364 
(-5969, 23465) 
12456 
(7029, 16639)
7913 
(-11382, 21244)
0.09 
(-0.27, 0.37) 
1.4 
(-1.10, 4.58) 
-0.51 
(-2.04, 0.67 ) 0.96 0.95 
SRA #3 7822 (2272, 13263) 
3426 
(-12732, 19653)
8398 
(2080, 14702)
9031 
(-18833, 36872)
0.08 
(-0.07, 0.23) 
1.1 
(-0.57, 2.83)
-0.50 
(-1.36, 0.36) 0.92 0.94 
SRA #4 10541 (7170, 14367) 
3149 
(-14322, 21030)
7184 
(1143, 13084)
7375 
(-18112, 32075)
-0.04 
(-0.41, 0.30) 
1.3 
(-1.08, 3.85)
-0.52 
(-1.66, 0.58) 0.95 0.96 
SRA #5 7649 (1248, 13741) 
7203 
(-4070, 25057) 
12844 
(2971, 19882)
7832 
(-12672, 21832)
0.16 
(-0.01, 0.46) 
1.4 
(-1.33, 4.60)
-0.84 
(-3.26, 1.09) 0.91 0.94 
SRA #6 10320 (6579, 15042) 
7830 
(2505, 24847) 
13452 
(4927, 16693)
7767 
(-5818, 10747) 
0.10 
(-0.16, 0.42) 
1.6 
(-1.26, 6.34)
-0.88 
(-4.23, 1.11) 0.94 0.98 
SRA #7 13289 (7258, 20691) 
4572 
(-19964, 29782)
8374 
(600, 15910) 
8902 
(-29864, 45997)
-0.01 
(-0.58, 0.49) 
1.2 
(-1.81, 4.45)
-0.43 
(-1.68, 0.77) 0.92 0.92 
Mean 10433 5960 10772 8145 0.08 1.3 -0.61 0.93 0.94 
SE 798 870 1003 231 0.03 0.1 0.07 0.01 0.01 
C1-C7, best-fit constitutive parameters for each artery computed by fitting original pressure-diameter and force-length data to a 7 
parameter mixed polynomial-exponential model of biaxial strain energy using the Levenberg-Marquardt algorithm; values in 
parentheses represent 95% confidence intervals for each estimated parameter; R2(Sθθ) and R2(Szz), correlation coefficients calculated 
for circumferential and axial second Piola-Kirchoff stresses. 
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Table 8. Best Fit Constitutive Parameters of Small Renal Arteries Isolated from rhRLX-treated Mice 
 
Vessel  C1 C2 C3 C4 C5 C6 C7 R2 (Sθθ) R2 (Szz)
SRA #8 8532 (3672, 13146) 
5289 
(-10326, 21487)
11846 
(5229, 18284) 
7867 
(-14645, 29865)
0.09 
(-0.04, 0.25) 
1.4 
(-0.58, 3.30)
-0.65 
(-1.76, 0.44) 0.93 0.95 
SRA #9 6559 (1556, 11391) 
1782 
(-8135, 15680) 
7252 
(2567, 10884) 
7921 
(-12608, 23058)
0.12 
(0.00, 0.24) 
1.1 
(-0.83, 3.38)
-0.42 
(-1.54, 0.49) 0.94 0.92 
SRA #10 7585 (4289, 11122) 
6896 
(-1501, 20730) 
14069 
(6289, 19204) 
7439 
(-6860, 16467) 
0.10 
(0.00, 0.25) 
1.5 
(-0.24, 3.79)
-0.97 
(-2.77, 0.37) 0.96 0.98 
SRA #11 6242 (4400, 8919) 
9801 
(9951, 20756) 
19687 
(11640, 20611)
7974 
(-2975, 6819) 
0.11 
(0.01, 0.25) 
1.2 
(-0.43, 4.61)
-1.04 
(-5.14, 0.75) 0.92 0.96 
SRA #12 10905 (6470, 16003) 
2601 
(-13083, 18573)
4939 
(1671, 8147) 
8045 
(-19514, 34812)
0.02 
(-0.27, 0.28) 
1.1 
(-0.74, 2.93)
-0.25 
(-0.79, 0.28) 0.95 0.94 
SRA #13 12256 (7212, 17301) 
7190 
(-5836, 20216) 
8320 
(5035, 11604) 
5176 
(-9319, 19671) 
0.16 
(-0.03, 0.34) 
1.7 
(-0.46, 3.75)
-0.49 
(-1.26, 0.28) 0.96 0.97 
SRA #14 6743 (1491, 11994) 
8255 
(1614, 14896) 
9761 
(7455, 12067) 
2118 
(-4768, 9004) 
0.46 
(0.11, 0.081) 
1.7 
(-0.58, 3.94)
-0.68 
(-1.75, 0.40) 0.94 0.94 
Mean 8403 5973 10839 6649 0.15 1.4 -0.64 0.94 0.95 
SE 881 1108 1858 847 0.05 0.1 0.11 0.01 0.01 
C1-C7, best-fit constitutive parameters for each artery computed by fitting original pressure-diameter and force-length data to a 7 
parameter mixed polynomial-exponential model of biaxial strain energy using the Levenberg-Marquardt algorithm; values in 
parentheses represent 95% confidence intervals for each estimated parameter; R2(Sθθ) and R2(Szz), correlation coefficients calculated 
for circumferential and axial second Piola-Kirchoff stresses. 
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Figure 25. Equibiaxial Strain Energy of Small Renal Arteries from Female Mice Administered 
Low Dose rhRLX 
 
Equibiaxial strain energy-Green-Lagrange strain relationships of small renal arteries isolated 
from mice treated with low dose rhRLX (1 μg/h) or vehicle for 5 days.  Original pressure-
diameter and force-length data were fitted to a 7 parameter mixed polynomial-exponential model 
of biaxial strain energy using the Levenberg-Marquardt algorithm.  Best-fit constitutive 
parameters were then used to obtain strain energy values for a given equibiaxial Green-Lagrange 
strain (i.e. Eθθ = Ezz).  Computed strain energy data at a common value of strain were averaged 
over all animals within a group to yield the relationships shown here. 
 
We still felt, however, that using equibiaxial strain energy as a measure of vascular wall 
stiffness confined us to a very specific and perhaps limited strain space.  Instead, in order to get a 
more accurate representation of the biaxial mechanical behavior of these arteries, we needed to 
consider strain energy as a function of varying (and not necessarily equal) levels of 
circumferential and axial strain.  Thus, we computed the strain energies of small renal arteries 
isolated from vehicle and rhRLX-treated mice at various levels of circumferential and axial 
strain.  Of note, we used a strain space that was representative of our experimental conditions.  
Figure 26 illustrates the difference in strain energy between the two groups.  Comparing arteries 
from rhRLX-treated mice to those from control mice, we found that under conditions of low 
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circumferential strain there is little-to-no difference in strain energy regardless of the level axial 
strain.  However, as circumferential strain increases, there is a trend of increasingly lower levels 
of strain energy in the arteries from the rhRLX-treated mice compared to the vehicle group.  This 
trend becomes more pronounced at higher levels of axial strain and ultimately the maximum 
difference in strain energy between small renal arteries from rhRLX-treated mice and those from 
vehicle-administered mice occurs at maximum circumferential and axial strains.  In fact, we 
computed tissue strain energy for each artery under maximum loading conditions (Eσσ: 1.38, Ezz: 
0.88) and found a strong trend, albeit statistically insignificant (P = 0.09), that the relaxin group 
exhibited lower magnitudes of strain energy under these loading conditions (Figure 27).  Thus, 
our data suggest that under conditions of high circumferential and axial loads, small renal 
arteries isolated from rhRLX-treated mice exhibit some degree of reduced wall stiffness when 
compared to arteries from control mice. 
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Figure 26.  Two Dimensional Behavior of Tissue Strain Energy of Small Renal Arteries from 
Female Mice Administered Low Dose rhRLX 
 
Difference in strain energy-Green-Lagrange strain relationships of small renal arteries isolated 
from mice treated with low dose rhRLX (1 μg/h) or vehicle for 5 days.  Original pressure-
diameter and force-length data were fitted to a 7 parameter mixed polynomial-exponential model 
of biaxial strain energy using the Levenberg-Marquardt algorithm.  Best-fit constitutive 
parameters were then used to compute strain energy values for varying levels of circumferential 
and axial Green-Lagrange strains.  Computed strain energy data at a common value of biaxial 
strain were averaged over all animals within a group.  The average values of strain energy for the 
relaxin group were then subtracted from those of the vehicle group to yield the relationships 
shown here. 
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Figure 27. Strain Energy under Maximum Loading Conditions of Small Renal Arteries from 
Female Mice Administered Low Dose rhRLX 
 
Tissue strain energy under maximum axial and circumferential Green-Lagrange strains of small 
renal arteries isolated from mice treated with low dose rhRLX (1 μg/h) or vehicle for 5 days.  
Original pressure-diameter and force-length data were fitted to a 7 parameter mixed polynomial-
exponential model of biaxial strain energy using the Levenberg-Marquardt algorithm.  Best-fit 
constitutive parameters were then used to obtain tissue strain energy under maximum loading 
conditions.  Maximum strain energy data were averaged for all animals within a group to yield 
the data illustrated here.  The difference in maximum strain energy was not quite significant 
between the two groups (P = 0.09 by Student’s “t” test). 
 
5.4.2.2 External Iliac Arteries from rhRLX-Treated Mice 
Although relaxin did not induce any significant geometric modification of the vascular 
wall of external iliac arteries (i.e. AM0 was unchanged in external iliac arteries from rhRLX-
treated mice compared to control mice) we still wanted to verify that our inability to detect any 
difference in the vascular wall mechanical properties of these arteries was not a result of limited 
approach; as it seemed to be the case in small renal arteries.  Thus, we examined the biaxial 
mechanical behavior of external iliac arteries isolated from rhRLX-treated and control mice 
using similar techniques as above.   
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Tables 9 and 10 lists the best fit constitutive parameters were yielded using the mixed 
polynomial-exponential model of strain energy for each external iliac artery along with the 95% 
confidence intervals for each predicted parameter and the correlation coefficients of the second 
Piola-Kirchhoff stresses.  Similar to our results from small renal arteries, 95% confidence 
intervals for the predicted parameters indicated that certain parameters might not be significantly 
different from zero.  However, for reasons discussed above (see Section 5.2.2.1), we believe that 
we can accurately predict 2nd Piola-Kirchoff stresses, and the resulting strain energy, as a 
function of biaxial Green-Lagrange strains based on goodness of fit of the stress-strain behavior. 
External iliac arteries from rhRLX-treated mice did not exhibit any significant changes in 
equibiaxial strain energy at varying levels of strain (Figure 28).  However, unlike small renal 
arteries, when we computed the average strain energies of external iliac arteries from the two 
groups at various levels of circumferential and axial strain, we found that under any loading 
conditions there was no relaxin-induced change in tissue strain energy (Figure 29).  
Accordingly, there was no difference between the two groups in tissue strain energy under 
maximum loading conditions as there was for small renal arteries.  Therefore, our data suggest 
that under varying conditions of circumferential and axial loads, external iliac arteries from 
rhRLX-treated mice do not exhibit a change in tissue stiffness when compared to arteries from 
control mice. 
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Table 9. Best Fit Constitutive Parameters of External Iliac Arteries Isolated from Control Mice 
Vessel  C1 C2 C3 C4 C5 C6 C7 R2 (Sθθ) R2 (Szz)
EIA #1 -872 (-6337, 4593) 
2081 
(-2330, 6491)
3109 
(1894, 4323)
3201 
(-6233, 12635)
0.35 
(0.09, 0.61) 
0.66 
(-0.06, 1.37)
-0.17 
(-0.42, 0.09) 0.93 0.87 
EIA #2 2971 (2517, 3425) 
2418 
(1802, 3034) 
2072 
(1800, 3034)
178 
(-8,364) 
0.16 
(0.09, 0.23) 
1.35 
(0.96,1.75) 
-0.27 
(-0.48, -0.06) 0.99 0.99 
EIA #3 1333 (455, 2210) 
4032 
(3008, 5057) 
3832 
(3338, 4326)
179 
(-103, 406) 
0.29 
(0.20, 0.37) 
1.14 
(0.66, 1.62) 
-0.41 
(-0.71, -0.11) 0.96 0.97 
EIA #4 -208 (-914, 498) 
3561 
(1972, 5151) 
3674 
(2374, 4975)
1374 
(-920, 3668) 
0.09 
(0.05, 0.12) 
0.60 
(0.24, 0.95) 
-0.68 
(-1.17, -0.19) 0.87 0.97 
Mean 806 3023 3172 1233 0.22 0.94 -0.38 0.94 0.95 
SE 1212 654 563 1010 0.06 0.18 0.11 0.04 0.04 
C1-C7, best-fit constitutive parameters for each artery computed by fitting original pressure-diameter and force-length data to a 7 
parameter mixed polynomial-exponential model of biaxial strain energy using the Levenberg-Marquardt algorithm; values in 
parentheses represent 95% confidence intervals for each estimated parameter; R2(Sθθ) and R2(Szz), correlation coefficients calculated 
for circumferential and axial second Piola-Kirchoff stresses. 
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Table 10. Best Fit Constitutive Parameters of External Iliac Arteries Isolated from rhRLX-Treated Mice 
Vessel  C1 C2 C3 C4 C5 C6 C7 R2 (Sθθ) R2 (Szz)
EIA #5 1556 (447, 2665) 
4437 
(3205, 5669) 
3421 
(2772, 4070) 
37 
(-45, 117) 
0.60 
(0.37, 0.83) 
2.27 
(1.05, 3.48) 
-0.82 
(-1.63, -0.01) 0.96 0.97 
EIA #6 4116 (2164, 6068) 
2342.3 
(200, 4485) 
2640 
(1669, 3611)
120 
(-302, 541) 
0.25 
(-0.15, 0.65) 
1.54 
(0.02, 3.07)
-0.06 
(-0.82, 0.69) 0.92 0.93 
EIA #7 603 (-1006, 2212) 
2639 
(-29, 5307) 
5097 
(4166, 6020)
1390 
(-1036, 3816)
0.27 
(0.16, 0.38) 
0.89 
(0.34, 1.43)
-0.21 
(-0.54, 0.12) 0.96 0.96 
EIA #8 2551 (1843, 3259) 
3331 
(2659, 4002)
2922 
(2571, 3273)
14 
(-12, 39) 
0.55 
(0.37, 0.73) 
1.92 
(1.18, 2.65)
-0.30 
(-0.75, -0.04) 0.97 0.97 
Mean 2207 3187 3520 390 0.42 1.65 -0.37 0.95 0.96 
SE 1062 658 778 473 0.09 0.29 0.16 0.02 0.01 
C1-C7, best-fit constitutive parameters for each artery computed by fitting original pressure-diameter and force-length data to a 7 
parameter mixed polynomial-exponential model of biaxial strain energy using the Levenberg-Marquardt algorithm; values in 
parentheses represent 95% confidence intervals for each estimated parameter; R2(Sθθ) and R2(Szz), correlation coefficients calculated 
for circumferential and axial second Piola-Kirchoff stresses. 
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Figure 28. Equibiaxial Strain Energy of External Iliac Arteries from Female Mice Administered 
Low Dose rhRLX  
 
Equibiaxial strain energy-Green-Lagrange strain relationships of external iliac arteries isolated 
from mice treated with low dose rhRLX (1 μg/h) or vehicle for 5 days.  Original pressure-
diameter and force-length data were fitted to a 7 parameter mixed polynomial-exponential model 
of biaxial strain energy using the Levenberg-Marquardt algorithm.  Best-fit constitutive 
parameters were then used to obtain strain energy values for a given equibiaxial Green-Lagrange 
strain (i.e. Eθθ = Ezz).  Computed strain energy data at a common value of strain were averaged 
over all animals within a group to yield the relationships shown here. 
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Figure 29. Two Dimensional Behavior of Tissue Strain Energy of External Iliac Arteries Female 
Mice Administered Low Dose rhRLX  
 
Difference in strain energy-Green-Lagrange strain relationships of external iliac arteries isolated 
from mice treated with low dose rhRLX (1 μg/h) or vehicle for 5 days.  Original pressure-
diameter and force-length data were fitted to a 7 parameter mixed polynomial-exponential model 
of biaxial strain energy using the Levenberg-Marquardt algorithm.  Best-fit constitutive 
parameters were then used to obtain strain energy values for varying levels of circumferential 
and axial Green-Lagrange strains.  Computed strain energy data at a common value of biaxial 
strain were averaged over all animals within a group.  The average values of strain energy for the 
relaxin group were then subtracted from those of the vehicle group to yield the relationships 
shown here. 
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Figure 30. Strain Energy under Maximum Loading Conditions of External Iliac Arteries from 
Female Mice Administered Low Dose rhRLX 
 
Tissue strain energy under maximum axial and circumferential Green-Lagrange strains of 
external iliac arteries isolated from mice treated with low dose rhRLX (1 μg/h) or vehicle for 5 
days.  Original pressure-diameter and force-length data were fitted to a 7 parameter mixed 
polynomial-exponential model of biaxial strain energy using the Levenberg-Marquardt 
algorithm.  Best-fit constitutive parameters were then used to obtain tissue strain energy under 
maximum loading conditions.  Maximum strain energy data were averaged for all animals within 
a group to yield the data illustrated here.  The difference in maximum strain energy was not quite 
significant between the two groups (P = 0.09 by Student’s “t” test). 
 
5.4.2.3 Summary 
Under conditions of low axial and circumferential loads, there are no relaxin-induced 
changes in vascular wall stiffness properties as quantified by tissue strain energy.  However, 
under conditions of high biaxial loads small renal (and not external iliac) arteries from rhRLX-
treated mice exhibit reduced wall stiffness.  This finding suggests that there may be relaxin-
mediated alterations in vascular wall biochemical composition of small renal arteries.  Thus, we 
next examined the effects of relaxin on vascular wall collagen and elastin content.  In addition, to 
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determine the mechanistic basis of the relaxin-mediated vascular wall geometric remodeling, we 
examined the hormone’s effects on vascular smooth muscle cell hypertrophy and hyperplasia. 
Of note, to determine whether our current data are comparable to previously published 
works, we compared the strain energy from our mouse external iliac arteries to that reported by 
Schulze-Bauer et al. for human external iliac arteries [43].  Interestingly, they observed much 
lower magnitudes of circumferential and axial stretches in human iliac arteries than we report 
here for mouse iliac arteries.  Thus, we only compared strain energies from their study and ours 
in a region of circumferential and axial strains that was common between the two groups.  We 
found that within this common strain domain, strain energies were generally similar in 
magnitude under conditions high circumferential strain irrespective of the level of axial strain, 
and under conditions low circumferential and axial strains.   However, under conditions of high 
axial strain and low circumferential strain, the magnitude of strain energy reported for the human 
iliac arteries were much higher than what we report here for mouse iliac arteries. 
5.5 ARTERIAL BIOCHEMICAL COMPOSITION AND STRUCTURE IN FEMALE 
RELAXIN-TREATED MICE 
Specific Aim 5A.  To analyze smooth muscle cell characteristics (size and count) in small renal 
and external iliac arteries isolated from rhRLX-treated mice. 
Specific Aim 5B.  To determine elastin and collagen content in small renal and external iliac 
arteries isolated from rhRLX-treated mice. 
Specific Aim 6B.  To analyze smooth muscle cell characteristics (size and count) in small renal 
and external iliac arteries isolated from Rlx+/+ and Rlx-/- mice. 
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Specific Aim 6C.  To determine elastin and collagen content in small renal and external iliac 
arteries isolated from Rlx+/+ and Rlx-/- mice. 
 
To determine the structural basis for the relaxin-induced increase in unstressed arterial 
muscle area and decrease in vascular wall stiffness, we examined smooth muscle cell (SMC) size 
and density, as well as collagen and elastin content in small renal and external iliac arteries 
isolated from rhRLX-treated and control mice, as well as, Rlx+/+ and Rlx-/- mice. 
5.5.1 Smooth Muscle Cell Characteristics 
We measured SMC size in these arteries using two different techniques described above 
(see Section 4.4).  Average SMC sizes measured from arterial cross-sections of small renal 
arteries isolated from vehicle and rhRLX-treated mice, as well as Rlx+/+ and Rlx-/- mice, are 
illustrated in Figure 31.  Arteries from mice administered rhRLX did not exhibit significant 
changes in SMC size when compared to those from mice administered the vehicle control 
(111.3±4.3 vs 105.0±3.1 μm2; P=NS; Fig. 31A).  Isolated SMCs from enzymatically digested, 
rhRLX-treated small renal arteries were also similar in size to SMCs isolated from control 
arteries (145.5±4.2 vs 143.2±6.4 μm2; P=NS; Fig. 31B).   Finally, SMC size measured from 
arterial cross-sections of small renal arteries isolated from Rlx-/- mice were not significantly 
different from those from Rlx+/+ mice (110.2±3.1 vs 112.6±2.8μm2; P=NS; Fig. 31C).  These 
findings indicate the relaxin mediated increase unstressed muscle area of small renal arteries is 
not attributable to SMC hypertrophy.   
Of note, SMCs isolated from enzymatically digested arteries appeared to be larger in size 
when compared to SMCs within arterial cross-sections.  We believe that this difference in cell 
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size may be a result of some level of residual smooth muscle tone within the intact arteries.  
Importantly, there was no difference in SMC size between rhRLX-treated small renal arteries 
and control arteries irrespective of the method used to quantify cell size.   
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Figure 31. Smooth Muscle Cell Size of Small Renal Arteries from Female Mice Administered 
Low Dose rhRLX, and Male Rlx+/+ and Rlx-/- mice. 
 
Average smooth muscle cell (SMC) size of small renal arteries isolated from (A&B) mice treated 
with low dose rhRLX (1 μg/h) or vehicle for 5 days, and (B) Rlx+/+ and Rlx-/- mice.  (A) Isolated 
small renal arteries were enzymatically digested or (B) intact kidneys were sectioned at 6 μm 
thickness and stained for smooth muscle actin. Smooth muscle cells were identified by positive 
staining for smooth muscle actin.  The sizes of individual islolated SMCs or SMCs within an 
arterial cross-section were determined. Representative SMC size of a given arterial cross-section 
was computed as the average SMC size of all discernable SMCs within 4-10 serial cross-sections 
of that artery.  Data presented here are the composite average representative SMC size of each 
treatment group or genotype.  
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Figure 32 illustrates SMC density in small renal arteries isolated from rhRLX-treated, 
and vehicle-administered mice (Fig. 32A), as well as Rlx+/+ and Rlx-/- mice (Fig. 32B).  Arteries 
from rhRLX-treated mice were characterized by a significant increase in SMC density when 
compared to those from control mice (6.1±0.1 vs 5.0±0.1 cells/1000 μm2; mean±SEM; P<0.001).  
Of note, although wall area was increased in the arteries from rhRLX-treated mice, there was an 
even larger increase the number of smooth muscle cells thus resulting in the increase in SMC 
density. Conversely, arteries from Rlx-/- mice were characterized by a significant decrease in 
smooth muscle cell density when compared to those from Rlx+/+ mice (3.7±0.1 vs 4.4 ±0.1 
cells/1000 μm2; P<0.05).  
 
Figure 32. Smooth Muscle Cell Density of Small Renal Arteries from Female Mice 
Administered Low Dose rhRLX, and Male Rlx+/+ and Rlx-/- mice. 
 
Average smooth muscle cell (SMC) density of small renal arteries isolated from (A) mice treated 
with low dose rhRLX (1 μg/h) or vehicle for 5 days, and (B) Rlx+/+ and Rlx-/- mice.  Kidneys 
were sectioned at 6 μm thickness and stained for smooth muscle actin and nuclei. Small renal 
arteries were identified by positive staining for smooth muscle actin.  Smooth muscle cell density 
for each arterial cross-section was quantified as the ratio of number of SMC (determined by 
counting DAPI-stained nuclei) to arterial wall area.  Representative SMC density of a given 
artery was computed as the average SMC density of 4-10 serial cross-sections of that artery.  
Data presented here are the composite average representative SMC density of each treatment 
group or genotype. * P < 0.05 vs vehicle or vs Rlx-/-. 
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With respect to external iliac arteries, we did not observe any significant differences in 
wall area between arteries from rhRLX-treated and control mice; nor were there differences in 
the number of smooth muscle cells.  Consequently, SMC density was not significantly altered in 
external iliac arteries from rhRLX-treated mice compared to control mice (3.9±0.2 vs 4.0±0.2 
cells/1000 μm2; P=NS; Fig. 33A).  As expected, we observed similar results in external iliac 
arteries from the Rlx-/- and Rlx+/+ mice (3.6±0.4 vs 3.8±0.7 cells/1000 μm2; P=NS; Fig. 33B).  
 
 
Figure 33. Smooth Muscle Cell Density of External Iliac Arteries from Female Mice 
Administered Low Dose rhRLX, and Male Rlx+/+ and Rlx-/- mice. 
 
Average smooth muscle cell (SMC) density of external iliac arteries isolated from (A) mice 
treated with low dose rhRLX (1 μg/h) or vehicle for 5 days, and (B) Rlx+/+ and Rlx-/- mice.  
External iliac arteries were sectioned at 6 μm thickness and stained for smooth muscle actin and 
nuclei. Smooth muscle cell density for each arterial cross-section was quantified as the ratio of 
number of SMC (determined by counting DAPI-stained nuclei) to arterial wall area.  
Representative SMC density of a given artery was computed as the average SMC density of 4-10 
serial cross-sections of that artery.  Data presented here are the composite average representative 
SMC density of each treatment group or genotype. 
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5.5.2 Collagen and Elastin Content 
As discussed before (see Section 4.5), relative collagen content was quantified as the 
ratio of collagen concentration to total protein concentration and relative elastin content was 
quantified as the ratio of the mass of elastin to tissue dry weight.  Small renal arteries isolated 
from rhRLX-treated mice were characterized by a significant reduction in relative collagen 
content (0.13±0.01 vs 0.19±0.01 μg collagen/μg protein; mean±SEM; P<0.02) compared to 
control mice (Fig. 34A) with no significant change in elastin content (104±4 vs 97±14 μg 
elastin/mg dry weight; Fig. 34B). In contrast, there were no significant changes in collagen 
content (0.25±0.02 vs 0.28±0.04 μg collagen/μg protein; Fig. 34C) or elastin content (89±12 vs 
83±5 μg elastin/mg dry weight; Fig. 34D) in external iliac arteries from the rhRLX-treated mice 
compared to control mice.  
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Figure 34. Relative Collagen and Elastin Content in Small Renal and External Iliac Arteries 
from Female Mice Administered Low Dose rhRLX. 
 
Relative collagen (A&C) and elastin (B&D) content of small renal and external iliac arteries 
isolated from mice treated with low dose rhRLX (1 μg/h) or vehicle for 5 days.  Collagen and 
total protein concentrations were determined using the Sircol Collagen Assay and the Pierce 
BCA Protein Assay, respectively.  Elastin amount was determined using the Fastin Elastin 
Assay.  Data presented here represents relative collagen content expressed as the ratio of 
collagen to total protein concentration and relative elastin content expressed as the amount of 
elastin per tissue dry weight.  * P < 0.05 vs vehicle group.  SRA: small renal arteries; EIA: 
external iliac arteries. 
 
91 
 Small renal arteries isolated from Rlx-/- mice exhibited significantly increased collagen to 
total protein ratio (0.27±0.02 vs 0.19±0.03 μg collagen/μg protein; mean±SEM; P<0.05) 
compared to Rlx+/+ mice (Fig. 35A).  There were no significant changes in collagen to total 
protein ratio (0.41±0.05 vs 0.30±0.04 μg collagen/μg protein; Fig. 35B) in external iliac arteries 
from the Rlx-/- mice compared to Rlx+/+ mice.  Due to the limited availability of samples, we 
were unable to assess elastin content in these arteries.  However, based on our other work, we do 
not anticipate there will be a relaxin-mediated alteration in elastin content in these arteries.   
 
 
Figure 35. Relative Collagen Content in Small Renal and External Iliac Arteries from Male Rlx-/- 
and Rlx+/+ mice 
 
Relative collagen content of small renal (A) and external iliac (B) arteries isolated from Rlx+/+ 
and Rlx-/- mice.  Collagen and total protein concentrations were determined using the Sircol 
Collagen Assay and the Pierce BCA Protein Assay, respectively.  Data presented here represents 
relative collagen content expressed as the ratio of collagen to total protein concentration.  * P < 
0.05 vs Rlx-/- group.  SRA: small renal arteries; EIA: external iliac arteries. 
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5.5.3 Summary 
Relaxin induces both geometric and compositional vascular wall remodeling.  The 
relaxin-induced geometric remodeling results in an increase in vascular wall area attributable to 
smooth muscle cell hyperplasia and not hypertrophy.  The relaxin induced compositional 
remodeling is a result of decreased collagen content with no change in elastin content. 
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6.0  DISCUSSION 
6.1 EFFECTS OF RELAXIN ON SYSTEMIC HEMODYNAMICS AND ARTERIAL 
PROPERTIES 
6.1.1 Relaxin: A Systemic Vasodilator 
Because relaxin is a potent renal vasodilator when administered to conscious, 
nonpregnant rats [16], and mediates renal vasodilation and hyperfiltration during pregnancy in 
conscious, gravid rats [23], we reasoned that the hormone might affect systemic hemodynamics 
and arterial load as well.  Thus, one of the major objectives of this work was to determine 
whether relaxin administration to conscious, nonpregnant rats modifies both the steady and 
pulsatile components of arterial load.  To this end, we found chronic administration of rhRLX to 
conscious, nonpregnant, female rats reduces steady arterial load by decreasing SVR, and reduces 
pulsatile arterial load by increasing global AC. 
Analogous to previous work on relaxin in the renal circulation [16, 24, 25, 35], the 
hormone proved to be a general vasodilator reducing SVR and increasing CO each by 
approximately 20%, thereby maintaining MAP.  As in pregnancy, this increase in CO was due 
primarily to an increase in stroke volume with a lesser contribution from heart rate [15, 54].  
Although the renal circulation clearly participated in this systemic vasodilatory response, other 
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peripheral circulations undoubtedly contributed as well, but their relative contributions remain to 
be identified.  Because relaxin administration reduced the myogenic reactivity of small 
mesenteric, and small renal arteries [28], we speculate that the hormone also vasodilates the 
mesenteric circulation.  Others have shown that relaxin is most likely vasodilatory in several 
organ beds including heart, uterus, breast, liver and mesentery [20].  Therefore, these organ beds 
are likely to have contributed to the overall reduction in SVR and reciprocal rise in CO. 
Concurrently with the decline in SVR, the pulsatile arterial load also fell.  Global AC 
increased by approximately 20% during infusion of rhRLX.  The magnitude of this change is 
comparable to the rise in global AC observed in human pregnancy (and rat pregnancy as 
indicated by our data; see Section 5.1.7) which peaks at about 30% above nonpregnant values 
during the first trimester [6] and coincides with the rise in circulating relaxin [21].  The increase 
in global AC observed here is similar to the rise in the compliance coefficient of the descending 
thoracic aorta measured in conscious pregnant rats that begins to increase with the rise in 
circulating relaxin [55]. Finally, consistent with an increase in global AC, pulse pressure 
remained unchanged in spite of a ~20% increase in stroke volume. 
6.1.2 Potential Mechanisms of Action of Relaxin 
Although the precise mechanisms for the relaxin-induced reduction in steady and 
pulsatile arterial loads are currently unknown, we propose three possible pathways (as reviewed 
in [33]).  First, the hormone has been shown to exert renal vasodilation by increasing vascular 
gelatinase activity which, in turn, processes big endothelin to ET1-32 [25, 32].  Subsequently, ET1-
32 stimulates the production of endothelial nitric oxide via the endothelial ETB receptor subtype.  
This vasodilatory pathway may also be activated in other organ circulations during relaxin 
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infusion, thereby contributing to the reduction is SVR and increase in global AC.  Second, 
vascular gelatinase and other matrix metalloproteinases can remodel extracellular matrix, as 
well, thereby contributing to the increase in global AC (along with the decrease in arterial tone).  
In fact, we found evidence of this remodeling process in this work as indicated by small renal 
arteries from rhRLX-treated mice exhibiting significantly reduced collagen content (see Section 
5.5.2).  Third, there is the possibility that relaxin induces the formation of new blood vessels 
and/or increases branching of existing vasculature [20, 56], which can contribute to the reduction 
in SVR and/or the increase in global AC.  Interestingly, this process of angiogenesis may also 
require the participation of vascular gelatinase activity [57], the endothelial ETB receptor, and 
NO [58].  Of note, increased skin capillary density has been reported in normal pregnancy [59] 
but it is not known whether relaxin is responsible for this pregnancy-associated angiogenesis. 
6.1.3 Dose Response to Relaxin 
Previous work demonstrated that the influence of relaxin on the renal circulation is 
biphasic in nature [24, 35].  Our initial work examining the effects of relaxin on systemic 
hemodynamics and arterial properties involved the administration of low doses of rhRLX to rats 
that yielded serum levels comparable to that observed in early gestation (~15 ng/ml) [21].  At 
this stage of pregnancy, CO is approximately 25% above nonpregnant values [15, 34].  However, 
during the late stages of pregnancy in rats, at which point serum relaxin levels are much higher 
(~80 ng/ml), some works have shown that CO is further increased to 50% above nonpregnant 
values [34] while others have shown that there is no further increase in CO ([15] and our current 
work).  We administered higher doses of rhRLX to yield serum concentrations corresponding to 
mid and late-pregnancy, in order to determine whether systemic hemodynamics and arterial 
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properties would be further augmented.  Analogous to relaxin’s  influence in the renal circulation 
and on osmoregulation [35], the effects of relaxin on systemic hemodynamics and arterial 
properties were biphasic.  In contrast to our expectations, higher infusion rates of relaxin 
administered for 6 days yielding serum concentrations corresponding to late pregnancy in the rat, 
when CO is highest and SVR lowest [15], had no statistically significant effects on systemic 
hemodynamics and arterial properties.  This finding suggests relaxin alone is unlikely to be 
responsible for the alterations in systemic hemodynamics and arterial properties during the later 
stages of pregnancy.  Alternatively, during late gestation, increasing serum concentrations of 
relaxin may require other pregnancy factors to further augment and maintain the increase in CO 
and decrease in arterial load.  Therefore, high dose relaxin infusion alone, in the absence of these 
other factors, is incapable of reproducing these changes.   
There are several other possible explanations for this observation:  (1) high dose relaxin 
infusion, may lead to classical downregulation of the LGR7 relaxin receptor in the vasculature 
especially if a rapid (hours) rather than gradual (days) increase in relaxin levels in blood is 
achieved [60];  (2) high dose relaxin infusion, may also lead to inactivation of this receptor 
through proteolytic cleavage at a glycine-leucine bond in the extracellular domain by gelatinases 
or other matrix metalloproteinases that relaxin stimulates [25]; and (3) high levels of circulating 
relaxin leads to excessive production of ET1-32 via proteolytic cleavage of big ET at a glycine-
leucine bond to the active peptide, ET1-32 [25, 32].  Too much ET1-32 may then interact not only 
with the endothelial ETB receptor to produce nitric oxide, but also with the vascular smooth 
muscle ETA and ETB receptors, thereby neutralizing the vasodilatory action of the endothelial 
ETB receptor. 
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6.1.4 Gender-Independence of Relaxin’s Effects 
Analogous to previous work on relaxin in the renal circulation [24], this hormone elicited 
similar effects on systemic hemodynamics and arterial properties in both male and female rats 
even though relaxin is traditionally considered to be a female hormone and is not believed to 
circulate in male rats [21].  Of note, the renal effects of relaxin were observed in ovariectomized 
rats suggesting female sex steroids play little or no intermediary role [16].  Other studies have 
demonstrated relaxin increases coronary blood flow in male rats and guinea-pigs [19], and exerts 
chronotropic effects on the heart in male rats [61].  Recombinant human relaxin has also been 
shown to induce a significant increase in renal plasma flow in male human subjects comparable 
to observations made in females [62].  Additionally, the relaxin-1 and LGR7 gene and mRNA 
have been shown to be expressed by several arteries in male mice [52], while male mice 
deficient in the relaxin-1 gene exhibit fibrosis in several organs attributed to the absence of 
locally produced relaxin [63-65]; and in some cases, fibrosis is reversed with exogenous relaxin 
administration [64, 65].  Interestingly, although not statistically significant, results from our work 
examining the effects of relaxin on systemic hemodynamics and arterial properties tended to 
show a delay in the response to relaxin treatment in males when compared to females.  This 
finding suggests there may be a reduced efficacy of the relaxin/relaxin receptor system in males.  
Although this issue needs to be explored further in order to elucidate any potential mechanisms 
for this seemingly delayed response in male rats, it is interesting to note that previous work 
showed that small renal arteries from male mice may be characterized by lower expression levels 
of the LGR7 receptor mRNA compared to female mice [52].  In addition, the three potential 
pathways for relaxin-induced changes in systemic arterial properties discussed above (see 
Section 6.1.2) are likely to exhibit different temporal patterns, with the reduction in tone being 
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the fastest and angiogenesis being the slowest.  It is possible, therefore, that there is a difference 
in the relative contributions of these three pathways between males and females.  
6.1.5 Role of Relaxin in Mediating the Cardiovascular Adaptations to Pregnancy 
Our work with nonpregnant rats clearly shows that exogenously administered relaxin 
yielding serum concentrations in nonpregnant female rats comparable to those observed in early 
to mid-pregnant rats elicits alterations in systemic hemodynamics and arterial properties that 
mimic pregnancy.  Next, we directly tested whether endogenous, circulating relaxin mediates the 
cardiovascular adaptations of pregnancy.  This was accomplished by neutralizing circulating 
relaxin with specific antibodies.  Using this technique, we were able to show that relaxin 
mediates the increase in CO and global AC, as well as the decrease in SVR during midterm 
pregnancy in rats. 
Our current findings are consistent with earlier work which showed that either 
neutralization of circulating relaxin by antibodies or elimination by ovariectomy, abolished renal 
and osmoregulatory adaptations in midterm pregnant rats [23].   In both the renal and systemic 
circulations, there was total abrogation of the gestational changes by neutralization or 
elimination of circulating relaxin indicating the absence of other contributing or compensatory 
mechanisms at this stage of pregnancy.  In addition, the osmoregulatory changes were either 
totally or largely prevented. 
The decline in SVR and increase in global AC during pregnancy can be attributed, at 
least in part, to a reduction in vascular smooth muscle tone [5].  Another contribution may come 
from maternal angiogenesis [59] and, as discussed above, relaxin has been shown to exhibit 
angiogenic attributes [20, 56].  We believe that the same mechanisms involving upregulation of 
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vascular gelatinase by relaxin which acts through the endothelial ETB receptor/nitric oxide 
vasodilatory pathway to trigger the gestational decline in renal vascular resistance, likely 
contributes to the decline in SVR during pregnancy; although different mechanisms in other 
circulatory beds are also likely to contribute [66, 67]. 
The findings from the present study indicate that circulating relaxin alone, without any 
other contributing or compensatory agents, mediates the transition of the systemic circulation 
from the virgin to the pregnant state in the gravid rat model.  To determine whether relaxin alone 
maintains these adaptations in the systemic circulation through the late stages of pregnancy, we 
examined the effects of neutralizing circulating relaxin in late-pregnant rats on systemic 
hemodynamics and arterial properties.  As discussed above this is still work in progress and the 
data presented here are preliminary (see Section 5.1.8).  However, even with this preliminary 
data certain trends are evident.  First, it appears that unlike during midgestation when the 
increase in CO was primarily a result of an increase in SV with little change in HR, the increase 
in CO in late pregnant rats appears to be governed by an increase in HR with little change in SV.  
This apparent difference in the mechanisms for the increase in CO during mid and late gestation 
needs to be explored further.  Second, our data strongly suggest that although relaxin still plays a 
role in maintaining the adaptations in hemodynamics and arterial properties during the late stages 
of pregnancy, it is most likely not the only mediator.  In contrast to during mid-pregnancy when 
eliminating circulating relaxin completely abolished the increase in CO and global AC and 
decrease in SVR, neutralizing circulating relaxin in late pregnant rats only partially eliminated 
these changes.  It is likely that as pregnancy progresses other factors are recruited that act in 
concert with relaxin to maintain the changes in hemodynamics and arterial properties.  Another 
possible reason for the partial response to the MCA1 antibody in late pregnant rats may be the 
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efficacy of the antibody during this stage of pregnancy.  It is possible that during the late stages 
of pregnancy when circulating relaxin levels are at the highest, the MCA1 antibody only partially 
neutralizes the hormone.  In that case there may still be low concentrations of relaxin circulating 
in the MCA1-treated late-pregnant rats which could account for the partial increase in CO and 
global AC and decrease in SVR that we observed in these animals.  To investigate this 
phenomenon, we could study ovariectomized late pregnant rats in which case we would be 
certain that there would be no circulating relaxin. 
6.2 EFFECTS OF RELAXIN ON ARTERIAL WALL STRUCTURE AND 
VASCULAR REMODELING 
6.2.1 Relaxin-Induced Compositional Remodeling of the Vascular Wall 
The increase in vascular gelatinase observed during pregnancy or after administration of 
recombinant human relaxin (rhRLX) to nonpregnant rats led us to consider that, in addition to 
reducing vascular smooth muscle tone, relaxin may also induce structural remodeling of the 
arterial wall. Vascular gelatinase activity has been implicated in vascular remodeling through 
degradation of extracellular matrix proteins such as collagen and elastin [68]. We postulated that 
both the reduction in smooth muscle tone and arterial remodeling could contribute to the increase 
in global AC in vivo during pregnancy, and after relaxin administration to nonpregnant rats.  
Accordingly, we examined the effects of relaxin on arterial collagen and elastin content.  We 
found relaxin does induce compositional remodeling of small renal arteries by reducing relative 
collagen content.  This finding is consistent with several other published reports implicating 
101 
relaxin’s ability to antagonize the synthesis of or promote degradation of collagen.  On the 
cellular level, rhRLX treatment has been shown to reduce the expression of collagen in human 
dermal fibroblasts and neonatal rat fibroblasts following stimulation with TGF-β1 [69, 70].  On 
the tissue level, rhRLX treatment has been shown to reduce collagen content in rodent models of 
renal, pulmonary, hepatic and cardiac fibrosis [69, 71-74].  Additionally, administration of 
rhRLX to hypoxic rats reduced accumulation of collagen in the main pulmonary artery [75].  
Relaxin-deficient mice have also been shown to exhibit an accelerated, age-related increase in 
collagen content in the lung, heart, kidneys and skin [63-65, 76, 77].  These findings in Rlx-/- 
mice are consistent with our current work in which we found small renal arteries from Rlx-/- mice 
exhibit significantly increased levels of collagen compared to control counterparts.  Furthermore, 
administration of rhRLX to older Rlx-/- mice significantly reversed the established fibrosis in 
lungs, kidneys and heart (reviewed in [76]). 
Pregnancy has also been associated with compositional remodeling of the vascular wall.  
Mackey et al. reported that mesenteric arteries isolated from late pregnant rats are characterized 
by significantly reduced collagen content when compared to nonpregnant controls [12].  In 
addition, uterine arteries have been shown to exhibit a pregnancy-associated reduction in 
collagen content [7].  It is possible that endogenous, circulating relaxin plays a role in vascular 
wall compositional remodeling during pregnancy. 
6.2.2 Relaxin-Induced Geometric Remodeling of the Vascular Wall 
In addition to the relaxin-induced compositional remodeling, small renal arteries form 
rhRLX-treated and Rlx+/+ mice, as well as rhRLX-treated rats, exhibited geometric remodeling of 
the vascular wall.  Specifically, these arteries were characterized by a significant increase in 
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vascular wall area, as a result of smooth muscle cell hyperplasia, when compared to arteries from 
respective control animals.  The increase in wall area may be a result of direct actions of relaxin 
on the vascular wall; although we do not currently have any evidence to support this conjecture.  
Geometric remodeling of the vascular wall has also been reported in pregnant animals.  Osol and 
colleagues first reported that uterine radial arteries from late pregnant rats were characterized by 
a significant increase in vascular wall cross-sectional area when compared to those from 
nonpregnant rats [8].  In subsequent work they showed that vascular smooth muscle cells 
isolated from radial arteries were significantly elongated during late gestation and that the rate of 
proliferation of these cells and those from the main uterine artery was significantly increased.  
Accordingly, they concluded that smooth muscle cell hypertrophy and hyperplasia were 
underlying factors in the observed increase in vascular wall area of uterine arteries during 
gestation [11, 78].  In other studies, remodeling of the uterine artery (including increased 
vascular wall cross-sectional area resulting for smooth muscle cell hyperplasia) in 
psuedopregnant mice was comparable to that observed in normal pregnant mice.  This finding 
indicated the presence of the fetus is not required for uterine artery remodeling during pregnancy 
and that maternal factors are most likely responsible for the changes in the vascular wall [79]. 
It is also likely the relaxin-mediated increase in wall area is secondary to the increase in 
blood flow observed during exogenous rhRLX administration or during pregnancy.  Geometric 
remodeling of the vascular wall has also been reported in arteries during other physiological and 
experimentally induced conditions that result in a chronic increase in blood flow.  Rat mesenteric 
arteries subjected to chronically elevated blood flow have been shown to exhibit a time-
dependent increase in vascular wall area [80].  In another study using a similar animal model, 
mesenteric arteries subjected to chronically reduced blood flow were characterized by decreased 
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vascular wall area resulting from both the loss and reduction in size of smooth muscle cells [81].  
Conversely, chronically elevated blood flow in similar arteries yielded increased wall area as 
result of increased smooth muscle cell proliferation [81].  It has been suggested that a chronic 
increase in blood flow results in an increase in wall shear stress, which leads to an elevation of 
the strain on arterial smooth muscle cells.  This in turn can stimulate the expression of oncogenes 
and the production of growth factors which contribute to the hypertrophy of the vascular wall 
(reviewed in [82]). 
To summarize, the exact mechanism through which relaxin elicits vascular wall 
geometric remodeling is not currently known.  Relaxin, when exogenously administered, locally 
produced, or when circulating during pregnancy, may directly trigger geometric remodeling of 
the vascular wall through smooth muscle cell hyperplasia.  On the other hand the relaxin-induced 
vascular wall geometric remodeling may be an indirect result of the relaxin-mediated increase in 
flow. 
6.2.3 Functional Relevance of Relaxin-Induced Vascular Wall Remodeling  
In order to determine the functional relevance of the relaxin-mediated vascular wall 
remodeling of small renal arteries, we examined the passive mechanical properties of these 
arteries.  In these experiments, isolated small renal arteries were treated with papaverine and 
EGTA in order to eliminate vascular smooth muscle tone and enable us to quantify passive 
arterial compliance.  Our results indicated that at any given midwall radius, circumferential wall 
stress of small renal arteries from relaxin-treated rats and mice was significantly reduced when 
compared to arteries from vehicle-infused counterparts.  Similarly, small renal arteries from 
Rlx+/+ mice were characterized by significantly lower circumferential wall stress for any given 
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midwall radius when compared to arteries from Rlx-/- mice.  Of note, an increase in arterial 
compliance in small arteries, as we observed in small renal arteries, has been shown to 
significantly contribute to an overall increase in global arterial compliance [83].   Additionally, 
similar changes in the passive mechanics of mesenteric resistance arteries have been reported for 
late gestation in the rat [12].  Because vascular gelatinase activity plays a pivotal role in the 
remodeling of the extracellular matrix and also in the renal vasodilatory response to relaxin [25, 
68], there are likely overlapping hormonal and cellular signaling mechanisms for the 
vasodilatory and vascular compliance changes during pregnancy and during rhRLX 
administration.   
The increase in passive compliance of small renal arteries following relaxin treatment 
could be attributed to both the relaxin-mediated vascular wall compositional (reduced collagen 
content) and geometric (increased wall area) remodeling observed in these arteries.  To 
determine the relative contributions of each type of remodeling, we examined the stiffness 
properties of the vascular wall using stress-strain analysis with the expectation that the 
structurally remodeled arteries from rhRLX-treated mice would exhibit reduced vascular wall 
stiffness.  Contrary to our expectations, our initial analysis examining uniaxial (circumferential) 
wall stress-strain behavior showed that the relaxin-induced reduction in relative collagen content 
did not translate into reduced vessel wall stiffness.  To ensure that we were not limited in our 
approach by characterizing arterial mechanical behavior in the circumferential direction only, we 
implemented a more physiologically relevant model of arterial mechanical behavior (i.e. a 
biaxial strain energy model).  Using this model, we determined that vascular wall stiffness was 
not modified by relaxin under conditions of low circumferential and axial loads.  However, at 
higher loads the relaxin-induced compositional remodeling became functionally relevant as the 
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arteries from the rhRLX-treated mice exhibited increasingly reduced vascular wall stiffness.  
Ultimately, the greatest reduction in vascular wall stiffness was observed at the highest loads.  
Interestingly, the difference in vascular wall stiffness between the arteries from the rhRLX-
treated and control mice seems to be more dependent on circumferential rather than axial strain.  
These findings suggest the relaxin-induced decrease in collagen content of small renal arteries is 
functionally relevant only under conditions of high circumferential and, to a smaller degree, axial 
loads.  Thus, under conditions of low circumferential and axial loads, the increased passive 
compliance observed in these arteries following relaxin treatment is primarily attributable to the 
relaxin-induced geometric remodeling.   
There are several possible explanations as to why vascular wall stiffness is unchanged in 
small renal arteries from rhRLX-treated mice when subjected to low circumferential and axial 
loads, even though collagen content is significantly reduced in these arteries.  First, it is possible 
that the magnitude of change in collagen content that we observed is not enough to elicit 
alterations in the passive vascular wall mechanical properties of these arteries.  Second, passive 
vascular wall mechanical properties are not only determined by the relative content and 
mechanical properties of the individual load-bearing components of the vascular wall (i.e. 
collagen and elastin) but also by the way in which these components are architecturally arranged.  
Thus, overall collagen content may be significantly reduced in small renal arteries from rhRLX-
treated mice but the architectural arrangement of collagen and elastin fibers may be unchanged.  
Of note, we do not currently have any data on the effects of relaxin on collagen and elastin fiber 
organization in the vascular wall.   Although both of these scenarios are possible, we do not 
believe that they are likely.   
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Instead, our findings are more consistent with published works on the relative 
contributions of collagen and elastin on arterial passive mechanical properties.  It is generally 
accepted that under conditions of low wall strain, elastin is the primary load-bearing component 
of the vascular wall and that as wall strain increases, collagen plays a more prominent role in 
supporting passive wall tension.  To this end, Cox examined the passive mechanical properties of 
several different artery-types under in-vitro uniaxial (circumferential) loading conditions and 
reported that at low levels of circumferential strain corresponding to transmural pressures of up 
to 100 mmHg, only about 10% of collagen fibers support wall stress [84].  He reasoned that in 
addition to the ratio of collagen-to-elastin content and total connective tissue composition, 
arterial wall mechanics strongly depends on the differences in the recruitment of collagen fibers 
at different transmural pressures.  Similar findings have been reported for dog aortae under in 
vivo conditions.  Armentano et al. showed that significant participation of collagen fibers in 
vessel resistance to deformation occurs at mean aortic pressure of 118 mmHg and resistance to 
stretch at lower pressures is mainly supported by elastin fibers [85].  Finally, Dobrin and 
Canfield examined the passive biaxial mechanical behavior of dog carotid arteries following 
treatment with elastase or collagenase [86]. They showed that treatment with elastase 
significantly reduced circumferential and axial stress at low and high levels of biaxial strain 
indicating that elastin bears a portion of the distending load in both the circumferential and axial 
directions.  Conversely, degradation of collagen had no significant effects on axial stress and 
reduced circumferential stress only when the arteries were pressurized by at least 60 mmHg.  
This indicates that collagen fibers are only load bearing in the circumferential direction and at 
higher levels of circumferential strain. 
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Combining these findings with our current work, we have shown that relaxin induces 
geometric remodeling of small renal arteries by increasing arterial wall area and compositional 
remodeling by reducing relative collagen content.  Under conditions of low circumferential and 
axial loads, there are no significant differences in the vascular wall mechanical properties of 
small renal arteries isolated from rhRLX-treated mice compared to those from control mice.  
This is because under these conditions, elastin fibers are the primary load-bearing components of 
the vascular wall and relaxin does not elicit any changes in vascular elastin content.  Under 
conditions of increasing biaxial loads (more particular increasing circumferential load), the 
reduced collagen content of small renal arteries from rhRLX-treated mice yields increasing lower 
levels of vascular wall stiffness compared to arteries from control mice.     
Based on these observations, we began to investigate what the physiologic set points for 
circumferential and axial loads are.  That is, we wanted know the magnitudes of biaxial strains 
for small renal arteries under normal physiologic loading conditions.  Our preliminary data 
indicate that these arteries are subjected to low levels of circumferential and axial strains (Eθθ: 
~1.1 and Ezz: ~0.5) in situ.  At these magnitudes of biaxial strains, we did not observe any 
difference in tissue strain energy between the rhRLX-treated and control small renal arteries (see 
Figure 26).  Interestingly, previous work has shown that during pregnancy there is a significant 
increase in the volume of the kidney.  Thus, it is quite likely that renal arteries during pregnancy 
are subjected to higher levels of stretch in axial direction, and perhaps even in the circumferential 
direction.  It is also likely that similar increases in kidney volume and loading conditions of 
small renal arteries occur with relaxin infusion in nonpregnant animals.  If these conjectures 
regarding increased circumferential and axial loads are true then our data indicate that the 
rhRLX-treated arteries will have reduced vascular wall stiffness compared to control arteries at 
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the same lading conditions.  Thus, if rhRLX-treated small renal arteries were subjected to 
elevated levels of biaxial loads without compensatory remodeling of the vascular wall and 
reduced stiffness then these arteries would have had significantly increased wall stress.  Thus, the 
relaxin-induced reduction in stiffness at high loads can be considered to be an adaptive response 
that guards against excessive rise in wall stress. 
6.2.4 Site-Specificity of the Effects of Relaxin on Systemic Arterial Circulation 
The relaxin-mediated arterial remodeling appears to be specific to small renal arteries.  
External iliac arteries isolated from rhRLX-treated and Rlx+/+ mice did not exhibit alterations in 
wall area, smooth muscle cell density, or collagen content compared to the respective controls.  
Consequently, passive compliance was also unchanged in these arteries.  We found similar 
results in isolated aortae in that relaxin treatment did not induce any significant alterations in 
smooth muscle cell density or collagen content in these arteries either (see Appendix B).  Of 
note, the pregnancy-induced smooth muscle cell hyperplasia in uterine arteries in late pregnant 
rats was not observed in mesenteric arteries from the same rats [78].  Additionally, 
pseudopregnancy did not induce significant changes in wall area or smooth muscle cell 
characteristics in carotid arteries or abdominal and thoracic aortae [79].  There are a couple of 
possible explanations for this phenomenon.  First, if the vascular remodeling observed following 
relaxin treatment and during pregnancy is secondary to the increase in blood flow, it is possible 
that certain artery beds are not subject to the same magnitude of increase in flow or, more 
importantly, increase in shear stress that occurs in the renal and uterine circulations.  
Consequently, the stimulus for vascular remodeling is not as potent in these artery beds 
following relaxin treatment or during pregnancy.  However, if the relaxin induced vascular 
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remodeling is a direct effect of the hormone’s actions on the vascular wall, it is also possible that 
the LGR7 receptor is more predominantly expressed by certain vascular beds than others.  In 
fact, other work has suggested that small renal arteries from male mice may exhibit lower 
expression levels of the LGR7 receptor mRNA compared to female rats [52] and our current 
work suggests there is a difference in the temporal response to relaxin between male and female 
rats.  It is just as likely that this difference in receptor expression or temporal response to relaxin 
between genders exist for different vascular beds. 
6.2.5 Unexpected Findings 
Because isolated renal arteries from rhRLX-treated mice and rats were characterized by 
increased passive compliance, we expected to observe similar alterations in the passive 
mechanical properties of arteries from midterm pregnant rats.  However, there were no 
differences in the passive compliance or wall area of small renal and larger mesenteric arteries 
isolated from virgin and gravid rats; nor did the relaxin neutralizing or control antibodies impact 
arterial passive mechanics. 
There are several potential explanations for the observed lack of relaxin’s effects on 
vascular passive properties during this stage of pregnancy.  First, rat relaxin is not as potent as 
human relaxin. Therefore, although circulating levels of rat relaxin during midterm pregnancy 
are sufficient to reduce arterial tone, they may be inadequate to affect vascular remodeling.  
Indeed, previous work has shown human relaxin is more potent than rat relaxin based on the 
isolated rat atria chronotropy bioassay [87].  Bearing this in mind, the increase in global AC 
observed in midterm pregnant rats appears to be primarily attributable to reduction in vascular 
smooth muscle tone and not to vascular remodeling.  It should be noted that circulating levels of 
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relaxin are considerably higher during late gestation in the rat.  Therefore, arteries isolated from 
late-pregnant rats may be more compliant.  Indeed, previous reports indicated that renal and 
mesenteric arteries isolated from late-pregnant rats exhibit both increased passive compliance 
and reduced tone [12, 88].  Another possibility is that there are counter-regulatory factors 
circulating during pregnancy (versus the administration of rhRLX alone to nonpregnant rats) that 
offset the vascular remodeling properties of endogenous relaxin at least during midgestation.  
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7.0  TAKE HOME MESSAGES 
On the whole animal level, relaxin increases cardiac output and global arterial 
compliance, and reduces systemic vascular resistance without any changes in mean arterial 
pressure in nonprengnant rats.   Of note, we have also shown that relaxin exerts similar effects in 
hypertensive rat models (see Appendix C) [89].  Relaxin also mediates the cardiovascular 
adaptations to pregnancy in the gravid rat model.  On the isolated artery level, relaxin induces 
vascular wall geometric and compositional remodeling in an artery-type-specific manner.  
Further, the relaxin-induced geometric remodeling of small renal arteries results in an increase in 
passive arterial compliance while the relaxin-induced compositional remodeling results in a 
reduction in vascular wall stiffness under high circumferential and axial loads. 
Increased arterial stiffness is observed in many physiological (normal aging, post-
menopausal state) and pathological (accelerated aging, chronic hypertension, diabetes, heart 
failure) conditions.  Vascular stiffening results in modifications of systemic hemodynamics that 
negatively impact both the heart and the vessels.  Based on its constellation of cardiovascular 
actions, we speculate that relaxin may prove to be a very useful therapeutic agent in improving 
vascular (stiffness and dilation) in the aforementioned cardiovascular states.  Relaxin may be 
particularly useful in preeclampsia where cardiac output and global arterial compliance are 
reduced, and systemic vascular resistance and mean arterial pressure are increased [90], resulting 
in marked and selective organ hypo-perfusion.  In this setting, relaxin administration may 
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improve maternal organ perfusion without unduly lowering MAP, thereby avoiding compromise 
of uterine blood flow.  In fact, there may be a potential role for aberrant relaxin regulation in 
abnormal pregnancies such as preeclampsia wherein the cardiovascular adaptations to pregnancy 
are inadequate. 
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APPENDIX A 
BIAXIAL TESTING SYSTEM FOR ISOLATED ARTERIES 
An isobaric arteriograph system (Living Systems Instrumentation, Burlington, VT USA) 
was modified to enable us to make simultaneous measurement of pressure-diameter and force-
length curves.  The modified system consists of 3 major components:  and vessel chamber with a 
micro cannula attached to a movable arm and a digital micrometer (Figure 36), a force 
transducer positioner (Figure 37), and a force transducer holder (Figure 38).  SolidWorks 
engineering drawings of the individual components are illustrated below.  Figure 39 illustrates a 
working assembly of the entire system. 
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Figure 36. SolidWorks Schematic of Isolated Vessel Chamber. 
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Figure 37. SolidWorks Schematic of Force Transducer Positioner. 
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Figure 38. SolidWorks Schematic of Force Transducer Holder. 
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Figure 39. SolidWorks Schematic of Working Assembly Vascular Biaxial Testing 
System. 
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APPENDIX B 
VASCULAR WALL EFFECTS OF RELAXIN ON ISOLATED AORTAE 
B.1 PREAMBLE 
Our work examining the effects of relaxin on vascular wall biochemical composition and 
smooth muscle cell (SMC) characteristics indicated that the vascular wall remodeling effects of 
relaxin were observed in small renal arteries and not external iliac arteries.  This led us to 
consider the possibility that the vascular wall remodeling effects of relaxin were artery type 
specific.  To begin to investigate this phenomenon, we examined the effects of relaxin on 
vascular wall collagen and elastin content as well as SMC density and size in aortae isolated 
from rhRLX-treated and control mice and Rlx+/+ and Rlx-/- mice.  Of note, due to their larger size 
we were unable to acquire any data on the vascular wall mechanical properties of these arteries 
(our mechanical testing apparatus for isolated arteries can only be used for small arteries). 
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B.2 SMOOTH MUSCLE CELL CHARACTERISTICS 
Figure 40 illustrates SMC density in aortae isolated from rhRLX-treated, and vehicle-
administered mice (Fig. 40A), as well as Rlx+/+ and Rlx-/- mice (Fig. 40B).  There was no 
significant difference in SMC density in aortae from rhRLX-treated mice compared to those 
from control mice (± vs ± cells/1000 μm2; mean±SEM; P = NS).  Similarly, SMC density in 
aortae from Rlx-/- mice was unchanged compared to those from Rlx+/+ mice (± vs  ± cells/1000 
μm2; P = NS). 
 
 
Figure 40. Smooth Muscle Cell Density of Aortae from Female Mice Administered Low Dose 
rhRLX, and Male Rlx+/+ and Rlx-/- mice. 
 
Average smooth muscle cell (SMC) density of aortae isolated from (A) mice treated with low 
dose rhRLX (1 μg/h) or vehicle for 5 days, and (B) Rlx+/+ and Rlx-/- mice.  Aortae were sectioned 
at 6 μm thickness and stained for smooth muscle actin. Smooth muscle cell density for each 
arterial cross-section was quantified as the ratio of number of SMC to arterial wall area.  
Representative SMC density of a given artery was computed as the average SMC density of 4-10 
serial cross-sections of that artery.  Data presented here are the composite average representative 
SMC density of each treatment group or genotype. 
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B.3 COLLAGEN AND ELASTIN CONTENT 
Relative collagen content was quantified as the ratio of collagen concentration to total 
protein concentration and relative elastin content was quantified as the ratio of the mass of 
elastin to tissue dry weight (see Section 4.5).   Similar to external iliac arteries, aortae isolated 
from rhRlx-treated mice did not exhibit a significant change in relative collagen content 
compared to those from control mice (± vs ± μg collagen/μg protein; mean±SEM; P = NS; 
Figure 41A). Additionally, elastin content was also unchanged in these arteries compared to 
those from control mice (± vs ± μg elastin/mg dry weight; Figure 41B). 
 
 
Figure 41. Relative Collagen and Elastin Content in Aortae from Female Mice Administered 
Low Dose rhRLX. 
 
Relative collagen (A) and elastin (B) content of aortae isolated from mice treated with low dose 
rhRLX (1 μg/h) or vehicle for 5 days.  Collagen and total protein concentrations were 
determined using the Sircol Collagen Assay and the Pierce BCA Protein Assay, respectively.  
Elastin amount was determined using the Fastin Elastin Assay.  Data presented here represents 
relative collagen content expressed as the ratio of collagen to total protein concentration and 
relative elastin content expressed as the amount of elastin per tissue dry weight. 
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We observed comparable results in aortae isolated from Rlx-/- and Rlx+/+ mice with the 
arteries from Rlx-/- mice not exhibiting any significant change collagen to total protein ratio 
compared to those from Rlx+/+ mice (± vs ± μg collagen/μg protein; mean±SEM; P = NS; Figure 
42).  Due to the limited availability of samples, we were unable to assess elastin content in aortae 
from Rlx+/+ mice.  However, based on our other work, we do not anticipate there will be a 
relaxin-mediated alteration in elastin content in these arteries. 
 
 
Figure 42. Relative Collagen Content in Aortae from Male Rlx-/- and Rlx+/+ mice 
 
Relative collagen content of aortae isolated from Rlx+/+ and Rlx-/- mice.  Collagen and total 
protein concentrations were determined using the Sircol Collagen Assay and the Pierce BCA 
Protein Assay, respectively.  Data presented here represents relative collagen content expressed 
as the ratio of collagen to total protein concentration. 
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B.4 SUMMARY 
To summarize, similar to external iliac arteries, administration of rhRLX to nonpregnant 
female mice did not yield any significant alterations in SMC density or arterial collagen and 
elastin content in aortae.  Similar observations were made in aortae from Rlx-/- and Rlx+/+ mice.  
We currently do not have any data on the effects of relaxin on vascular wall mechanical 
properties of aortae.  However, we anticipate that there will be no relaxin-mediated alterations in 
this as well.  This is further evidence suggesting that the vascular wall remodeling effects of 
relaxin are indeed artery type specific.  Although we do not know the exact mechanism for the 
artery-type specificity of relaxin, there are several possible explanations for this phenomenon 
discussed above (see Section 6.2.4). 
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APPENDIX C 
RELAXIN INCREASES CARDIAC OUTPUT AND REDUCES SYSEMIC ARTERIAL 
LOAD IN HYPERTENSIVE RATS 
C.1 PREAMBLE 
Although not directly related to the Specific Aims of the current work, we believe that 
relaxin’s effects on systemic arterial load may be particularly beneficial in treating vascular 
disorders (discussed in Section 7.0 above).  Currently, the effects (both magnitude and temporal 
pattern) of relaxin on systemic hemodynamics and arterial properties in hypertensive animal 
models are not known. We have initiated a study to examine the cardiovascular effects of rhRLX 
in hypertensive rats using two models – Long-Evans rats chronically administered angiotensin II 
(AII) and spontaneously hypertensive rats (SHR).  The details of this work are described below. 
C.2 INTRODUCTION 
Our work to date has revealed that relaxin acts outside the reproductive system and plays 
a role in regulating renal and cardiovascular function.  Specifically, chronic administration of 
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recombinant human relaxin (rhRLX) to nonpregnant female and male normotensive rats, elicits a 
vasodilatory response resulting in increased cardiac output as well as reduced steady and 
pulsatile components of the arterial load [48, 50].  Furthermore, the magnitude of change in 
arterial load in response to relaxin treatment is dependent on the baseline value of arterial load 
[50].  That is, rats that exhibited higher systemic vascular resistance (SVR) or lower global 
arterial compliance (AC) at baseline responded more robustly to relaxin administration.  Based 
on this observation, we reasoned that relaxin administration may be particularly effective in 
chronic hypertension in which arterial load is typically elevated.  In fact, St-Louis et al. and 
Massicotte et al. [17, 18] showed that relaxin administration to female spontaneously 
hypertensive rats (SHR) caused a significant decrease in mean arterial pressure as early as 6 
hours after the onset of relaxin infusion that persisted throughout the 5 days of relaxin infusion.  
However, these studies did not examine the effects of relaxin on other hemodynamic variables 
and arterial properties.  Other studies have also reported that relaxin antagonizes the actions of 
angiotensin II (AII) in rats [16, 74].  Therefore, the primary goal of this study was to investigate 
the impact of rhRLX on systemic hemodynamics and arterial properties in two models of 
hypertension: rats made hypertensive by chronic administration of AII and SHR rats. 
Relaxin-induced changes in systemic hemodynamics and arterial load properties were 
observed in normotensive rats at the earliest timepoint studied (3 days) and these changes 
persisted throughout the entire 7 days of rhRLX infusion [48, 50].  Other studies have shown that 
rhRLX vasodilates the renal circulation as early as 1-2 hours following the onset of intravenous 
infusion of the hormone [35].  Therefore, the second goal of the present study was to determine 
if the changes in systemic hemodynamics and arterial properties produced by relaxin would be 
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observed during short term (up to 6 hours) intravenous infusion of the hormone, especially in the 
hypertensive rats wherein arterial load is elevated at baseline. 
C.3 METHODS 
Animals 
Long-Evans female rats (age: 12-14 weeks) were purchased from Harlan Sprague-
Dawley (Frederick, Maryland USA) or Taconic (Germantown, NY USA).  Male and female 
spontaneously hypertensive rats (age: 12-15 weeks) were purchased from Hilltop (Scottdale, 
Pennsylvania USA).  They were provided PROLAB RMH 2000 diet containing 0.48% sodium 
(PME Feeds Inc., St. Louis, MO USA) and water ad libitum and were maintained on a 12:12-h 
light-dark cycle. 
Instrumentation for Measurements in Conscious State: Surgical Procedure 
The surgical procedure has been described previously in detail (see Section 4.1.2).  
Briefly, rats were anesthetized with 60 mg/kg ketamine i.m. and 21 mg/kg pentobarbital i.p.  
Ampicillin and atropine were given s.c. intraoperatively. The rats were then instrumented, using 
sterile technique, as follows: (i) a tygon catheter implanted in the right jugular vein with the tip 
lying at the junction of the anterior vena cava and right atrium, (ii) a thermodilution microprobe 
(22 cm long, F#1.5; Columbus Instruments, Columbus, OH USA) implanted in the abdominal 
aorta via the left femoral artery with the tip lying 1.0 cm below the left renal artery, and (iii) a 
mouse pressure catheter (TA11PA-C20, F#1.2; Data Science International, St. Paul, MN USA) 
implanted in the right carotid artery with the tip lying at the junction of the right carotid artery 
and aortic arch.  For the acute administration of rhRLX, another tygon catheter was implanted in 
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the inferior vena cava via the left femoral vein such that the tip lay 1.0 cm below the left renal 
artery. 
After instilling 0.05 ml of a heparin solution into the venous catheter(s) and plugging it 
with a straight pin, rats were given ampicillin by drinking water for 2 days (100 mg/50 ml with 2 
tablespoons of dextrose).  Terbutrol was given s.c. for post-operative analgesia. 
Animal Models of Systemic Hypertension 
Female Long-Evans rats 12-14 weeks of age, chronically administered AII via 
subcutaneous osmotic minipumps (60-120 ng/min) were used as one model of hypertension.  
Male spontaneous hypertensive rats 12-15 weeks of age were used as the second model of 
systemic hypertension. 
Administration of Recombinant Human Relaxin (rhRLX) 
The rhRLX (BAS, San Mateo, California USA) was provided as a 5.0 mg/ml solution in 
a buffer (20 mM sodium acetate, pH 5.0) and was diluted as necessary in the same buffer.  For 
the acute infusion protocol, rhRLX was administered as an i.v. bolus over 3 min (2.0 μg/0.3 ml) 
followed by a continuous i.v. infusion for up to 6 hours at 4 μg/h.  For chronic administration, 
one Alzet model 2001 osmotic minipump (Durect Corporation, Cupertino, CA USA) was 
inserted subcutaneously in the back of the animal under isoflurane anesthesia for rhRLX delivery 
up to 7 days at the dose of 4 μg/h.  
Experimental Protocols 
Acute administration of rhRLX to female normotensive rats (Figure 43).  Five days after 
surgery, 4 to 7 baseline measurements of systemic hemodynamics were obtained over a 2 hour 
period followed by intravenous bolus (2.0 μg/0.3 ml) and continuous infusion of rhRLX at 4 
μg/h for 4 hours.  Systemic hemodynamics were assessed every hour. 
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Figure 43. Timeline of Acute Administration of rhRLX to Normotensive Rats 
 
Recombinant human relaxin was administered acutely, via i.v. infusion, to female normotensive 
rats over 4 hours.  Measurements of systemic hemodynamics were made before and periodically 
during the 4 hour infusion period. 
 
 
Acute administration of rhRLX or vehicle to female, AII-treated rats (Figure 44).  Four to 
7 control measurements of systemic hemodynamics were obtained over a 2 hour period prior to 
the administration of AII.  Two days after initiating the AII infusion, 4 to 7 measurements of 
systemic hemodynamics were again obtained over a 2 hour period, followed by intravenous 
bolus (2.0 μg/0.3 ml) and continuous infusion of rhRLX at 4μg/h for 6 hours, or vehicle for 
rhRLX (20 mM sodium acetate, pH 5.0).  Systemic hemodynamics were assessed every 2 hours 
during the 6-hour rhRLX or vehicle infusion.  This protocol (i.e., acute infusion of rhRLX over a 
6-hour period) was repeated 5 days after initiating the AII infusion. 
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Figure 44. Timeline of Acute Administration of rhRLX to AII-Treated Rats 
 
Female rats were chronically administered AII for 5 days.  On days 2 and 5 following the 
initiation of AII infusion, rhRLX was administered acutely, via i.v. infusion, over 6 hours.  
Measurements of systemic hemodynamics were made before and after AII infusion prior to 
rhRLX infusion.  Systemic hemodynamic measurements were made again during the 6 hour 
rhRLX infusion. 
 
 
Acute and chronic administration of rhRLX to male spontaneously hypertensive rats 
(Figure 45).  For the acute administration protocol, 4 to 7 baseline measurements of systemic 
hemodynamics were obtained over a 2-hour period, 5 days after surgery followed by intravenous 
bolus (2.0 μg/0.3 ml) and continuous infusion of rhRLX (4 μg/h) for 6 hours.  Systemic 
hemodynamics were assessed every 2 hours during the 6-hour rhRLX infusion.  Following the 6-
hour infusion, the rats were implanted with a subcutaneous osmotic minipump that delivered 
rhRLX for 7 days at the dose of 4 μg/h.  Systemic hemodynamics were again measured 1, 4 and 
6 days following implantation of the minipump.   
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Figure 45. Timeline of Acute and Chronic Administration of rhRLX to SHR Rats 
 
Male SHR rats were administered rhRLX acutely for 6 hours followed by chronic rhRLX 
administration for 7 days.  Measurements of systemic hemodynamics were made before and 
during acute rhRLX infusion, and during chronic rhRLX infusion. 
 
 
 
Postmortem Procedures 
After completion of the measurement for the last time point of study, rats were 
anesthetized with 60 mg/kg pentobarbital i.v.  Blood was obtained from the abdominal aorta for 
measurement of serum rhRLX levels.  The position of the jugular catheter relative to the right 
atrium, the placement of the pressure catheter relative to the aortic arch, and the position of the 
thermocouple relative to the left renal artery were recorded. 
Systemic Hemodynamics and Arterial Mechanical Properties 
See Section 4.1.5 – 4.1.8 for experimental procedures used.   
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Statistical Analysis  
Data are presented as means + SEM.  One-factor repeated measures ANOVA was used to 
compare mean values at various time points during the administration of rhRLX to the baseline 
value.  Two-factor ANOVA with repeated measures on both factors was used to compare mean 
values obtained during acute rhRLX infusion on days 2 and 5 following the initiation of AII 
infusion (Factor 1: different time points during acute rhRLX infusion; Factor 2: different AII 
infusion duration).  If significant main effects were observed, pairwise comparisons between 
groups were performed using Fisher’s LSD test.  The Student’s paired t-test was used to compare 
composite mean values during chronic rhRLX infusion with baseline values.  P<0.05 was taken 
to be significant. 
C.4 RESULTS 
Portions of this work have been previously published elsewhere [89].   
Acute administration of rhRLX to AII-treated rats.  As detailed in Methods, each rat was 
administered rhRLX i.v. for a 6-hour period on days 2 and 5 after the initiation of the AII 
treatment.  Because there was no statistically significant difference between days 2 and 5 for any 
of the systemic hemodynamics and arterial properties (by 2-factor repeated measure ANOVA), 
the results were averaged.  Control values of HR, SV, CO and MAP prior to AII administration 
were 399±7 bpm, 0.34±0.02 ml, 135±6 ml/min, and 111±2 mmHg, respectively.  Following 
treatment with AII (defined as the baseline condition for rhRLX treatment), HR, SV, CO and 
MAP were 367±14 bpm, 0.31±0.02 ml, 114±4 ml/min, and 138±6 mmHg, respectively.  Figure 
46 illustrates the temporal patterns of changes in these hemodynamic variables (expressed as 
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percentages of baseline) in response to short-term i.v. infusion of rhRLX.  Short-term rhRLX 
treatment resulted in a significant increase from baseline in CO within 2 hours after the initiation 
of the infusion.  This increase in CO was due to increases in both SV and HR (Fig. 46).  After 6 
hours of rhRLX infusion, CO remained elevated (35±8%) above baseline, mainly due to the 
augmentation of SV to 26±6% above baseline.  There was no statistically significant changes 
observed in MAP during the rhRLX infusion (Fig. 46). 
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Figure 46. Temporal Pattern of Changes in Systemic Hemodynamics in AII-Treated Female 
Rats Administered Acute Low Dose rhRLX 
 
Temporal changes in systemic hemodynamics in response to intravenous infusion of 
recombinant human relaxin (rhRLX) in female rats (n=7) chronically administered angiotensin II 
by osmotic minipump (60 ng/min) (see Methods for details).  Rats were administered a 2 μg/0.3 
ml bolus of rhRLX, followed by an infusion rates of 4 μg/h.  Cardiac output (A), heart rate (B), 
stroke volume (C), and mean arterial pressure (D) during rhRLX administration are presented as 
percentages of baseline.  * P<0.05 vs. baseline (post-hoc Fisher’s LSD). 
 
Control value of SVR prior to AII administration was 49.9±2.1 mmHg.s/ml.  Following 
treatment with AII (i.e., the baseline condition for rhRLX treatment), SVR increased to 74.6±3.9 
mmHg.s/ml (P<0.001).  Figure 47 illustrates the temporal effects of acute i.v. infusion of rhRLX 
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on systemic arterial properties.  There was a significant decrease from baseline in SVR within 2 
hours following the onset of rhRLX infusion and global arterial compliance, as indicated by both 
measures (ACarea and SV/PP), was significantly increased within 4 hours. 
 
 
Figure 47. Temporal Pattern of Changes in Systemic Arterial Properties in AII-Treated Female 
Rats Administered Acute Low Dose rhRLX 
 
Temporal changes in systemic arterial properties in response to intravenous infusion of 
recombinant human relaxin (rhRLX) in female rats (n=7) chronically administered angiotensin II 
by osmotic minipump (60 ng/min) (see Methods for details).  Rats were administered a 2 μg/0.3 
ml bolus of rhRLX, followed by an infusion rates of 4 μg/h.  Systemic vascular resistance (A) 
and two measures of global arterial compliance ACarea (A), and SV/PP (C) during rhRLX 
administration are presented as percentages of baseline.  * P<0.05 vs. baseline (post-hoc Fisher’s 
LSD). 
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As in our other work, we calculated a composite mean change from baseline for each 
variable by averaging values at all successive time points during the infusion of rhRLX that were 
characterized by a significant change from baseline but were not significantly different from 
each other.  This yielded increases in CO and global arterial compliance of 24.9±3.9 and 
34.3±12.6% from baseline, respectively and a decrease in SVR of 17.2±3.5% (all P<0.05 vs. 
baseline).  The serum concentration of rhRLX measured in blood obtained after 6 hours of 
infusion was 26.0±0.6 ng/ml. 
Three rats were subjected to the same protocol except they were administered the vehicle 
for rhRLX, rather than rhRLX.  There were no significant changes from baseline in systemic 
hemodynamics or arterial properties during the 6-hour vehicle infusion (data not shown). 
Acute administration of rhRLX to male spontaneously hypertensive rats.  Baseline values 
of HR, SV, CO, and MAP were 385±13 bpm, 0.33±0.02 ml, 129±7 ml/min, and 175±7 mmHg, 
respectively.  As detailed in Methods, systemic hemodynamics and arterial properties were 
assessed continuously during the 6-hour infusion of rhRLX.  There were no statistically 
significant changes in the systemic hemodynamics or arterial properties among the data for 
various timepoints during the 6-hour infusion.  Therefore, figure 48 illustrates the combined 
mean change from baseline of the systemic hemodynamic variables measured over the 6-hour 
period.  As compared to baseline, there was a slight, but statistically significant, increase in HR 
(Fig. 48B) which was offset by a small, but not statistically significant, decrease in SV (Fig. 
48C), such that CO remained unchanged (Fig. 48A).  Similarly, MAP was unchanged during the 
short term rhRLX infusion (Fig. 48D). 
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Figure 48. Temporal Pattern of Changes in Systemic Hemodynamics in Male SHR Rats 
Administered Chronic Low Dose rhRLX 
 
Temporal changes in systemic hemodynamics in response to acute and chronic administration of 
rhRLX in male spontaneously hypertensive rats (n=7).  For acute administration, rats were given 
an i.v. 2 μg/0.3 ml bolus of rhRLX, followed by an infusion rate of 4μg/h.  For chronic 
administration, rhRLX was delivered by subcutaneous osmotic minipump at 4 μg/h.  Cardiac 
output (A), heart rate (B), stroke volume (C), and mean arterial pressure (D) during rhRLX 
administration are presented as percentages of baseline.  Bar graphs represent the combined 
mean change throughout the 6 hours of acute, or days 1, 4 and 6 of chronic rhRLX 
administration.  * P<0.05 vs. baseline; † P<0.05 vs. short-term rhRLX-treated rats (post-hoc 
Fisher’s LSD). 
 
Baseline values of SVR, ACarea, and SV/PP were 83.7±5.6 mmHg.s/ml, 3.8±0.2 
μl/mmHg, and 5.3±0.4 μl/mmHg, respectively.  Figure 49 illustrates the combined mean change 
136 
of the systemic arterial properties obtained during the 6-hour infusion of rhRLX.  Short-term 
infusion of rhRLX did not yield any statistically significant changes. 
 
 
Figure 49. Temporal Pattern of Changes in Systemic Arterial Properties in Male SHR Rats 
Administered Chronic Low Dose rhRLX 
 
Temporal changes in arterial properties in response to acute and chronic administration of 
rhRLX in male spontaneously hypertensive rats (n=7).  For acute administration, rats were given 
an i.v. 2 μg/0.3 ml bolus of rhRLX, followed by an infusion rate of 4μg/h.  For chronic 
administration, rhRLX was delivered by subcutaneous osmotic minipump at 4 μg/h.  Systemic 
vascular resistance (A), and two measures of global arterial compliance ACarea (B), and SV/PP 
(C) during rhRLX administration are presented as percentages of baseline.  Bar graphs represent 
the combined mean change throughout the 6 hours of acute, or days 1, 4 and 6 of chronic rhRLX 
administration.  * P<0.05 vs. baseline; † P<0.05 vs. short-term rhRLX-treated rats (post-hoc 
Fisher’s LSD). 
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Chronic administration of rhRLX to male spontaneously hypertensive rats.  There were 
no statistically significant differences in systemic hemodynamics and arterial properties assessed 
at days 1, 4 and 6 of rhRLX administration by s.c. osmotic minipump.  Therefore, combined 
mean changes of these variables obtained over the 6 day chronic infusion of rhRLX are 
illustrated in figures 41 and 42.  Chronic rhRLX treatment resulted in a significant increase in 
HR compared to baseline (Fig. 48B).  Similarly, SV was significantly increased from baseline 
(Fig. 48C).  The increase in HR and SV resulted in a significant increase in CO (Fig. 48A).  
MAP was not significantly altered during the chronic rhRLX infusion (Fig. 48D).  SVR was 
significantly reduced from baseline during the chronic rhRLX infusion (Fig. 49A) and both 
measures of global arterial compliance were significantly increased from baseline (Fig. 49B & 
49C).  The serum concentration of rhRLX measured in blood obtained after 7 days of infusion 
was 29.8±0.76 ng/ml. 
Acute administration of rhRLX to female Long-Evans, normotensive rats (n=7).  Figure 
50 illustrates the temporal changes in systemic hemodynamics in response to acute i.v. infusion 
of rhRLX in normotensive rats expressed as percentages of baseline.  Baseline values of HR, SV, 
CO and MAP were 425±17 bpm, 0.30±0.01 ml, 129±7 ml/min, and 112±3 mmHg, respectively.  
During the 4-hour i.v. infusion of rhRLX, there were no significant changes from baseline in HR, 
SV, or CO (Fig. 50A-50C).  There was a small (<10%), albeit significant increase in MAP 1 
hour after the onset of rhRLX infusion and this increase persisted throughout the 4-hour infusion 
(Fig. 50D).  Combining all the timepoints studied yielded overall changes of 4.4±2.9%, 
2.3±2.6%, and 7.1±4.1% in HR, SV, and CO, respectively (all P=NS vs. baseline).  Similarly, 
there was an overall increase of 9.8±3.0% in MAP (P<0.05 vs. baseline). 
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Figure 50. Temporal Pattern of Changes in Systemic Hemodynamics in Female Normotensive 
Rats Administered Low Dose rhRLX 
 
Temporal changes in systemic hemodynamics in response to intravenous infusion of rhRLX in 
female Long Evans, normotensive rats.  Rats were first administered a 2 μg/0.3 ml bolus of 
rhRLX over 3 min, followed by an infusion rate of 4 μg/h.  Cardiac output (A), heart rate (B), 
stroke volume (C), and mean arterial pressure (D) during rhRLX administration are presented as 
percentages of baseline.  * P<0.05 vs. baseline (post-hoc Fisher’s LSD). 
 
The temporal responses of systemic arterial properties during acute i.v. infusion of 
rhRLX expressed as percentages of baseline are illustrated in figure 51.  Baseline values of 
SVR, ACarea, and SV/PP were 53.1±3.2 mmHg.s/ml, 7.1±0.4 μl/mmHg, and 8.8±0.7 μl/mmHg, 
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respectively.  Short-term infusion of rhRLX yielded no statistically significant changes from 
baseline in any systemic arterial properties.  Because there were no statistically significant 
differences among various timepoints (1-4 hours) for any of the variables, data were combined 
for all timepoints studied. This yielded overall changes of 4.1±4.1%, -2.9± 2.9%, and 5.5±4.3% 
in SVR, ACarea, and SV/PP, respectively (all P=NS vs. baseline).  The serum concentration of 
rhRLX measured in blood obtained after 4 hours of infusion was 13.4±3.5 ng/ml. 
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Figure 51. Temporal Pattern of Changes in Systemic Arterial Properties in Female 
Normotensive Rats Administered Low Dose rhRLX 
 
Temporal changes in systemic arterial properties in response to intravenous infusion of rhRLX in 
female Long Evans, normotensive rats.  Rats were first administered a 2 μg/0.3 ml bolus of 
rhRLX, followed by an infusion rate of 4 μg/h.  Systemic vascular resistance (A) and two 
measures of global arterial compliance ACarea (A), and SV/PP (C) during rhRLX administration 
are presented as percentages of baseline.  
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C.5 DISCUSSION 
Major findings of the present study are as follows: (1) rhRLX reduces arterial load (a 
decrease in systemic vascular resistance and an increase in global arterial compliance) and 
increases cardiac output in hypertensive rats, without any effect on mean arterial pressure; (2) 
The temporal pattern of these changes are model-specific.  While rats with AII-induced 
hypertension respond to rhRLX administration rapidly (within 2 hours), spontaneously 
hypertensive rats, like normotensive rats, respond more slowly (at least 1 day).  To our 
knowledge, this investigation of relaxin on systemic hemodynamics and arterial properties in 
hypertensive animal models is unprecedented. 
In other work, we reported that chronic administration of rhRLX to normotensive rats, 
elicits a systemic vasodilatory response that is observed as early as 3 days following the onset of 
rhRLX infusion (see Section 5.1.3 and Section 5.1.6).  In other work, rhRLX elicited a 
vasodilatory response in the renal circulation that is observed during both acute (within 1-2 
hours) and chronic (2-5 days) administration of the hormone [16, 35].  In fact, the hormone 
mediates the renal circulatory (and osmoregulatory) changes of pregnancy in this species [23].  
In the current study we did not observe a systemic vasodilatory response when the hormone was 
administered acutely to normotensive rats for 1 to 6 hours.  This finding suggests that certain 
organ beds such as the kidneys are able to respond more quickly to the vasodilatory actions of 
relaxin1.  Consistent with this concept is the observation that following preconstruction with 
phenylephrine, small renal, but not mesenteric or coronary arteries isolated from rats demonstrate 
an immediate relaxation response to rhRLX (Jackie Novak and Kirk P. Conrad, unpublished 
                                                 
1 N.B.  Because baseline renal blood flow (RBF) is only ~20% of CO, the expected increase in CO caused by a 20-
40% increase in RBF by rhRLX is not readily detectable. 
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data, 2004).  Furthermore, Fisher et al. reported that isolated human gluteal, but not pulmonary 
resistance arteries showed a rapid relaxation response to relaxin [91].  It is therefore possible that 
when administered acutely, relaxin preferentially vasodilates certain organ beds, and is 
ineffective in vasodilating others at least on a short term bases.  Of note, acute i.v. infusion of 
rhRLX did result in a slight, but significant increase in MAP similar to previously reported 
observations [92]. 
Interestingly, rhRLX did elicit a rapid systemic vasodilatory response when acutely 
administered to rats with AII-mediated hypertension.  In fact, the present work in hypertensive 
rats was spurned by our previous observation showing that normotensive rats with higher 
magnitudes of arterial load at baseline responded more robustly to chronic relaxin treatment.  
Rats with AII-mediated hypertension responded with an even greater increase in cardiac output 
and decrease in arterial load in a much shorter period of time than normotensive rats (vide 
supra).  Pregnancy, and more specifically relaxin, has previously been shown to antagonize the 
vascular actions of AII.  Conscious pregnant rats were less responsive to the renal and systemic 
vasoconstrictory effects of AII, both at mid- [27] and late-gestation [26, 93].  Chronic 
administration of relaxin to nonpregnant rats also attenuated AII-induced renal vasoconstriction 
[16].  Finally, Samuel et al. reported that relaxin reduced cardiac collagen synthesis and 
accumulation in myofibroblasts that had been stimulated with AII [74]. 
In contrast to AII-treated rats, spontaneously hypertensive rats did not respond to acute 
infusion of rhRLX.  This finding was contrary to our expectations because recent reports 
demonstrated that AII contributes to hypertension in SHR rats through the angiotensin type 1 
receptor [94, 95], and because relaxin has been shown to be a functional AII antagonist [16, 74].  
The lack of response was not due to inadequate serum concentrations of rhRLX.  In fact, the 
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circulating levels in all the studies in hypertensive rats were ~2X higher than normotensive 
animals.  We do not have a ready explanation for why SHR rats did not respond acutely to 
rhRLX, however they did respond to chronic rhRLX administration.  Based on our other work, 
the reduction in SVR and increase in global AC due to chronic rhRLX administration results 
from a reduction in vascular smooth muscle tone and remodeling of arterial extracellular matrix.  
Because relaxin possesses angiogenic attributes [20, 56], angiogenesis may also contribute to the 
changes in systemic hemodynamics and arterial properties. 
In our work examining the effects of exogenous relaxin administration on systemic 
hemodynamics and arterial properties including the current study, we observed that the decline in 
SVR elicited by rhRLX is unaccompanied by a significant change in MAP.  In fact, this situation 
resembles pregnancy in humans and other species where a profound reduction in SVR is 
associated with only a modest decline in MAP [5, 15, 34].  The decline in SVR is offset by a 
comparable rise in CO, thereby maintaining MAP.  Four mechanisms may contribute to this 
reciprocal increase in CO during relaxin administration.  First, relaxin is a positive chronotropic 
agent both in vitro and in vivo (at least in rats), an observation reported by us and several others 
[61, 96, 97].  Second, relaxin produces a positive inotropic effect in isolated ventricular tissue 
from rat and guinea pig heart [96-98].  Third, the fall in SVR and increase in arterial compliance 
reduce ventricular afterload, thereby abetting the increase in CO.  Finally, because MAP does not 
fall, our studies suggest that relaxin is a pure arterial vasodilator, thus permitting 
venoconstriction and/or reduction in passive venous compliance that maintains the ventricular 
end diastolic volume or preload despite the decline in SVR. To our knowledge, there are no 
published studies on relaxin and the venous circulation.  However, Edouard et al. conducted a 
longitudinal study examining venous behavior throughout normal pregnancy in women, and they 
144 
observed increased venous tone in the lower limb beginning in the first trimester that was 
strongly correlated with left ventricular diastolic diameter [99].  In summary, based on these 
previous findings and the present work, we speculate that relaxin may exert different actions in 
the venous and arterial circulations.  Specifically, relaxin elicits a vasodilatory response in the 
arterial circulation, while augmenting venous tone either directly or indirectly (e.g., via 
potentiation of humoral venoconstriction or baroreflex mediated sympathetic tone).  
Consequently, the fall in SVR induced by relaxin is paralleled by an increase in CO and it is by 
this mechanism that MAP is maintained during relaxin administration. 
Of note, other studies have reported that, contrary to what we observed in this 
investigation, MAP is significantly reduced in SHR rats in response to acute and chronic infusion 
of relaxin [17, 18].  These studies differed from the current investigation in that the animals used 
were female SHR rats.  Therefore, to determine if female SHR rats show a different response to 
relaxin infusion than males, we obtained arterial pressure measurements before and during 
rhRLX infusion in 7 female SHR rats.  (Note: Due to their small size (<210g), we only 
instrumented the animals with the mouse pressure catheter.  In our experience, ligation of the 
femoral artery in small rats leads to hind limb ischemia.)  Five days after the implantation of the 
mouse pressure catheter in the right carotid artery, the rats were briefly anaesthetized with 
isoflurane and implanted with an osmotic minipump that delivered rhRLX at 4 μg/h for 6 days.  
The serum level of rhRLX after 6 days of infusion was 28.6±2.16 ng/ml.  Baseline values of HR 
and MAP were 405±2 bpm and 171±2 mmHg, respectively.  When compared to baseline, HR 
was significantly increased during rhRLX infusion comparable to the male SHR rats.  There was 
a small, but statistically significant decrease in MAP 6 hours following the infusion of rhRLX.  
However, MAP was not significantly different from baseline at any of the subsequent timepoints 
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studied.  We attribute the small decrease in MAP at 6 hours to the hypotensive effects of 
isoflurane anesthesia.  The hypotensive response to isoflurane anesthesia has been well 
documented in various strains of rats and SHR rats have been shown to be more sensitive in this 
regard [100, 101].  We do not have an immediate explanation for why we were unable to 
reproduce the results of St-Louis et al. and Massiochotte et al. [17, 18]; differences in surgical 
procedures and experimental approaches may contribute to this discrepancy. 
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APPENDIX D 
DETAILED IMMUNOFLUORESCENCE PROTOCOLS 
D.1 PREPARATION AND SECTIONING OF ISOLATED ARTERIES  
After arteries are excised from the animal, they should be cleaned of all connective tissue 
then placed in 2% paraformaldehyde/PBS (fixing solution) in the fridge for ~4 hours.  Arteries 
should then be rinsed with PBS and placed in 30% Sucrose/ PBS (cryoprotecting solution) for 
24-48 hours in the fridge before being embedded in OCT.   
To embed arteries in OCT molds, pour a small amount of OCT into a plastic embedding 
mold until it is half full and allow the OCT to settle for ~1 hour.  Next, you must freeze 
isopentane over liquid nitrogen (LN).  We found that this works best if you pour some LN into a 
large, wide container. Then pour some isopentane into a beaker and dunk the beaker into the LN. 
Wait for 2-5 min until isopentane starts to turn opaque.  Have the plastic embedding mold with 
the OCT ready. Place the mold in the isopentane to freeze the OCT (shouldn’t take more than a 
minute).  Place the horizontally on top of the frozen OCT.  Cut a small thin red string about the 
same length as the artery and place it next to the artery on top of the frozen OCT.  We found that 
this was the only way to identify where the artery is after the OCT mold is frozen.  This is 
especially important for small arteries.  Pour OCT onto the mold and fill it to the top.  Plunge the 
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mold into the isopentane bath for at least 30 sec or until OCT is completely frozen. Retrieve the 
mold, wrap in tin foil, label with permanent ink, and immediately store in a -80°C freezer until 
you are ready for sectioning.  When necessary, transport molds on ice. 
We found that small renal arteries were too small to embed individually in OCT.  
Therefore, we embedded the entire kidney.  To do this, we gently removed the capsule and 
oriented the kidney so that the main renal artery faces upward.  Then with a sharp razor, we 
made a cut in the horizontal plain a little less than halfway down the kidney.  Then we placed 
both halves face-down in the OCT mold.  The molds were frozen and stored the using the same 
techniques described above. 
To section OCT blocks, fix sample block to the chuck with OCT media.  Take several 
6μm thick sections onto Superfrost Microscope Slides.  We typically took at 15-20 sections per 
sample.  Three-to-four sections were discarded in between each section that was stored.  Slides 
can be stored at -80oC until they are ready to be stained. 
D.2 PROTOCOL FOR IMMUNOFLUORESCENCE STAINING OF ATERIAL 
CROSS-SECTIONS 
This protocol was obtained from the Center for Biologic Imaging (CBI) website [102]. 
1. Rehydrate with 2 washes of 1xPBS.  
2. 3 washes .5% BSA.  
3. BLOCK with 2% BSA for 45 minutes.  
4. 5 washes of .5% BSA.  
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5. Primary antibody for 60 minutes (prepared in .5% BSA, vortexed, and spun down for 5 
minutes at 14000 RPM).  
6. 5 washes of BSA.  
7. Secondary antibody for 60 minutes (prepared in .5% BSA, vortexed, and spun down for 5 
minutes at 14000 RPM).  
8. 5 washes of .5% BSA.  
9. 5 washes of PBS.  
10. Hoescht stain for 30 seconds (prepared in de-ionized water at 1 mg/100 mL). 
11. 3 washes with PBS.  
12. Cover slip with gelvatol mounting medium [102] and refrigerate.  
13. Slides must dry overnight and be stored at 4 C in the dark.  
Note: Do not let tissue sections dry up, keep in liquid at all times until gelvatol step. 
D.3 PROTOCOL FOR IMMUNOFLUORESCENCE STAINING OF CULTURED 
CELLS 
This protocol was also obtained from the CBI website [102]. 
1. Wash off Media with 3 washes of 1xPBS  
2. Fix in 2% paraformaldehyde for 15 minutes, made in PBS.  
3. Permeabilize with 0.1% Triton X made in PBS solution for 15 min.  
4. Rehydrate with 3 washes of PBS.  
5. 5 washes of .5% BSA.  
6. BLOCK with 2% BSA for 45 minutes.  
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7. 5 washes of .5% BSA.  
8. Primary antibody in .5% BSA for 60 minutes (prepared in .5% BSA, vortexed, and spun 
down for 5 minutes at 14000 RPM).  
9. 5 washes of .5% BSA.  
10. Secondary antibody in .5% BSA for 60 minutes (prepared in .5% BSA, vortexed, and 
spun down for 5 minutes at 14000 RPM).   
11. 5 washes of .5% BSA.  
12. 5 washes of PBS.  
13. Hoescht stain for 30 seconds.  
14. 2 wash with PBS.  
15. Cover slip with gelvatol and refrigerate.  
16. Slides or coverslips must dry overnight at 4 C in the dark. 
Note: Do not let cells dry up, keep in liquid at all times until gelvatol step. 
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APPENDIX E 
COLLAGEN AND ELASTIN ASSAY PROTOCOLS 
E.1 SIRCOL COLLAGEN ASSAY 
This assay protocol was obtained from Dr. Rachelle Prantil-Baun. 
Chemicals Needed: 
1. Pepsin 
2. 0.01N and 0.001N HCL 
 
3. Sircol Collagen Assay Kit (Biocolor Ltd., Northern Ireland; purchased from Accurate 
Chemical Company; Catalog #: CLRS1111) 
 
Supplies Needed: 
1. Centrifuge Tubes 
2. Vortex Genie 
3. 15ml conical Tubes 
4. 50 ml conical Tubes 
5. Pipette tips (5μl, 20μl, 200μl, 1000μl) 
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6. Cuvettes and caps or 96 well plate 
 
Equipment Needed: 
1. Rocker Platform 
2. Micro-centrifuge 
3. Pipette guns of various accuracies 
4. UV spectrophotometer or microplate reader 
 
PROTOCOL: 
Tissue Digestion: 
1. Tissue should be cleaned of any extraneous tissue and weighed in its hydrated state. 
2. Tissue is then freeze-dried for 4 hours (we used a lyophilizer for this purpose). 
3. Weigh and record tissue dry weight. 
4. Prepare 0.01 N and 0.001N HCL solutions and prepare pepsin-HCL solution (for 
digestion): 
a. Solution A: add 0.05 g of pepsin to 50 ml of 0.01N HCL solution and gently stir. 
b. Solution B: add 0.005 g of pepsin to 50 ml of 0.001N HCL solution and gently 
stir.  This solution is used for smaller tissue samples; see Step 6 below. 
c. These solution needs to made fresh daily. 
5. Mince tissue into small pieces and deposit into a microcentrifuge tube. 
6. Add pepsin-HCL solution to the microcentrifuge tube: 
a. Add 100μl of pepsin-HCL Solution A for every 0.001g of tissue. 
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b. For smaller tissue add samples 1 ml of pepsin-HCL Solution B for every 0.001g 
of tissue. 
7. Parafilm the centrifuge tubes and label. 
8. Place on rocker platform in the refrigerator and allow to digest for 48 hours. 
Assessment of Collagen: 
1. Post-tissue digestion, vortex the solution and take 100 μl of the digested solution and 
place into a new microcentrifuge tube.  Then take another 50 μl of the digested solution 
and place into a separate microcentrifuge tube and dilute with 50 μl of pepsin-HCL 
solution so that you have a solution of 1:2 digested tissue. 
a. Repeat the same process for another tube, but this time make a solution for 1:4 
digested tissue. 
b. Repeat again for 1:8 digested tissue. 
c. Label each tube with the appropriate dilution. 
2. Prepare collagen standards: 
 
Table 11. Collagen Assay Standard Solutions 
Volume of Stock Solution 
(0.5 mg/ml Collagen) 
Volume of Dilutent 
(0.01N or 0.001N pepsin-HCL)
Final Collagen Concentration
(μg/ml) 
0 μl 100 μl 0 μg/ml 
5 μl 95 μl 25 μg/ml 
8 μl 92 μl 40 μg/ml 
16 μl 84 μl 80 μg/ml 
20 μl 80 μl 100 μg/ml 
30 μl 70 μl 150 μg/ml 
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3. Add 1 ml of Sirius Red dye from assay kit to all centrifuge tubes (standards and diluted 
digested tissue). 
4. Place all tubes on the rocking platform for 1 hour. 
5. Spin down tubes using a microcentrifuge for 10 min at 10,000 RPM. 
a. Note: once spun down, tissue should be compacted enough so that it is not 
floating or mobile.  If tissue is still floating, repeat step 5. 
6. Pour out supernatant into a specimen cup, maintaining the precipitate at the bottom of the 
centrifuge tube and do your best to rid the tube of as much supernatant as possible.  It is 
helpful to use a q-tip for this step. 
7. Digest precipitate with 1 ml of Acetic Acid solution from assay kit. 
8. Vortex each tube for ~30 seconds or until completely dissolved. 
9. Pipette 3 200μl aliquots of each sample into separate wells of a 96 well plate.   
10. Place plate into a microplate reader and read absorbance values anywhere from 530 nm to 
570 nm.  We obtained the best results reading at an absorbance of 560 nm. 
Calculating Unknown Collagen Concentrations: 
11. Plot absorbance vs. collagen standard concentration. 
a. This should be a linear curve (Figure 52). 
12. Calculate collagen concentration based on best fit linear equation. 
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Figure 52. Sample Collagen Assay Standard Curve 
 
Absorbance values were plotted vs known collagen concentrations.  Experimental data were 
fitted to a linear equation (collagen concentration, y; absorbance, x).  Best-fit constitutive 
parameters were then used to compute unknown collagen concentrations for a given absorbance. 
 
E.2 FASTIN ELASTIN ASSAY 
This assay protocol was obtained from Dr. Rachelle Prantil-Baun. 
Chemicals Needed: 
All the chemicals need are provided in the assay kit (Biocolor Ltd., Northern Ireland; purchased 
from Accurate Chemical Company; Catalog #: CLRF2000) 
. 
Supplies Needed: 
1. Centrifuge Tubes 
2. Vortex Genie 
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3. 15ml conical Tubes 
4. 50 ml conical Tubes 
5. Pipette tips (5μl, 20μl, 200μl, 1000μl) 
6. Cuvettes and caps or 96 well plate 
7. Microcon YM-3 Centrifugal Filter Unit (Millipore; Cat #:42403) 
 
Equipment Needed: 
1. Rocker Platform 
2. Micro-centrifuge 
3. Pipette guns of various accuracies 
4. UV spectrophotometer or microplate reader 
 
PROTOCOL: 
1. Tissue should be cleaned of any extraneous tissue and weighed in its hydrated state. 
2. Tissue is then freeze-dried overnight (we used a lyophilizer for this purpose). 
3. Weigh and record tissue dry weight. 
4. Put the entire artery (UNMINCED!) into a 1.5 mL microfuge tube.  Add 20 volumes of 
0.25 M oxalic acid (stock: 1.58 g oxalic acid + 50 ml de-ionized water).   
a. For example, if tissue dry weight is 0.1 g, then add 2 ml of 0.25 M oxalic acid.   
5. Heat microfuge tube at 90oC for 1 hour. 
6. Chill tubes to room temperature quickly.  Use an “ice water slurry”. 
7. Centrifuge the tubes at 3000 RPM at 4oC for 10 minutes.   
a. Repeat this step until ALL of the tissue is compacted to the bottom. 
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8. Remove and save the supernatant.  Label this supernatant, E1.  Keep in an ice bucket or 
in the refrigerator. 
9. To the pellet in Step 9, go back to Step 3 and add oxalic acid again.   
a. Add the same volume as original step.   
10. Repeat the heating and centrifuging as in Steps 4 – 8.  Label this supernatant, E2.   
 
11. To this pellet from Step 10, repeat the oxalic acid extraction again as above.  Call this 
supernatant E3.   
12. Repeat the extraction a fourth time.  Label the supernatant E4.   
a. For smaller tissue sample it might be necessary to repeat the extraction steps 5 or 
6 times in order to ensure that there is a high yield of elastin. 
13. Concentrate the acid extracts with a Microcon YM-3 Centrifugal Filter Unit.   
a. Add 500 μl of extract to filter and centrifuge at 14,000 RPM for 90 minutes. 
b. Repeat until entire volume of extract is filter. 
c. In order to retrieve elastin from filter, turn filter upside down in a separate 
centrifuge tubes and spin at 14,000 RPM for 10 min. 
14. Add 1 ml of elastin precipitating reagent to each centrifuge tube. 
a. At this point you can combine all the extracts for each given sample by gently 
triturating elastin precipitating reagent in each centrifuge tube. 
15. Place tubes in the fridge overnight. 
16. After 24 hours, place extracts in a bath of ice in the fridge for ~30 minutes to ensure the 
tubes are at 0-4oC. 
17. Centrifuge tubes at 12,000 RPM at 4oC for 10min. 
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18. During this time you should prepare elastin standards: 
a. Place 0μl, 5μl, 10μl, 20μl, 30μl, 40μl of elastin into separate tubes. 
b. Add 1ml of Fastin elastin dye reagent to each tube. 
c. Add 100μl of 90% ammounium sulfate solution. 
19. After extracts have spun down, pour off the supernatant. 
a. Do this very well, b/c the trichloracetic acid in the precipitating agent binds to the 
elastin dye. 
20. Add 1 ml of dye reagent to the extract tubes and 100ul of 90% ammonium sulfate. 
21. Place extracts and standards on rocker (on slow x4) for 1 hour. 
22. Centrifuge at 12,000 RPM for 10 minutes at room temperature. 
23. Pour off supernatant. 
24. Add 1 ml of destaining agent and vortex. 
a. Note: it is pretty tough to dissolve the solid so you might have to vortex several 
times. 
25. Pipette 3 200μl aliquots of each sample into separate wells of a 96 well plate.   
26. Place plate into a microplate reader and read absorbance values anywhere at close to 405 
nm as possible.  We obtained the best results reading at an absorbance of 450 nm. 
Calculating Unknown Elastin Amounts: 
27. Plot absorbance vs. mass of elastin. 
a. This should be a linear curve (Figure 53). 
28. Calculate mass of elastin based on best fit linear equation. 
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Figure 53. Sample Elastin Assay Standard Curve. 
 
Absorbance values were plotted vs known elastin concentrations.  Experimental data were fitted 
to a linear equation (elastin concentration, y; absorbance, x).  Best-fit constitutive parameters 
were then used to compute unknown elastin concentrations for a given absorbance. 
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APPENDIX F 
MATLAB PROGRAMS 
F.1 ANALYSIS OF AORTIC PRESSURE WAVEFORMS AND CARDIAC OUTPUT 
MEASUREMENTS  
This program is subdivided into several components which were assessed by a main 
program using callbacks.  The main program is designed as a graphical user interface with 
several different handles that correspond to the various callbacks.  The code for the main 
program is as follows: 
clear 
Fig=figure(1); 
clf 
set(Fig, 'Name', 'Global Arterial Compliance Analysis Program'); 
set(Fig,'menubar','none'); 
  
  
% handle1 defines the callback used to load pressure data 
handle1 = uimenu('Label','Load'); 
handle1_1 = uimenu('Label','Load Data','callback','Load_Data','enable','on'); 
set(handle1_1,'parent',handle1); 
set(handle1,'children',handle1_1); 
  
% handle2 defines the callback used to pick a section of the pressure data to be analyzed 
handle2 = uimenu('Label','Pick Section','callback','Pick_Section','enable','off'); 
 
% handle3 defines the callback used to select individual beats on the pressure waveform 
handle3 = uimenu('Label','Select Beats','callback','Defn_Beats','enable','off'); 
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% handle4 defines the callback used to plot individual beats of the pressure waveform 
handle4 = uimenu('Label','Plot Beats','callback','Plot_Cycles','enable','off'); 
 
% handle5 defines the callback used to plot the average pressure waveform 
handle5 = uimenu('Label',''Compute Ave Press Waveform','callback',' Compute_Mean_Cycle 
','enable','off'); 
 
% handle6 defines the callback used to select the dicrotic notch on the average pressure waveform 
handle6 = uimenu('Label','Pick DN','callback','Dicrotic_Notch','enable','off'); 
  
% handle7 defines the callback used to define the various user inputs 
handle7 = uimenu('Label','User Inputs','enable','on'); 
handle7_1 = uimenu('Label','CO,'callback','User_Inputs','enable','on'); 
handle7_2 = uimenu('Label','Sampling Frequency','enable','on'); 
handle7_21 = uimenu('Label','View Current Sampling Frequency','callback','Enter_Freq','enable','on'); 
handle7_22 = uimenu('Label','Change Default Sampling Frequency','callback','Change Defaut 
Freq','enable','on'); 
set(handle7_1,'parent',handle7); 
set(handle7_2,'parent',handle7); 
set(handle7,'children',[handle7_2 handle7_1]); 
set(handle7_21,'parent',handle7_2); 
set(handle7_22,'parent',handle7_2); 
set(handle7_2,'children',[handle7_22 handle7_21]); 
  
% handle8 defines the callback used to compute global AC 
handle8 = uimenu('Label','Analyze!','callback','Compute_AC','enable','off'); 
  
% handle9 defines the callback used to save the results 
handle9 = uimenu('Label','Save','enable','on'); 
handle9_1 = uimenu('Label','Save Results As...','callback','Save_Results_As','enable','off'); 
handle9_2 = uimenu('Label','Save Results','callback','Save_Results','enable','off'); 
handle9_3 = uimenu('Label','Save Figure','callback','Save_Figure','enable','off'); 
set(handle9_1,'parent',handle9); 
set(handle9_2,'parent',handle9); 
set(handle9_3,'parent',handle9); 
set(handle9,'children',[handle9_3 handle9_2 handle9_1]); 
  
% handle10 defines the callback close the program 
handle10 = uimenu('Label','Exit','callback','close all'); 
  
 
The code for the “Load_Data” callback (handle1) is as follows: 
%%  User selects file to load 
[DataName,DataDirectory]=uigetfile('*.txt','Choose The Data File'); 
if exist(sprintf('%s%s',DataDirectory(1:end-1),DataDirectory(end))) = = 7 || ... 
        exist(sprintf('%s%s',DataName(1:end-1),DataName(end))) = = 2 
    cd(DataDirectory) 
    data=textread(DataName); 
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    cd(ScriptDir); 
  
%%  Load Pressure-Diameter data 
    % Fill in time and pressure arrays 
    time = data(:,1); 
    pressure = data(:,2); 
  
%%  Plot Data 
    figure(1); 
    hold off 
    subplot('position',[.05,.7,.9,.25]) 
    plot(time, pressure); 
    title(DataName); 
    ylabel('Pressure (units)'); 
    xlabel('Time (sec)'); 
  
    set(handle2,'enable','on'); 
    set(handle3,'enable','on'); 
    set(handle7,'enable','on'); 
end 
 
The code for the “Pick_Section” callback (handle2) is as follows: 
%%  Plot Data 
section='y'; 
while section=='y' 
    figure(1); 
    subplot('position',[.05,.7,.9,.25]) 
    plot(time, pressure); 
    ylabel('Pressure (units)'); 
    xlabel('Time (sec)'); 
    title(DataName); 
    ylabel('Pressure (mmHg)'); 
  
%%  Find and define a section selected by the user 
    [x1,y1]=ginput(2); 
    findpoint1=1; 
    while abs(time(findpoint1,1)-x1(1,1)) > 0.01; 
        findpoint1=findpoint1+1; 
    end 
    findpoint2=findpoint1+1; 
    while abs(time(findpoint2,1)-x1(2,1)) > 0.01; 
        findpoint2=findpoint2+1; 
    end 
  
%%  Plot the new sectoin 
    subplot('position',[.05,.7,.9,.25]) 
    plot(time(findpoint1:findpoint2),pressure(findpoint1:findpoint2)) 
    title('Selected Section'); 
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    ylabel('Pressure (units)'); 
    xlabel('Time (sec)'); 
  
    button = questdlg('Do you want to pick a different section?',... 
        'Differnt Section','Yes','No','Yes'); 
    if strcmp(button,'Yes') 
        section='y'; 
    elseif strcmp(button,'No') 
        section='n'; 
    end 
  
end 
  
%%  Redefine variables to reflect the selected section 
TempTime=time; 
TempPressure=pressure; 
clear time; 
clear pressure; 
time=TempTime(findpoint1:findpoint2); 
pressure=TempPressure(findpoint1:findpoint2); 
clear TempTime; 
clear TempPressure; 
  
%%  Enable relavant selections 
set(handle1,'enable','on'); 
set(handle2,'enable','off'); 
set(handle3,'enable','on'); 
set(handle7,'enable','on'); 
set(handle10,'enable','on'); 
set(handle11,'enable','on'); 
 
The code for the “Defn_Beats” callback (handle3) is as follows: 
%%  Re-plot the Data 
subplot('position',[.05,.7,.9,.25]) 
plot(time, pressure) 
title('Selected Section'); 
ylabel('Pressure (units)'); 
xlabel('Time (sec)'); 
hold on 
  
%%  User Selects end-diastolic pressures for first two beats 
if exist('man_select') == 0 
    [x,y]=ginput(2); 
  
    find_point2=1; 
    count=0; 
    longest=1; 
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    %The purpose of the following section is to determine the length 
    %(period) of the longest beat.  This is needed in order to store 
    %the arrays corresponding to each beat in the same matrix. 
     
    %%  Identify first end-diastolic pressure 
    while count<length(x)-1 
        count=count+1; 
        find_point1=find_point2; 
        if count==1 
            while abs(time(find_point1,1)-x(count,1)) > 0.01; 
                find_point1=find_point1+1; 
            end 
            temp1=pressure(find_point1:find_point1+80); 
            [y1 z1]=min(temp1); 
            find_point1Temp=find_point1+z1; 
            if find_point1-5>0 
                clear temp1; 
                temp1=pressure(find_point1-5:find_point1+40); 
                [y1 z1]=min(temp1); 
                find_point1Temp=find_point1+z1-5; 
            end 
            if find_point1-10>0 
                clear temp1; 
                temp1=pressure(find_point1-10:find_point1+40); 
                [y1 z1]=min(temp1); 
                find_point1Temp=find_point1+z1-10; 
            end 
            if find_point1-20>0 
                clear temp1; 
                temp1=pressure(find_point1-20:find_point1+40); 
                [y1 z1]=min(temp1); 
                find_point1Temp=find_point1+z1-20; 
            end 
            if find_point1-40>0 
                clear temp1; 
                temp1=pressure(find_point1-40:find_point1+40); 
                [y1 z1]=min(temp1); 
                find_point1Temp=find_point1+z1-40; 
            end 
            find_point1=find_point1Temp; 
        end 
  
%%  Identify next end-diastolic pressure 
        find_point2=find_point1+1; 
        while abs(time(find_point2,1)-x(count+1,1)) > 0.01; 
            find_point2=find_point2+1; 
        end 
  
  
        temp2=pressure(find_point2-40:find_point2); 
        if find_point2+5<length(pressure) 
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            clear temp2; 
            temp2=pressure(find_point2-40:find_point2+5); 
        end 
        if find_point2+10<length(pressure) 
            clear temp2; 
            temp2=pressure(find_point2-40:find_point2+10); 
        end 
        if find_point2+20<length(pressure) 
            clear temp2; 
            temp2=pressure(find_point2-40:find_point2+20); 
        end 
        if find_point2+40<length(pressure) 
            clear temp2; 
            temp2=pressure(find_point2-40:find_point2+40); 
        end 
  
        [y2 z2]=min(temp2); 
        find_point2=find_point2+z2-40; 
    end 
  
%%  Use two selected EDPs to find other points 
    TempPeriod=time(find_point2,1) - time(find_point1,1);  %Estimate Period 
    TempFreq=1/(time(3)-time(2));       %Estimate Sample Frequency 
    Nsamps=round(TempPeriod*TempFreq);  %Estimate Number of Samples 
    SecLength=time(length(time))-x(1);  %Estimate The Length of the Section 
    Nbeats=round(SecLength*TempFreq/Nsamps);  %Estimate Total Number of Beats 
  
    for i=3:Nbeats 
        if x(i-1) + TempPeriod <= time(length(time)) 
            x(i)=x(i-1) + TempPeriod; 
        end 
    end 
  
%%  Identify first end-diastolic pressure 
    longest=1; 
    find_point2=1; 
    count=0; 
    while count<length(x)-1 
        count=count+1; 
        find_point1=find_point2; 
        if count==1 
            while abs(time(find_point1,1)-x(count,1)) > 0.01; 
                find_point1=find_point1+1; 
            end 
            temp1=pressure(find_point1:find_point1+round(Nsamps/2)); 
            [y1 z1]=min(temp1); 
            find_point1Temp=find_point1+z1; 
            if find_point1-5>0 
                clear temp1; 
                temp1=pressure(find_point1-5:find_point1+round(Nsamps/2)); 
                [y1 z1]=min(temp1); 
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                find_point1Temp=find_point1+z1-5; 
            end 
            if find_point1-10>0 
                clear temp1; 
                temp1=pressure(find_point1-10:find_point1+round(Nsamps/2)); 
                [y1 z1]=min(temp1); 
                find_point1Temp=find_point1+z1-10; 
            end 
            if find_point1-20>0 
                clear temp1; 
                temp1=pressure(find_point1-20:find_point1+round(Nsamps/2)); 
                [y1 z1]=min(temp1); 
                find_point1Temp=find_point1+z1-20; 
            end 
            if find_point1-40>0 
                clear temp1; 
                temp1=pressure(find_point1-40:find_point1+round(Nsamps/2)); 
                [y1 z1]=min(temp1); 
                find_point1Temp=find_point1+z1-40; 
            end 
            find_point1=find_point1Temp; 
        end 
  
%%  Identify subsequent end-diastolic pressures 
        find_point2=find_point1+1; 
        while abs(time(find_point2,1)-x(count+1,1)) > 0.01; 
            find_point2=find_point2+1; 
        end 
  
  
        temp2=pressure(find_point2-round(Nsamps/2):find_point2); 
        if find_point2+5<length(pressure) 
            clear temp2; 
            temp2=pressure(find_point2-round(Nsamps/2):find_point2+5); 
        end 
        if find_point2+10<length(pressure) 
            clear temp2; 
            temp2=pressure(find_point2-round(Nsamps/2):find_point2+10); 
        end 
        if find_point2+20<length(pressure) 
            clear temp2; 
            temp2=pressure(find_point2-round(Nsamps/2):find_point2+20); 
        end 
        if find_point2+40<length(pressure) 
            clear temp2; 
            temp2=pressure(find_point2-round(Nsamps/2):find_point2+40); 
        end 
        if find_point2+80<length(pressure) 
            clear temp2; 
            temp2=pressure(find_point2-round(Nsamps/2):find_point2+80); 
        end 
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        [y2 z2]=min(temp2); 
        find_point2=find_point2+z2-round(Nsamps/2); 
  
%%  Determine the length of the longest beat 
        if length(pressure(find_point1:find_point2))>longest 
            longest=length(pressure(find_point1:find_point2)); 
        end 
        hold on 
  
%%  Plot each EDP 
        plot(time(find_point1,1),pressure(find_point1),'*r') 
        plot(time(find_point2,1),pressure(find_point2),'*r') 
  
  
        TimePoints(count)=time(find_point1); 
        PressPoints(count)=pressure(find_point1); 
  
        TimePoints(count+1)=time(find_point2); 
        PressPoints(count+1)=pressure(find_point2); 
    end 
  
end 
 
The code for the “Plot_Cycles” callback (handle4) is as follows: 
%%  Create matrix to store each beat 
cycles=zeros(longest,count); 
newtime=zeros(longest,count); 
  
%%  Identify first end-diastolic pressure 
%Redefine each beat in order to store them 
find_point2=1; 
count=0; 
while count<length(x)-1 
    count=count+1; 
    find_point1=find_point2; 
    if count==1 
        while abs(time(find_point1,1)-x(count,1)) > 0.01; 
            find_point1=find_point1+1; 
        end 
        temp1=pressure(find_point1:find_point1+round(Nsamps/2)); 
        [y1 z1]=min(temp1); 
        find_point1Temp=find_point1+z1; 
        if find_point1-5>0 
            clear temp1; 
            temp1=pressure(find_point1-5:find_point1+round(Nsamps/2)); 
            [y1 z1]=min(temp1); 
            find_point1Temp=find_point1+z1-5; 
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        end 
        if find_point1-10>0 
            clear temp1; 
            temp1=pressure(find_point1-10:find_point1+round(Nsamps/2)); 
            [y1 z1]=min(temp1); 
            find_point1Temp=find_point1+z1-10; 
        end 
        if find_point1-20>0 
            clear temp1; 
            temp1=pressure(find_point1-20:find_point1+round(Nsamps/2)); 
            [y1 z1]=min(temp1); 
            find_point1Temp=find_point1+z1-20; 
        end 
        if find_point1-40>0 
            clear temp1; 
            temp1=pressure(find_point1-40:find_point1+round(Nsamps/2)); 
            [y1 z1]=min(temp1); 
            find_point1Temp=find_point1+z1-40; 
        end 
        find_point1=find_point1Temp; 
    end 
  
%%  Identify subsequent end-diastolic pressures 
    find_point2=find_point1+1; 
    while abs(time(find_point2,1)-x(count+1,1)) > 0.01; 
        find_point2=find_point2+1; 
    end 
  
  
    temp2=pressure(find_point2-round(Nsamps/2):find_point2); 
    if find_point2+5<length(pressure) 
        clear temp2; 
        temp2=pressure(find_point2-round(Nsamps/2):find_point2+5); 
    end 
    if find_point2+10<length(pressure) 
        clear temp2; 
        temp2=pressure(find_point2-round(Nsamps/2):find_point2+10); 
    end 
    if find_point2+20<length(pressure) 
        clear temp2; 
        temp2=pressure(find_point2-round(Nsamps/2):find_point2+20); 
    end 
    if find_point2+40<length(pressure) 
        clear temp2; 
        temp2=pressure(find_point2-round(Nsamps/2):find_point2+40); 
    end 
    if find_point2+80<length(pressure) 
        clear temp2; 
        temp2=pressure(find_point2-round(Nsamps/2):find_point2+80); 
    end 
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    [y2 z2]=min(temp2); 
    find_point2=find_point2+z2-round(Nsamps/2); 
  
%%  Store each beat in the cycles matrix 
    new_cyc=pressure(find_point1:find_point2); 
    cycles(1:find_point2-find_point1+1,count)=... 
        pressure(find_point1:find_point2); 
%%  Create new time array corresponding to new beats 
    newtime(1:find_point2-find_point1+1,count)=(0:(1/Freq):((1/Freq)*(length(new_cyc)-1)))'; 
     
%%  Plot each beat 
    subplot('position',[.08,.1,.4,.5]) 
    plot(newtime(1:find_point2-find_point1+1,count),cycles(1:find_point2-find_point1+1,count)) 
    title('Individual Beats'); 
    ylabel('Pressure (units)'); 
    xlabel('Time (sec)'); 
    hold on 
     
    subplot('position',[.05,.7,.9,.25])%,'replace') 
    plot(time, pressure) 
    title('Selected Section'); 
    ylabel('Pressure (units)'); 
    xlabel('Time (sec)'); 
    hold on 
     
    plot(time(find_point1:find_point2),pressure(find_point1:find_point2),'.r') 
  
    pause on 
    pause 
end 
subplot('position',[.05,.7,.9,.25])%,'replace'); 
plot(time, pressure) 
hold on 
plot(TimePoints,PressPoints,'*r') 
title('Selected Section'); 
ylabel('Pressure (mmHg)'); 
  
%%  Enable relavant selections 
set(handle1,'enable','on'); 
set(handle2,'enable','off'); 
set(handle3,'enable','off'); 
set(handle4,'enable','off'); 
set(handle5,'enable','on'); 
set(handle7,'enable','on'); 
set(handle10,'enable','on'); 
 
The code for the “Compute_Mean_Cycle” callback (handle5) is as follows: 
%%  Replot pressure waveform without beat markers 
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subplot('position',[.05,.7,.9,.25]) 
plot(time, pressure) 
hold on 
title('Selected Section'); 
ylabel('Pressure (units)'); 
xlabel('Time (sec)'); 
  
%%  Plot each beat 
for i=1:count 
    cyc=1; 
    while cycles(cyc,i)>0 & cyc<longest 
        cyc=cyc+1; 
    end 
    cyc=cyc-1; 
  
    subplot('position',[.08,.1,.4,.5]) 
    plot(newtime(1:cyc,i),cycles(1:cyc,i)) 
    ylabel('Pressure (units)'); 
    xlabel('Time (sec)'); 
    title('Individual Beats'); 
    hold on 
end 
 
%%  Determine the period (T) of each beat 
for col=1:count 
    cyc=1; 
    while cycles(cyc,col)>0 & cyc<longest 
        cyc=cyc+1; 
    end 
    cyc=cyc-1; 
    T(col)=cyc/Freq; 
end 
  
%%  Calculate Average period 
    Tavg=mean(T);                    
  
%%  Create new time array from which interpolation will done 
    Ta=0:(1/Freq):Tavg;                
    Ta=Ta'; 
  
%%  Interpolate & find new pressure array 
for col=1:count 
    cyc=1; 
    while cycles(cyc,col)>0 & cyc<longest 
        cyc=cyc+1; 
    end 
    cyc=cyc-1; 
  
    Time=(0:(1/Freq):((cyc/Freq)-(1/Freq)))'; 
    x1=Time.*(Tavg/T(col)); 
    newpress(:,col)=interp1(x1,cycles(1:cyc,col),... 
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        Ta,'spline','extrap'); 
end 
newpress=newpress(1:length(newpress)-5,:); 
Ta=Ta(1:length(Ta)-5,:); 
  
%%  Calculate the average pressure waveform 
avgpress=mean(newpress');            
avgpress_mean=mean(avgpress); 
avgpress_min=min(avgpress); 
 
%%  Calculate min, max and mean pressure from the average press waveform 
avgpress_mean=mean(avgpress); 
avgpress_min=min(avgpress); 
avgpress_max=max(avgpress); 
  
%%  Plot average pressure waveform 
  
subplot('position',[.53,.1,.4,.5]) 
hold off 
plot(Ta,avgpress) 
ylabel('Pressure (mmHg)'); 
title('Average Beat (Scaled)'); 
xlabel('Time (sec)'); 
hold on 
  
%%  Enable relavant selections 
set(handle1,'enable','on'); 
set(handle2,'enable','off'); 
set(handle3,'enable','off'); 
set(handle4,'enable','off'); 
set(handle5,'enable','off'); 
set(handle6,'enable','on'); 
set(handle7,'enable','on'); 
set(handle10,'enable','on'); 
 
The code for the “Dicrotic_Notch” callback (handle6) is as follows: 
%%  Enables user to select dicrotic notch 
clear pressureone; 
another='y'; 
while another=='y' 
    hold off 
    subplot('position',[.53,.1,.4,.5]); 
    plot(Ta,avgpress) 
    ylabel('Pressure (mmHg)'); 
    title('Average Beat (Scaled)'); 
    xlabel('Time (sec)'); 
    hold on 
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    [inc,incy] = ginput(1); 
    find_point3=1; 
    while abs(Ta(find_point3,1)-inc(1,1)) > 0.01; 
        find_point3=find_point3+1; 
    end 
    incy=round(incy); 
    pressureone = avgpress(find_point3); 
    timeone = Ta(find_point3); 
    plot(timeone,pressureone,'*r'); 
  
    button = questdlg('Do you want to pick a different DN?',... 
        'Differnt DN','Yes','No','Yes'); 
    if strcmp(button,'Yes') 
        another='y'; 
    elseif strcmp(button,'No') 
        another='n'; 
    end 
end 
  
if exist('co') ~= 0 
    set(handle8,'enable','on'); 
else 
    set(handle8,'enable','off'); 
end 
  
%%  Enable relavant selections 
set(handle1,'enable','on'); 
set(handle2,'enable','off'); 
set(handle3,'enable','off'); 
set(handle4,'enable','off'); 
set(handle5,'enable','off'); 
set(handle6,'enable','on'); 
set(handle7,'enable','on'); 
set(handle10,'enable','on'); 
set(handle11,'enable','on'); 
 
The code for the “User_Inputs” callback (handle7) is as follows: 
prompstr = {'Enther the CO ml/min'}; 
titlestr = 'User Inputs'; 
initstr = {'120'}; 
UserInpts = inputdlg(prompstr,titlestr,1,initstr); 
co=str2num(UserInpts{1}); 
 
Finally, the code for the “Save_Results_As” callback (handle9) is as follows: 
%%  Prompt User to Decide to Save to An Existing File or a New One 
172 
button = questdlg('Do You Want Add to An Exiting File or Save to A New File?',... 
    'Save Output?','Existing File','New File','Existing File'); 
if strcmp(button,'Existing File') 
    Adddata='A'; 
elseif strcmp(button,'New File') 
    Adddata='N'; 
end 
 
%%  Save Output File 
if Adddata=='A' 
    Results_Dir=sprintf('%s%s',ScriptDir(1:end-7),'Results'); 
    cd(Results_Dir); 
    [ResFilename,FilePath] = uiputfile({'*.txt';'*.xls'},'Save As',DataName(1:length(DataName)-10)); 
    if ResFilename ~= 0 
         
        %Save Results 
        cd(FilePath); 
        fid=fopen(ResFilename,'a'); 
        fprintf(fid,'%s %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f 
%8.3f \n',... 
            DataName(1:length(DataName)-4), HR, co,avgpress_max, avgpress_min, avgpress_mean,... 
            avgpress_max-avgpress_min, svr,ad, pressureone,... 
            pressuretwo, compliance,pressdiff,sv,sv_pp*1000); 
        fclose(fid); 
         
        %Save Average Pressure Waveform 
        AvePress_Dir=sprintf('%s%s',ScriptDir(1:end-7),'Ave Press Waveforms'); 
        cd(AvePress_Dir); 
        fid2=fopen(sprintf('%s%s', DataName(1:end-4),'_AvePress.txt'),'w'); 
        fprintf(fid2,'%6.4f  %12.4f\n',[Ta avgpress']'); 
        fclose(fid2); 
    end 
elseif Adddata=='N' 
    Results_Dir=sprintf('%s%s',ScriptDir(1:end-7),'Results'); 
    cd(Results_Dir); 
    [ResFilename,FilePath] = uiputfile({'*.txt';'*.xls'},'Save As',DataName(1:length(DataName)-10)); 
    if ResFilename ~= 0 
         
        %Save Results 
        cd(FilePath); 
        fid=fopen(ResFilename,'w'); 
        fprintf(fid,'%s %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f %8.3f 
%8.3f \n',... 
            DataName(1:length(DataName)-4), HR, co,avgpress_max, avgpress_min, avgpress_mean,... 
            avgpress_max-avgpress_min, svr,ad, pressureone,... 
            pressuretwo, compliance,pressdiff,sv, sv_pp*1000); 
        fclose(fid); 
         
        %Save Average Pressure Waveform 
        AvePress_Dir=sprintf('%s%s',ScriptDir(1:end-7),'Ave Press Waveforms'); 
        cd(AvePress_Dir); 
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        fid2=fopen(sprintf('%s%s', DataName(1:end-4),'_AvePress.txt'),'w'); 
        fprintf(fid2,'%6.4f  %12.4f\n',[Ta avgpress']'); 
        fclose(fid2); 
    end 
end 
F.2 ANALYSIS OF PRESSURE-DIAMETER AND FORCE-LENGTH DATA  
Similar to the previous one (see Appendix F.1), this program is subdivided into several 
components which were assessed by a main program using callbacks.  The main program was 
again designed as a graphical user interface with several different handles that correspond to the 
various callbacks.  The code for the main program is as follows: 
clear 
Fig=figure(1); 
clc 
clf 
set(Fig, 'Name', 'Isolated Artery Biaxial Analysis Program'); 
set(Fig,'menubar','none'); 
set(Fig, 'PaperOrientation', 'portrait') 
  
% handle1 defines the callback used to load pressure-diameter and force-length data 
handle1 = uimenu('Label','Load','enable','on'); 
handle1_1 = uimenu('Label','Load New Data','callback','Load_Data,'enable','on'); 
set(handle1_1,'parent',handle1); 
set(handle1,'children',handle1_1); 
  
% handle2 defines the callback used to compute 2nd Piola Kirchoff stresses 
handle2 = uimenu('Label','Compute','enable','on'); 
handle2_1 = uimenu('Label','Piola-Kirchoff stresses','callback','PK_Stress,'enable','off'); 
set(handle2_1,'parent',handle2); 
set(handle2,'children',handle2_1); 
  
% handle3 defines the various callbacks used for curve fitting to different strain energy functions 
handle3 = uimenu('Label','Fit Curve','enable','on'); 
handle3_1 = uimenu('Label','Polynomial','callback','Fit_Polynomial','enable','off'); 
handle3_2 = uimenu('Label','Exponential','callback','Fit_Exponential','enable','off'); 
handle3_3 = uimenu('Label','Mixed','callback','Fit_Mixed','enable','off'); 
set(handle3_1,'parent',handle3); 
set(handle3_2,'parent',handle3); 
set(handle3_3,'parent',handle3); 
set(handle3,'children',[handle3_3 handle3_2 handle3_1]); 
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% handle4 defines the callbacks used to save results 
handle4 = uimenu('Label','Save','enable','on'); 
handle4_1 = uimenu('Label','Save Coefficients','callback','SaveType=1;Save_Res','enable','off'); 
handle4_2 = uimenu('Label','Save Curves','callback','SaveType=2;Save_Res','enable','off'); 
handle4_3 = uimenu('Label','Save Figure','callback','SaveType=3;Save_Res','enable','on'); 
set(handle4_1,'parent',handle4); 
set(handle4_2,'parent',handle4); 
set(handle4_3,'parent',handle4); 
set(handle4,'children',[handle4_3 handle4_2 handle4_1]); 
  
% handle5 defines the callback close the program 
handle5 = uimenu('Label','Exit','enable','on'); 
handle5_1 = uimenu('Label','EXIT!','callback','close all','enable','on'); 
set(handle5_1,'parent',handle5); 
set(handle5,'children',handle5_1); 
 
The code for the “Load_Data” callback (handle1) is as follows: 
%%  User loads Pressure-Diameter data 
[DataName,DataDirectory]=uigetfile('*.txt','Choose The Data File'); 
if exist(sprintf('%s%s',DataDirectory(1:end-1),DataDirectory(end))) = = 7  
  
    cd(DataDirectory) 
    data=textread(DataName); 
    cd(ScriptDir) 
 
%%  Assign variable names 
    UnldDi = data(1,1); 
    UnldDo = data(1,2); 
    UnldL = data(1,3); 
    [row col] = size(data); 
    data=data(2:row,1:col); 
    Press_mmHg = data(:,1); 
    Press_Pa = data(:,2); 
    Di = data(:,3); 
    Do = data(:,4); 
    Force_V=data(:,5); 
    Length=data(:,6); 
 
%%  Calculate Tmeasure, Ri, Ro, and Ai 
    Ri = Di/2; 
    Ro = Do/2; 
    Tmeasured=Ro-Ri; 
    Ai = pi*Ri.^2; 
 
%%  Determine where each curve begins and calculate Am 
    P0s=find(Press_mmHg==0); 
    for i=1:length(P0s) 
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        T0s(i)=Tmeasured(P0s(i)); 
        Di0s(i)=Di(P0s(i)); 
        Am0s(i)=pi*T0s(i)*(T0s(i) + Di0s(i)); 
    end 
 
%%  Calculate wall thickness for each measured Di based on Am 
    j=0; 
    for i=1:length(P0s) 
        j=j+1; 
        if i<length(P0s) 
            Tcalculated(P0s(i):P0s(i+1)) = sqrt((Am0s(j) + Ai(P0s(i):P0s(i+1)))/pi)... 
                - sqrt(Ai(P0s(i):P0s(i+1))/pi); 
        elseif i==length(P0s) 
            Tcalculated(P0s(i):length(Press_mmHg)) = sqrt((Am0s(j) + ... 
                Ai(P0s(i):length(Press_mmHg)))/pi)... 
                - sqrt(Ai(P0s(i):length(Press_mmHg))/pi); 
        end 
    end 
 
%%  Prompt user to input the unloaded dimensions and conversion factor for force measurements 
    prompt = {'Unloaded Inner Diameter (um)','Unloaded Outer Diameter (um)',... 
        'Unloaded Length (mm)'}; 
    dlg_title ='Unloaded Dimensions'; 
    num_lines=1; 
    def={num2str(UnldDi),num2str(UnldDo),num2str(UnldL)}; 
    inputvalues=inputdlg(prompt,dlg_title,num_lines,def); 
     
%%  Assign variable names to unloaded dimensions 
    UnldDi=str2num(inputvalues{1}); 
    UnldRi=UnldDi/2; 
    UnldDo=str2num(inputvalues{2}); 
    UnldRo=UnldDo/2; 
    UnldL=str2num(inputvalues{3}); 
    UnldT=UnldRo-UnldRi; 
    ForceConv=load('DefForceConv.txt'); 
    Force_mN=Force_V*ForceConv; 
    Force_N=Force_mN/1000; 
 
%%  Calculate axial and circumferential stretch 
    AxStr=Length/UnldL; 
    CrcmStr=Di/UnldDi; 
 
%%  Calculate axial and circumferential Cauchy stresses 
    Crc_Cauch_Strs = Press_Pa.*(((UnldRo/1E6).*(CrcmStr.^2)./(UnldT/1E6))-1); 
    Temp1 = (pi*UnldT/1E6); 
    Temp2 = (2*UnldRo/1E6)-(UnldT/1E6); 
    Temp3 = Crc_Cauch_Strs/2; 
    Temp4 = Temp1*Temp2; 
    Ax_Cauch_Strs = (Force_N/Temp4) + Temp3; 
 
%% Plot pressure-diameter, force-length and stretch-stress relationships 
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    hold off 
  
    TempLineProp={'-*r','-om','-xk','-+g','-vb','-pr','-hc','-dy',... 
            '*r','om','xk','+g','vb','pr','hc','dy'}; 
    for i=1:length(P0s) 
        if i<length(P0s) 
            subplot(2,2,1); 
            plot(Press_mmHg(P0s(i):P0s(i+1)-1),Di(P0s(i):P0s(i+1)-1),TempLineProp{i}) 
            ylabel('Inner Diameter (um)') 
            xlabel('Transmural Pressure (mmHg)') 
            hold on 
  
            subplot(2,2,3); 
            plot(CrcmStr(P0s(i):P0s(i+1)-1),Crc_Cauch_Strs(P0s(i):P0s(i+1)-1)... 
                ,TempLineProp{i}) 
            ylabel('Circumferential Cauchy Stress (Pa)') 
            xlabel('Circumferential Stretch') 
            hold on 
  
            subplot(2,2,4); 
            plot(CrcmStr(P0s(i):P0s(i+1)-1),Ax_Cauch_Strs(P0s(i):P0s(i+1)-1)... 
                ,TempLineProp{i}) 
            ylabel('Axial Cauchy Stress (Pa)') 
            xlabel('Circumferential Stretch') 
            hold on 
        elseif i==length(P0s) 
            subplot(2,2,1); 
            plot(Press_mmHg(P0s(i):length(Press_mmHg)),Di(P0s(i):length(Press_mmHg)),... 
                TempLineProp{i}) 
            ylabel('Diameter (um)') 
            xlabel('Transmural Pressure (mmHg)') 
            hold on 
  
            subplot(2,2,3); 
            plot(CrcmStr(P0s(i):length(CrcmStr)),Crc_Cauch_Strs(P0s(i):length(CrcmStr)),... 
                TempLineProp{i}) 
            ylabel('Circumferential Cauchy Stress (Pa)') 
            xlabel('Circumferential Stretch') 
            hold on 
  
            subplot(2,2,4); 
            plot(CrcmStr(P0s(i):length(CrcmStr)),Ax_Cauch_Strs(P0s(i):length(CrcmStr)),... 
                TempLineProp{i}) 
            ylabel('Axial Cauchy Stress(Pa)') 
            xlabel('Circumferential Stretch') 
            hold on 
        end 
        TempPltLegnd1{i}=['\lambda','z  = ',num2str(AxStr(P0s(i)),'%.2f')]; 
    end 
    subplot(2,2,1); 
    legend(TempPltLegnd1,'Location','SouthEast','FontSize',7) 
177 
    subplot(2,2,3); 
    legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
    subplot(2,2,4); 
    legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
    k=0; 
    for f=0:(P0s(2)-P0s(1))-1 
        i=1; 
        k=k+1; 
        for j=1:length(P0s) 
            AxStrCrv(i,1)=AxStr(P0s(j)+f); 
            AxStrCrv(i,2)=Force_mN(P0s(j)+f); 
            AxStrCrv(i,3)=Ax_Cauch_Strs(P0s(j)+f); 
            i=i+1; 
        end 
        subplot(2,2,2); 
        plot(AxStrCrv(:,1),AxStrCrv(:,2),TempLineProp{k}) 
        ylabel('Axial Force (mN)') 
        xlabel('Axial Stretch') 
        hold on 
        TempPltLegnd2{k}=[num2str(Press_mmHg(P0s(j)+f)),' mmHg']; 
        legend(TempPltLegnd2,'Location','SouthEast','FontSize',7) 
    end 
  
%%  Label Figure 
    FigLabel = uicontrol('Style','text','String',DataName(1:end-4),... 
        'units','normalized','Position', [.415 .95 .2 .035],... 
        'FontWeight','bold','FontSize',18,'BackgroundColor',[1 1 1]); 
 
    set(handle2_1,'enable','on') 
    set(handle3_1,'enable','on') 
    set(handle3_2,'enable','on') 
    set(handle3_3,'enable','on') 
    set(handle3_4,'enable','on') 
end 
 
The code for the “PK_Stress” callback (handle2) is as follows: 
delete(subplot(2,2,1)) 
delete(subplot(2,2,2)) 
delete(subplot(2,2,3)) 
delete(subplot(2,2,4)) 
 
%%  Calculate axial and circumferential 2nd Piola-Kirchoff stresses 
Crc_PK_Strs = Crc_Cauch_Strs./(CrcmStr.^2); 
Ax_PK_Strs = Ax_Cauch_Strs./(AxStr.^2); 
 
%%  Calculate axial and circumferential Green-Lagrange Strains 
Crc_GL_Str = ((CrcmStr.^2)-1)/2; 
Ax_GL_Str = ((AxStr.^2)-1)/2; 
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%% Plot axial and circumferential 2nd Piola-Kirchoff stresses and stretch 
TempLineProp={'-*r','-om','-xk','-+g','-vb','-pr','-hc','-dy'}; 
for i=1:length(P0s) 
    if i<length(P0s) 
        Plt1 = subplot('position',[.05,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):P0s(i+1)-1),Crc_PK_Strs(P0s(i):P0s(i+1)-1)... 
            ,TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    elseif i==length(P0s) 
        Plt1 = subplot('position',[.05,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):length(Crc_GL_Str)),... 
            Crc_PK_Strs(P0s(i):length(Crc_GL_Str)),TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    end 
    TempPltLegnd1{i}=['\lambda','z  = ',num2str(AxStr(P0s(i)),'%.2f')]; 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
for i=1:length(P0s) 
    if i<length(P0s) 
        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):P0s(i+1)-1),Ax_PK_Strs(P0s(i):P0s(i+1)-1)... 
            ,TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    elseif i==length(P0s) 
        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):length(Crc_GL_Str)),... 
            Ax_PK_Strs(P0s(i):length(Crc_GL_Str)),TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    end 
    TempPltLegnd1{i}=['\lambda','z  = ',num2str(AxStr(P0s(i)),'%.2f')]; 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
%%  Label Figure 
delete(FigLabel) 
FigLabel = uicontrol('Style','text','String',DataName(1:end-4),... 
        'units','normalized','Position', [.415 .95 .2 .035],... 
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        'FontWeight','bold','FontSize',18,'BackgroundColor',[1 1 1]); 
 
The code for the “Fit_Polynomial” callback (handle3_1) is as follows: 
Redo='N'; 
%%  Calculate axial and circumferential 2nd Piola-Kirchoff stresses if 
%%  necessary 
if exist('PK_Run') == 0 
    delete(subplot(2,2,1)) 
    delete(subplot(2,2,2)) 
    delete(subplot(2,2,3)) 
    delete(subplot(2,2,4)) 
    Crc_PK_Strs = Crc_Cauch_Strs./(CrcmStr.^2); 
    Ax_PK_Strs = Ax_Cauch_Strs./(AxStr.^2); 
 
%%  Calculate axial and circumferential Green-Lagrange Strains 
    Crc_GL_Str = ((CrcmStr.^2)-1)/2; 
    Ax_GL_Str = ((AxStr.^2)-1)/2; 
end 
 
%% Plot axial and circumferential 2nd Piola-Kirchoff stresses and Lagrange 
%% Strains 
subplot('position',[.05,.18,.4,.7]) 
hold off 
subplot('position',[.55,.18,.4,.7]) 
hold off 
TempLineProp={'*r','om','xk','+g','vb','pr','hc','dy'}; 
for i=1:length(P0s) 
    if i<length(P0s) 
        Plt1 = subplot('position',[.05,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):P0s(i+1)-1),Crc_PK_Strs(P0s(i):P0s(i+1)-1)... 
            ,TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    elseif i==length(P0s) 
        Plt1 = subplot('position',[.05,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):length(CrcmStr)),Crc_PK_Strs(P0s(i):length(CrcmStr)),... 
            TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
    end 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
for i=1:length(P0s) 
    if i<length(P0s) 
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        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):P0s(i+1)-1),Ax_PK_Strs(P0s(i):P0s(i+1)-1)... 
            ,TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    elseif i==length(P0s) 
        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):length(CrcmStr)),Ax_PK_Strs(P0s(i):length(CrcmStr)),... 
            TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    end 
    TempPltLegnd1{i}=['\lambda','z  = ',num2str(AxStr(P0s(i)),'%.2f')]; 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
%%  Prompt user to input the starting valuse of fit parameters 
prompt = {'Enter an initial value for C1','Enter an initial value for C2',... 
    'Enter an initial value for C3','Enter an initial value for C4',... 
    'Enter an initial value for C5','Enter an initial value for C6',... 
    'Enter an initial value for C7'}; 
dlg_title ='Input Given Parameters'; 
num_lines=1; 
if exist('optivalues_Poly')==1 
    for i=1:length(optivalues_Poly) 
        def{i}=num2str(optivalues_Poly(i)); 
    end 
else def={'34.2','-3.5','30.2','-5.8','22.0','11.1','-5.7'}; 
end 
  
inputvalues_Poly=inputdlg(prompt,dlg_title,num_lines,def); 
C1_Poly=str2num(inputvalues_Poly{1}); 
C2_Poly=str2num(inputvalues_Poly{2}); 
C3_Poly=str2num(inputvalues_Poly{3}); 
C4_Poly=str2num(inputvalues_Poly{4}); 
C5_Poly=str2num(inputvalues_Poly{5}); 
C6_Poly=str2num(inputvalues_Poly{6}); 
C7_Poly=str2num(inputvalues_Poly{7}); 
  
%%  Run optimization function 
Iter_Count_Poly=0; 
exitflag_Poly = 0; 
while exitflag_Poly == 0 && Iter_Count_Poly < 50 
     
    invalues_Poly = [C1_Poly C2_Poly C3_Poly ... 
        C4_Poly C5_Poly C6_Poly C7_Poly]; 
    variables_Poly = [Crc_GL_Str Ax_GL_Str]; 
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    CombStr_Poly = [Crc_PK_Strs;Ax_PK_Strs]; 
  
    [optivalues_Poly resnorm_Poly residuals_Poly exitflag_Poly ... 
        Opti_Info_Poly lambda_Poly jacobian_Poly] = ... 
        lsqcurvefit(@Optifun_Polynomial,invalues_Poly,... 
        variables_Poly,CombStr_Poly); 
    C1_Poly=optivalues_Poly(1); 
    C2_Poly=optivalues_Poly(2); 
    C3_Poly=optivalues_Poly(3); 
    C4_Poly=optivalues_Poly(4); 
    C5_Poly=optivalues_Poly(5); 
    C6_Poly=optivalues_Poly(6); 
    C7_Poly=optivalues_Poly(7); 
  
    Iter_Count_Poly=Iter_Count_Poly+1; 
end 
  
%%  Calculate Predicted Stresses 
Crc_Stress_Calc_Poly =(2*C1_Poly*Crc_GL_Str) + ... 
    (C2_Poly*Ax_GL_Str) + 3*C4_Poly*(Crc_GL_Str.^2) + ... 
    2*C5_Poly*(Crc_GL_Str.*Ax_GL_Str) + C6_Poly*(Ax_GL_Str.^2); 
  
Ax_Stress_Calc_Poly =(C2_Poly*Crc_GL_Str) + ... 
    (2*C3_Poly*Ax_GL_Str) +C5_Poly*(Crc_GL_Str.^2) + ... 
    2*C6_Poly*(Crc_GL_Str.*Ax_GL_Str) + 3*C7_Poly*(Ax_GL_Str.^2); 
  
%% Calculate R-squared values 
TSS_Crc_Poly = sum((Crc_PK_Strs-mean(Crc_PK_Strs)).^2); 
RSS_Crc_Poly = sum((Crc_PK_Strs-Crc_Stress_Calc_Poly).^2); 
RSquared_Crc_Poly = (TSS_Crc_Poly - RSS_Crc_Poly)/TSS_Crc_Poly; 
  
TSS_Ax_Poly = sum((Ax_PK_Strs-mean(Ax_PK_Strs)).^2); 
RSS_Ax_Poly = sum((Ax_PK_Strs-Ax_Stress_Calc_Poly).^2); 
RSquared_Ax_Poly = (TSS_Ax_Poly - RSS_Ax_Poly)/TSS_Ax_Poly; 
  
%%  Calculate Predicted Stresses for Plotting 
Crc_Str_Step_Poly = (max(Crc_GL_Str)-min(Crc_GL_Str))/100; 
Plt_Crc_Str_Poly = min(Crc_GL_Str):Crc_Str_Step_Poly:max(Crc_GL_Str); 
Plt_Crc_Str_Poly=Plt_Crc_Str_Poly'; 
  
for i=1:length(P0s) 
    Plt_Crc_Stress_Poly(:,i) =(2*C1_Poly*Plt_Crc_Str_Poly) + ... 
        (C2_Poly*Ax_GL_Str(P0s(i))) + 3*C4_Poly*(Plt_Crc_Str_Poly.^2) + ... 
        2*C5_Poly*(Plt_Crc_Str_Poly*Ax_GL_Str(P0s(i))) ... 
        + C6_Poly*(Ax_GL_Str(P0s(i))^2); 
  
    Plt_Ax_Stress_Poly(:,i) =(C2_Poly*Plt_Crc_Str_Poly) + ... 
        (2*C3_Poly*Ax_GL_Str(P0s(i))) + C5_Poly*(Plt_Crc_Str_Poly.^2) + ... 
        2*C6_Poly*(Plt_Crc_Str_Poly*Ax_GL_Str(P0s(i))) + ... 
        3*C7_Poly*(Ax_GL_Str(P0s(i))^2); 
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end 
 
%% Plot Calculated axial and circumferential 2nd Piola-Kirchoff stresses  
%%  and Lagrange strains  
TempLineProp={'-r','-m','-k','-g','-b','-r','-c','-y'}; 
for i=1:length(P0s) 
        subplot('position',[.05,.13,.4,.7]) 
        hold on 
        plot(Plt_Crc_Str_Poly,Plt_Crc_Stress_Poly(:,i)... 
            ,TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
%% Display R-Squared value 
TextPosition(1)=(max(Crc_GL_Str) - min(Crc_GL_Str))/15; 
v=axis; 
TextPosition(2)=v(3) + (v(4)-v(3))/2; 
RSqDisp_Crc=sprintf('%s%s','R^2 = ',num2str(RSquared_Crc_Poly,'%.2f')); 
RSqDisp_Crc_Hand=text(TextPosition(1),TextPosition(2),RSqDisp_Crc); 
set(RSqDisp_Crc_Hand,'FontWeight','bold') 
  
for i=1:length(P0s) 
        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Plt_Crc_Str_Poly,Plt_Ax_Stress_Poly(:,i)... 
            ,TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
        TempPltLegnd1{i}=['\lambda','z  = ',num2str(AxStr(P0s(i)),'%.2f')]; 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
%% Display R-Squared value 
TextPosition(1)=(max(Crc_GL_Str) - min(Crc_GL_Str))/15; 
v=axis; 
TextPosition(2)=v(3) + (v(4)-v(3))/2; 
RSqDisp_Ax=sprintf('%s%s','R^2 = ',num2str(RSquared_Ax_Poly,'%.2f')); 
RSqDisp_Ax_Hand=text(TextPosition(1),TextPosition(2),RSqDisp_Ax); 
set(RSqDisp_Ax_Hand,'FontWeight','bold') 
  
%%  Label Figure 
delete(FigLabel) 
TempLabel = sprintf('%s\n%s',DataName(1:end-4),'Polynomial Fit'); 
FigLabel = uicontrol('Style','text','String',TempLabel,... 
        'units','normalized','Position', [.415 .9 .2 .065],... 
        'FontWeight','bold','FontSize',14,'BackgroundColor',[1 1 1]); 
 
%%  Alert user that max number of iterations reached 
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if Iter_Count_Poly > 1 
    button = questdlg(sprintf('%s\n      %s%s%s',... 
        'Maximum number of iterations reached!',... 
        'Optimization ran ',num2str(Iter_Count_Poly),' times'),... 
        'NOTE!!','Rerun','OK','Rerun'); 
    if strcmp(button,'Rerun') 
        Redo='Y'; 
    elseif strcmp(button,'OK') 
        Redo='N'; 
    end 
end 
if Redo == 'Y' 
    Fit_Polynomial 
end 
 
The code for the “Fit_Exponential” callback (handle3_2) is as follows: 
Redo='N'; 
%%  Calculate axial and circumferential 2nd Piola-Kirchoff stresses if 
    %%  necessary 
if exist('PK_Run') == 0 
    delete(subplot(2,2,1)) 
    delete(subplot(2,2,2)) 
    delete(subplot(2,2,3)) 
    delete(subplot(2,2,4)) 
    Crc_PK_Strs = Crc_Cauch_Strs./(CrcmStr.^2); 
    Ax_PK_Strs = Ax_Cauch_Strs./(AxStr.^2); 
 
%%  Calculate axial and circumferential Green-Lagrange Strains 
    Crc_GL_Str = ((CrcmStr.^2)-1)/2; 
    Ax_GL_Str = ((AxStr.^2)-1)/2; 
end 
 
%% Plot axial and circumferential 2nd Piola-Kirchoff stresses and Lagrange 
%% Strains 
subplot('position',[.05,.55,.4,.4]) 
hold off 
subplot('position',[.55,.55,.4,.4]) 
hold off 
subplot('position',[.3,.06,.4,.4]) 
hold off 
TempLineProp={'*r','om','xk','+g','vb','pr','hc','dy'}; 
for i=1:length(P0s) 
    if i<length(P0s) 
        Plt1 = subplot('position',[.05,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):P0s(i+1)-1),Crc_PK_Strs(P0s(i):P0s(i+1)-1)... 
            ,TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
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        hold on 
         
    elseif i==length(P0s) 
        Plt1 = subplot('position',[.05,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):length(CrcmStr)),Crc_PK_Strs(P0s(i):length(CrcmStr)),... 
            TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
    end 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
for i=1:length(P0s) 
    if i<length(P0s) 
        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):P0s(i+1)-1),Ax_PK_Strs(P0s(i):P0s(i+1)-1)... 
            ,TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    elseif i==length(P0s) 
        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):length(CrcmStr)),Ax_PK_Strs(P0s(i):length(CrcmStr)),... 
            TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    end 
    TempPltLegnd1{i}=['\lambda','z  = ',num2str(AxStr(P0s(i)),'%.2f')]; 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
%%  Prompt user to input the starting values of fit parameters 
prompt = {'Enter an initial value for C1','Enter an initial value for C2',... 
    'Enter an initial value for C3','Enter an initial value for C4'}; 
dlg_title ='Input Starting Values'; 
num_lines=1; 
if exist('optivalues_Exp')==1 
    for i=1:length(optivalues_Exp) 
        def{i}=num2str(optivalues_Exp(i)); 
    end 
else def={'3776.056','0.209','0.175','0.148'}; 
end 
kE=1; 
inputvalues_Exp=inputdlg(prompt,dlg_title,num_lines,def); 
C1_Exp=str2num(inputvalues_Exp{1}); 
C2_Exp=str2num(inputvalues_Exp{2}); 
C3_Exp=str2num(inputvalues_Exp{3}); 
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C4_Exp=str2num(inputvalues_Exp{4}); 
  
%%  Run optimization function 
Iter_Count_Exp=0; 
exitflag_Exp = 0; 
while exitflag_Exp == 0 && Iter_Count_Exp < 50 
  
    invalues_Exp = [C1_Exp C2_Exp C3_Exp C4_Exp]; 
    variables_Exp = [Crc_GL_Str Ax_GL_Str]; 
  
    CombStr_Exp = [Crc_PK_Strs;Ax_PK_Strs]; 
  
    [optivalues_Exp resnorm_Exp residuals_Exp exitflag_Exp ... 
        Opti_Info_Exp lambda_Exp jacobian_Exp] = ... 
        lsqcurvefit(@Optifun_Exponential,invalues_Exp,... 
        variables_Exp,CombStr_Exp); 
    C1_Exp=optivalues_Exp(1); 
    C2_Exp=optivalues_Exp(2); 
    C3_Exp=optivalues_Exp(3); 
    C4_Exp=optivalues_Exp(4); 
  
    Iter_Count_Exp=Iter_Count_Exp+1; 
end 
 
%%  Calculate Predicted Stresses 
Q_Calc = C2_Exp*(Crc_GL_Str.^2) + C3_Exp*(Ax_GL_Str.^2) + ... 
    2*C4_Exp*(Crc_GL_Str.*Ax_GL_Str); 
  
Crc_Stress_Calc_Exp = (C1_Exp*2*C2_Exp*Crc_GL_Str + ... 
    C1_Exp*2*C4_Exp*Ax_GL_Str).*exp(Q_Calc); 
  
Ax_Stress_Calc_Exp = (C1_Exp*2*C3_Exp*Ax_GL_Str + ... 
    C1_Exp*2*C4_Exp*Crc_GL_Str).*exp(Q_Calc); 
  
%% Calculate R-squared values 
TSS_Crc_Exp = sum((Crc_PK_Strs-mean(Crc_PK_Strs)).^2); 
RSS_Crc_Exp = sum((Crc_PK_Strs-Crc_Stress_Calc_Exp).^2); 
RSquared_Crc_Exp = (TSS_Crc_Exp - RSS_Crc_Exp)/TSS_Crc_Exp; 
  
TSS_Ax_Exp = sum((Ax_PK_Strs-mean(Ax_PK_Strs)).^2); 
RSS_Ax_Exp = sum((Ax_PK_Strs-Ax_Stress_Calc_Exp).^2); 
RSquared_Ax_Exp = (TSS_Ax_Exp - RSS_Ax_Exp)/TSS_Ax_Exp; 
 
%%  Calculate Predicted Stresses for Plotting 
Crc_Str_Step_Exp = (max(Crc_GL_Str)-min(Crc_GL_Str))/100; 
Plt_Crc_Str_Exp = min(Crc_GL_Str):Crc_Str_Step_Exp:max(Crc_GL_Str); 
Plt_Crc_Str_Exp=Plt_Crc_Str_Exp'; 
  
for i=1:length(P0s) 
    Plt_Q_Calc(:,i) = C2_Exp*(Plt_Crc_Str_Exp.^2) + ... 
        C3_Exp*(Ax_GL_Str(P0s(i))^2) + ... 
186 
        2*C4_Exp*(Plt_Crc_Str_Exp*Ax_GL_Str(P0s(i))); 
  
    Plt_Crc_Stress_Exp(:,i) = (C1_Exp*2*C2_Exp*Plt_Crc_Str_Exp + ... 
        C1_Exp*2*C4_Exp*Ax_GL_Str(P0s(i))).*exp(Plt_Q_Calc(:,i)); 
  
    Plt_Ax_Stress_Exp(:,i) = (C1_Exp*2*C3_Exp*Ax_GL_Str(P0s(i)) + ... 
        C1_Exp*2*C4_Exp*Plt_Crc_Str_Exp).*exp(Plt_Q_Calc(:,i)); 
end 
  
  
%% Plot Calculated axial and circumferential 2nd Piola-Kirchoff stresses  
%%  and Lagrange strains 
  
TempLineProp={'-r','-m','-k','-g','-b','-r','-c','-y'}; 
for i=1:length(P0s) 
        subplot('position',[.05,.13,.4,.7]) 
        hold on 
        plot(Plt_Crc_Str_Exp,Plt_Crc_Stress_Exp(:,i)... 
            ,TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
 
%% Display R-Squared value 
TextPosition(1)=(max(Crc_GL_Str) - min(Crc_GL_Str))/15; 
v=axis; 
TextPosition(2)=v(3) + (v(4)-v(3))/2; 
RSqDisp_Crc=sprintf('%s%s','R^2 = ',num2str(RSquared_Crc_Exp,'%.2f')); 
RSqDisp_Crc_Hand=text(TextPosition(1),TextPosition(2),RSqDisp_Crc); 
set(RSqDisp_Crc_Hand,'FontWeight','bold') 
  
for i=1:length(P0s) 
        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Plt_Crc_Str_Exp,Plt_Ax_Stress_Exp(:,i)... 
            ,TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
        TempPltLegnd1{i}=['\lambda','z  = ',num2str(AxStr(P0s(i)),'%.2f')]; 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
%% Display R-Squared value 
TextPosition(1)=(max(Crc_GL_Str) - min(Crc_GL_Str))/15; 
v=axis; 
TextPosition(2)=v(3) + (v(4)-v(3))/2; 
RSqDisp_Ax=sprintf('%s%s','R^2 = ',num2str(RSquared_Ax_Exp,'%.2f')); 
RSqDisp_Ax_Hand=text(TextPosition(1),TextPosition(2),RSqDisp_Ax); 
set(RSqDisp_Ax_Hand,'FontWeight','bold') 
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%%  Label Figure 
delete(FigLabel) 
TempLabel = sprintf('%s\n%s',DataName(1:end-4),'Exponential Fit'); 
FigLabel = uicontrol('Style','text','String',TempLabel,... 
        'units','normalized','Position', [.415 .9 .2 .065],... 
        'FontWeight','bold','FontSize',14,'BackgroundColor',[1 1 1]); 
 
%%  Alert user that max number of iterations reached 
if Iter_Count_Exp > 1 
    button = questdlg(sprintf('%s\n      %s%s%s',... 
        'Maximum number of iterations reached!',... 
        'Optimization ran ',num2str(Iter_Count_Exp),' times'),... 
        'NOTE!!','Rerun','OK','Rerun'); 
    if strcmp(button,'Rerun') 
        Redo='Y'; 
    elseif strcmp(button,'OK') 
        Redo='N'; 
    end 
end 
if Redo == 'Y' 
    Fit_Exponential 
end 
Redo='N'; 
 
The code for the “Fit_Mixed” callback (handle3_3) is as follows: 
Redo='N'; 
%%  Calculate axial and circumferential 2nd Piola-Kirchoff stresses if 
%%  necessary 
if exist('PK_Run') == 0 
    delete(subplot(2,2,1)) 
    delete(subplot(2,2,2)) 
    delete(subplot(2,2,3)) 
    delete(subplot(2,2,4)) 
    Crc_PK_Strs = Crc_Cauch_Strs./(CrcmStr.^2); 
    Ax_PK_Strs = Ax_Cauch_Strs./(AxStr.^2); 
 
%%  Calculate axial and circumferential Green-Lagrange Strains 
    Crc_GL_Str = ((CrcmStr.^2)-1)/2; 
    Ax_GL_Str = ((AxStr.^2)-1)/2; 
end 
 
%% Plot axial and circumferential 2nd Piola-Kirchoff stresses and Lagrange 
%% Strains 
subplot('position',[.05,.18,.4,.7]) 
hold off 
subplot('position',[.55,.18,.4,.7]) 
hold off 
TempLineProp={'*r','om','xk','+g','vb','pr','hc','dy'}; 
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for i=1:length(P0s) 
    if i<length(P0s) 
        Plt1 = subplot('position',[.05,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):P0s(i+1)-1),Crc_PK_Strs(P0s(i):P0s(i+1)-1)... 
            ,TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    elseif i==length(P0s) 
        Plt1 = subplot('position',[.05,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):length(CrcmStr)),Crc_PK_Strs(P0s(i):length(CrcmStr)),... 
            TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
    end 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
for i=1:length(P0s) 
    if i<length(P0s) 
        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):P0s(i+1)-1),Ax_PK_Strs(P0s(i):P0s(i+1)-1)... 
            ,TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    elseif i==length(P0s) 
        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Crc_GL_Str(P0s(i):length(CrcmStr)),Ax_PK_Strs(P0s(i):length(CrcmStr)),... 
            TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
         
    end 
    TempPltLegnd1{i}=['\lambda','z  = ',num2str(AxStr(P0s(i)),'%.2f')]; 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
%%  Prompt user to input the starting valuse of fit parameters 
prompt = {'Enter an initial value for C1','Enter an initial value for C2',... 
    'Enter an initial value for C3','Enter an initial value for C4',... 
    'Enter an initial value for C5','Enter an initial value for C6',... 
    'Enter an initial value for C7'}; 
dlg_title ='Input Given Parameters'; 
num_lines=1; 
if exist('optivalues_Mixed')==1 
    for i=1:length(optivalues_Mixed) 
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        def{i}=num2str(optivalues_Mixed(i)); 
    end 
else def={'1549','4430','3419','36','0.602','2.257','-0.815'}; 
end 
  
inputvalues_Mixed=inputdlg(prompt,dlg_title,num_lines,def); 
C1_Mixed=str2num(inputvalues_Mixed{1}); 
C2_Mixed=str2num(inputvalues_Mixed{2}); 
C3_Mixed=str2num(inputvalues_Mixed{3}); 
C4_Mixed=str2num(inputvalues_Mixed{4}); 
C5_Mixed=str2num(inputvalues_Mixed{5}); 
C6_Mixed=str2num(inputvalues_Mixed{6}); 
C7_Mixed=str2num(inputvalues_Mixed{7}); 
  
%%  Run optimization function 
Iter_Count_Mixed=0; 
exitflag_Mixed = 0; 
while exitflag_Mixed == 0 && Iter_Count_Mixed < 50 
     
    invalues_Mixed = [C1_Mixed C2_Mixed C3_Mixed ... 
        C4_Mixed C5_Mixed C6_Mixed C7_Mixed]; 
    variables_Mixed = [Crc_GL_Str Ax_GL_Str]; 
  
    CombStr_Mixed = [Crc_PK_Strs;Ax_PK_Strs]; 
  
    [optivalues_Mixed resnorm_Mixed residuals_Mixed exitflag_Mixed ... 
        Opti_Info_Mixed lambda_Mixed jacobian_Mixed] = ... 
        lsqcurvefit(@Optifun_Mixed,invalues_Mixed,... 
        variables_Mixed,CombStr_Mixed); 
    C1_Mixed=optivalues_Mixed(1); 
    C2_Mixed=optivalues_Mixed(2); 
    C3_Mixed=optivalues_Mixed(3); 
    C4_Mixed=optivalues_Mixed(4); 
    C5_Mixed=optivalues_Mixed(5); 
    C6_Mixed=optivalues_Mixed(6); 
    C7_Mixed=optivalues_Mixed(7); 
  
    Iter_Count_Mixed=Iter_Count_Mixed+1; 
end 
  
%%  Calculate Predicted Stresses 
Q_Calc = C5_Mixed*(Crc_GL_Str.^2) + C6_Mixed*(Crc_GL_Str.*Ax_GL_Str) + ... 
    C7_Mixed*(Ax_GL_Str.^2); 
  
Crc_Stress_Calc_Mixed =(2*C1_Mixed*Crc_GL_Str) + (C2_Mixed*Ax_GL_Str) + ... 
    (2*C4_Mixed*C5_Mixed*Crc_GL_Str + C4_Mixed*C6_Mixed*Ax_GL_Str).*exp(Q_Calc); 
  
Ax_Stress_Calc_Mixed =(C2_Mixed*Crc_GL_Str) + (2*C3_Mixed*Ax_GL_Str) + ... 
    (C4_Mixed*C6_Mixed*Crc_GL_Str + 2*C4_Mixed*C7_Mixed*Ax_GL_Str).*exp(Q_Calc); 
  
%% Calculate R-squared values 
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TSS_Crc_Mixed = sum((Crc_PK_Strs-mean(Crc_PK_Strs)).^2); 
RSS_Crc_Mixed = sum((Crc_PK_Strs-Crc_Stress_Calc_Mixed).^2); 
RSquared_Crc_Mixed = (TSS_Crc_Mixed - RSS_Crc_Mixed)/TSS_Crc_Mixed; 
  
TSS_Ax_Mixed = sum((Ax_PK_Strs-mean(Ax_PK_Strs)).^2); 
RSS_Ax_Mixed = sum((Ax_PK_Strs-Ax_Stress_Calc_Mixed).^2); 
RSquared_Ax_Mixed = (TSS_Ax_Mixed - RSS_Ax_Mixed)/TSS_Ax_Mixed; 
  
%%  Calculate Predicted Stresses for Plotting 
Crc_Str_Step_Mixed = (max(Crc_GL_Str)-min(Crc_GL_Str))/100; 
Plt_Crc_Str_Mixed = min(Crc_GL_Str):Crc_Str_Step_Mixed:max(Crc_GL_Str); 
Plt_Crc_Str_Mixed=Plt_Crc_Str_Mixed'; 
  
for i=1:length(P0s) 
    Plt_Q_Calc(:,i) = C5_Mixed*(Plt_Crc_Str_Mixed.^2) + 
C6_Mixed*(Plt_Crc_Str_Mixed.*Ax_GL_Str(P0s(i))) + ... 
        C7_Mixed*(Ax_GL_Str(P0s(i)).^2); 
  
    Plt_Crc_Stress_Mixed(:,i) = (2*C1_Mixed*Plt_Crc_Str_Mixed) + (C2_Mixed*Ax_GL_Str(P0s(i))) + 
... 
        (2*C4_Mixed*C5_Mixed*Plt_Crc_Str_Mixed + 
C4_Mixed*C6_Mixed*Ax_GL_Str(P0s(i))).*exp(Plt_Q_Calc(:,i)); 
  
    Plt_Ax_Stress_Mixed(:,i) = (C2_Mixed*Plt_Crc_Str_Mixed) + (2*C3_Mixed*Ax_GL_Str(P0s(i))) + 
... 
        (C4_Mixed*C6_Mixed*Plt_Crc_Str_Mixed + 
2*C4_Mixed*C7_Mixed*Ax_GL_Str(P0s(i))).*exp(Plt_Q_Calc(:,i)); 
end 
 
%% Plot Calculated axial and circumferential 2nd Piola-Kirchoff stresses  
%%  and Lagrange strains 
 TempLineProp={'-r','-m','-k','-g','-b','-r','-c','-y'}; 
for i=1:length(P0s) 
        subplot('position',[.05,.13,.4,.7]) 
        hold on 
        plot(Plt_Crc_Str_Mixed,Plt_Crc_Stress_Mixed(:,i)... 
            ,TempLineProp{i}) 
        ylabel('Circumferential 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
%% Display R-Squared value 
TextPosition(1)=(max(Crc_GL_Str) - min(Crc_GL_Str))/15; 
v=axis; 
TextPosition(2)=v(3) + (v(4)-v(3))/2; 
RSqDisp_Crc=sprintf('%s%s','R^2 = ',num2str(RSquared_Crc_Mixed,'%.2f')); 
RSqDisp_Crc_Hand=text(TextPosition(1),TextPosition(2),RSqDisp_Crc); 
set(RSqDisp_Crc_Hand,'FontWeight','bold') 
  
for i=1:length(P0s) 
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%     if i<length(P0s) 
        Plt2 = subplot('position',[.55,.13,.4,.7]); 
        plot(Plt_Crc_Str_Mixed,Plt_Ax_Stress_Mixed(:,i)... 
            ,TempLineProp{i}) 
        ylabel('Axial 2nd Piola-Kirchoff Stress (Pa)') 
        xlabel('Circumferential Green-Lagrange Strain') 
        hold on 
        TempPltLegnd1{i}=['\lambda','z  = ',num2str(AxStr(P0s(i)),'%.2f')]; 
end 
legend(TempPltLegnd1,'Location','NorthWest','FontSize',7) 
  
%% Display R-Squared value 
TextPosition(1)=(max(Crc_GL_Str) - min(Crc_GL_Str))/15; 
v=axis; 
TextPosition(2)=v(3) + (v(4)-v(3))/2; 
RSqDisp_Ax=sprintf('%s%s','R^2 = ',num2str(RSquared_Ax_Mixed,'%.2f')); 
RSqDisp_Ax_Hand=text(TextPosition(1),TextPosition(2),RSqDisp_Ax); 
set(RSqDisp_Ax_Hand,'FontWeight','bold') 
  
%%  Label Figure 
delete(FigLabel) 
TempLabel = sprintf('%s\n%s',DataName(1:end-4),'Mixed Fit'); 
FigLabel = uicontrol('Style','text','String',TempLabel,... 
        'units','normalized','Position', [.415 .9 .2 .065],... 
        'FontWeight','bold','FontSize',14,'BackgroundColor',[1 1 1]); 
 
%%  Alert user that max number of iterations reached 
if Iter_Count_Mixed > 1 
    button = questdlg(sprintf('%s\n      %s%s%s',... 
        'Maximum number of iterations reached!',... 
        'Optimization ran ',num2str(Iter_Count_Mixed),' times'),... 
        'NOTE!!','Rerun','OK','Rerun'); 
    if strcmp(button,'Rerun') 
        Redo='Y'; 
    elseif strcmp(button,'OK') 
        Redo='N'; 
    end 
end 
if Redo == 'Y' 
    Fit_Mixed 
end 
 
The code for the polynomial optimization function (Optifun_Poly) is as follows: 
function Comb_Stress_Poly = Optifun_Polynomial(invalues_Poly,variables_Poly) 
global Comb_Stress_Poly 
C1_Poly=invalues_Poly(1); 
C2_Poly=invalues_Poly(2); 
C3_Poly=invalues_Poly(3); 
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C4_Poly=invalues_Poly(4); 
C5_Poly=invalues_Poly(5); 
C6_Poly=invalues_Poly(6); 
C7_Poly=invalues_Poly(7); 
  
Crc_GL_Str=variables_Poly(:,1); 
Ax_GL_Str=variables_Poly(:,2); 
  
  
Crc_Stress_Poly =(2*C1_Poly*Crc_GL_Str) + ... 
    (C2_Poly*Ax_GL_Str) + 3*C4_Poly*(Crc_GL_Str.^2) + ... 
    2*C5_Poly*(Crc_GL_Str.*Ax_GL_Str) + C6_Poly*(Ax_GL_Str.^2); 
  
Ax_Stress_Poly =(C2_Poly*Crc_GL_Str) + ... 
    (2*C3_Poly*Ax_GL_Str) +C5_Poly*(Crc_GL_Str.^2) + ... 
    2*C6_Poly*(Crc_GL_Str.*Ax_GL_Str) + 3*C7_Poly*(Ax_GL_Str.^2); 
  
Comb_Stress_Poly = [Crc_Stress_Poly;Ax_Stress_Poly]; 
 
The code for the exponential optimization function (Optifun_Exponential) is as follows: 
function Comb_Stress_Exp = Optifun_Exponential(invalues_Exp,variables_Exp) 
global Comb_Stress_Exp 
C1_Exp=invalues_Exp(1); 
C2_Exp=invalues_Exp(2); 
C3_Exp=invalues_Exp(3); 
C4_Exp=invalues_Exp(4); 
  
Crc_GL_Str=variables_Exp(:,1); 
Ax_GL_Str=variables_Exp(:,2); 
  
Q = C2_Exp*(Crc_GL_Str.^2) + C3_Exp*(Ax_GL_Str.^2) + ... 
    2*C4_Exp*(Crc_GL_Str.*Ax_GL_Str); 
  
Crc_Stress_Exp = (C1_Exp*2*C2_Exp*Crc_GL_Str + ... 
    C1_Exp*2*C4_Exp*Ax_GL_Str).*exp(Q); 
  
Ax_Stress_Exp = (C1_Exp*2*C3_Exp*Ax_GL_Str + ... 
    C1_Exp*2*C4_Exp*Crc_GL_Str).*exp(Q); 
  
Comb_Stress_Exp = [Crc_Stress_Exp;Ax_Stress_Exp]; 
 
The code for the mixed exponential-polynomial optimization function (Optifun_Mixed) is as 
follows: 
function Comb_Stress_Mixed = Optifun_Mixed(invalues_Mixed,variables_Mixed) 
global Comb_Stress_Mixed 
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C1_Mixed=invalues_Mixed(1); 
C2_Mixed=invalues_Mixed(2); 
C3_Mixed=invalues_Mixed(3); 
C4_Mixed=invalues_Mixed(4); 
C5_Mixed=invalues_Mixed(5); 
C6_Mixed=invalues_Mixed(6); 
C7_Mixed=invalues_Mixed(7); 
  
Crc_GL_Str=variables_Mixed(:,1); 
Ax_GL_Str=variables_Mixed(:,2); 
  
Q = C5_Mixed*(Crc_GL_Str.^2) + C6_Mixed*(Crc_GL_Str.*Ax_GL_Str) + ... 
    C7_Mixed*(Ax_GL_Str.^2); 
  
Crc_Stress_Mixed =(2*C1_Mixed*Crc_GL_Str) + (C2_Mixed*Ax_GL_Str) + ... 
    (2*C4_Mixed*C5_Mixed*Crc_GL_Str + C4_Mixed*C6_Mixed*Ax_GL_Str).*exp(Q); 
  
Ax_Stress_Mixed =(C2_Mixed*Crc_GL_Str) + (2*C3_Mixed*Ax_GL_Str) + ... 
    (C4_Mixed*C6_Mixed*Crc_GL_Str + 2*C4_Mixed*C7_Mixed*Ax_GL_Str).*exp(Q); 
  
Comb_Stress_Mixed = [Crc_Stress_Mixed;Ax_Stress_Mixed]; 
 
The code for the “Save_Res” callback (handle4) is as follows: 
ScriptDir=pwd; 
Results_Dir=sprintf('%s%s',ScriptDir(1:end-7),'Results'); 
Figures_Dir=sprintf('%s%s',ScriptDir(1:end-7),'Saved Figures'); 
 
%%  Save Coefficients 
if SaveType == 1 
    if exist('C1_Exp')==1 || exist('C1_Poly')==1 || exist('C1_Mixed')==1 
 
%%  Prompt User to Decide to Save to An Existing File or a New One 
        button = questdlg('Do You Want to Add to An Exiting File or Save to A New File?',... 
            'Save Output?','Existing File','New File','Existing File'); 
        if strcmp(button,'Existing File') 
            Adddata='A'; 
        elseif strcmp(button,'New File') 
            Adddata='N'; 
        end 
 
%%  Save Coefficients 
 %Append an existing file 
        if Adddata=='A' 
            cd(Results_Dir); 
            [ResFilename,FilePath] = uiputfile({'*.txt';'*.xls'},'Save As',... 
                sprintf('%s%s',DataName(1:end-4),'_Coefficients.txt')); 
            if ResFilename ~= 0 
                %Save coefficients for polynomial fit 
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                cd(FilePath); 
                if exist('C1_Poly')== 1  
                    fid1=fopen(ResFilename,'a'); 
                    fprintf(fid1,'%s\t %s\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t \n',... 
                        DataName(1:end-4), 'Polynomial',C1_Poly, C2_Poly,C3_Poly,... 
                        C4_Poly, C5_Poly, C6_Poly, C7_Poly); 
                    fclose(fid1); 
                end 
                 
   %Save coefficients for exponential fit 
                if exist('C1_Exp')== 1  
                    fid1=fopen(ResFilename,'a'); 
                    fprintf(fid1,'%s\t %s\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t \n',... 
                        DataName(1:end-4), 'Exponential',C1_Exp, C2_Exp, C3_Exp, C4_Exp, 0, 0, 0); 
                    fclose(fid1); 
                end 
                 
   %Save coefficients for Choi exponential fit 
                if exist('C1_ExpChoi')==1  
                    fid1=fopen(ResFilename,'a'); 
                    fprintf(fid1,'%s\t %s\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t \n',... 
                        DataName(1:end-4), 'Choi Exponential',C1_ExpChoi, C2_ExpChoi, C3_ExpChoi,        
C4_ExpChoi, 0, 0, 0); 
                    fclose(fid1); 
                end 
                 
   %Save coefficients for Mixed Model fit 
                if exist('C1_Mixed')==1  
                    fid1=fopen(ResFilename,'a'); 
                    fprintf(fid1,'%s\t %s\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t \n',... 
                        DataName(1:end-4), 'Mixed Model',C1_Mixed, C2_Mixed, C3_Mixed, ... 
                        C4_Mixed, C5_Mixed, C6_Mixed, C7_Mixed); 
                    fclose(fid1); 
                end 
            end 
            cd(ScriptDir); 
         
        %Save to a new file 
        elseif Adddata=='N' 
            cd(Results_Dir); 
            [ResFilename,FilePath] = uiputfile({'*.txt';'*.xls'},'Save As',... 
                sprintf('%s%s',DataName(1:end-4),'_Coefficients.txt')); 
            if ResFilename ~= 0 
                cd(FilePath); 
                %Save column labels 
                fid1=fopen(ResFilename,'w'); 
                fprintf(fid1,'%s\t %s\t %s\t %s\t %s\t %s\t %s\t %s\t %s\t \n',... 
                    'Vessel ID', 'Fit Type','C1', 'C2','C3', 'C4', 'C5', 'C6', 'C7'); 
                 fclose(fid1); 
                 
                %Save coefficients for polynomial fit 
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                if exist('C1_Poly')== 1  
                    fid1=fopen(ResFilename,'a'); 
                    fprintf(fid1,'%s\t %s\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t \n',... 
                        DataName(1:end-4), 'Polynomial',C1_Poly, C2_Poly,C3_Poly,... 
                        C4_Poly, C5_Poly, C6_Poly, C7_Poly); 
                     fclose(fid1); 
                end                
                 
   %Save coefficients for exponential fit 
                if exist('C1_Exp')== 1  
                    fid1=fopen(ResFilename,'a'); 
                    fprintf(fid1,'%s\t %s\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t \n',... 
                        DataName(1:end-4), 'Exponential',C1_Exp, C2_Exp, C3_Exp, C4_Exp, 0, 0, 0); 
                    fclose(fid1); 
                end 
                end 
 
                %Save coefficients for Mixed Model fit 
                if exist('C1_Mixed')==1  
                    fid1=fopen(ResFilename,'a'); 
                    fprintf(fid1,'%s\t %s\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t %6.3f\t \n',... 
                        DataName(1:end-4), 'Mixed Model',C1_Mixed, C2_Mixed, C3_Mixed, ... 
                        C4_Mixed, C5_Mixed, C6_Mixed, C7_Mixed); 
                    fclose(fid1); 
                end 
            end 
            cd(ScriptDir); 
        end 
    elseif exist('C1_Exp')==0 && exist('C1_Poly')==0 && exist('C1_ExpChoi')==0 
        msgbox(sprintf('%s\n%s',... 
            'THERE ARE NO COEFFICIENTS TO BE SAVED!',... 
            'PLEASE RUN OPTIMIZATION PROGRAM FIRST!'),... 
            'ERROR!','warn'); 
        cd(ScriptDir); 
    end 
end 
  
%%  Save Curves 
if SaveType == 2 
    clear Output2 
    %Save Output 
    cd(Results_Dir); 
    [ResFilename,FilePath] = uiputfile({'*.txt';'*.xls'},'Save As',... 
        sprintf('%s%s',DataName(1:end-4),'_Curves')); 
    if ResFilename ~= 0 
        cd(FilePath); 
  
        %Create output array for curves 
        Output=[Press_mmHg Di Do Force_mN Length CrcmStr AxStr Crc_Cauch_Strs ... 
            Ax_Cauch_Strs Crc_PK_Strs Ax_PK_Strs Crc_GL_Str Ax_GL_Str]; 
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        fid=fopen(ResFilename,'w'); 
        fprintf(fid,'%s\t %s\t %s\t %s\t %s\t %s\t %s\t %s\t %s\t %s\t %s\t %s\t %s\t \n',... 
            'P(mmHg)', 'Di(um)','Do(um)', 'Force(mN)',... 
            'Length(mm)', 'Strain(Circ)', 'Strain(Axial)',... 
            'Cauch Stress(Circ)', 'Cauch Stress(Axial)',... 
            'PK Stress(Circ)','PK Stress(Axial)',... 
            'GL Strain(Circ)','GL Strain(Axial)'); 
        fprintf(fid,'%6.2f\t %6.2f\t %6.2f\t %6.2f\t %6.2f\t %6.2f\t %6.2f\t %6.2f\t %6.2f\t %6.2f\t %6.2f\t 
%6.2f\t %6.2f\t \n',... 
            Output'); 
        fclose(fid); 
  
        %Create output arrays for polynomial fit 
        if exist('C1_Poly')== 1 
            Output2=[Plt_Crc_Str_Poly Plt_Crc_Stress_Poly Plt_Ax_Stress_Poly]; 
        end 
  
        %Create output array for exponential fit only 
        if exist('C1_Exp')== 1 
            Exp_Array =[Plt_Crc_Str_Exp Plt_Crc_Stress_Exp Plt_Ax_Stress_Exp]; 
            Arr_Size = size(Exp_Array); 
            Arr_Size = Arr_Size(2); 
            Output2(:,end+1:end+Arr_Size) = Exp_Array; 
        end 
         
        %Create output array for Mixed Model fit only 
        if exist('C1_Mixed')== 1 
            Mixed_Array =[Plt_Crc_Str_Mixed Plt_Crc_Stress_Mixed Plt_Ax_Stress_Mixed]; 
            Arr_Size = size(Mixed_Array); 
            Arr_Size = Arr_Size(2); 
            Output2(:,end+1:end+Arr_Size) = Mixed_Array; 
        end 
  
        %Save File 
        row=size(Output2); 
        row=row(2); 
        Fmt='%6.2f\t '; 
        for i=2:row 
            Fmt=sprintf('%s%s',Fmt,'%6.2f\t '); 
            if i==row 
                Fmt=sprintf('%s%s',Fmt,'\n'); 
            end 
        end 
  
        fid_2=fopen(sprintf('%s%s',ResFilename(1:end-11),'_Predicted.txt'),'w'); 
        fprintf(fid_2,Fmt,Output2'); 
        fclose(fid_2); 
    end 
    cd(ScriptDir); 
end 
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